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 Abstract 
Filamentous fungi and other microorganisms have amazing abilities to synthesize structural 
complex, diverse and unique small organic molecules. Many are bioactive and numerous 
compounds such as mycotoxins, antifungal, and anticancer agents have been reported in the 
literature within the last more than 100 years. New natural products (NPs) are continually 
discovered and with the increase in selective biological assays, previously described compounds 
often also display novel bioactivities, justifying their presence in novel screening efforts. 
 
Screening and discovery of compounds with activity towards chronic lymphocytic leukemia 
(CLL) cells is crucial since CLL is considered as an incurable disease. To discover novel agents 
that targets CLL cells is complicated. CLL cells rapidly undergo apoptosis in vitro when they are 
removed from their natural microenvironment, even though they are long-living cells in vivo. 
Fortunately viability of CLL cells can be maintained in vitro by co-cultivation with stromal cells 
mimicking in vivo conditions. This has led to the development of a co-culture assay that is ideally 
suited for screening of NPs. 
 
The main goal of this study has been to discover fungal NPs with activity towards CLL cells in 
vitro. We based our screening on a combined analytical and bio-guided approach of LC-DAD-
HRMS based dereplication, explorative solid-phase-extraction (E-SPE), and a co-culture platform 
of CLL and stromal cells. 
 
The activity was tracked to single compounds in seven of the most active extracts in a 
screening setup including 289 fungal extracts. The novel ophiobolin U was isolated together with 
the known ophiobolin C, H, K as well as 6-epiophiobolin G, K and N from three fungal strains in 
the Aspergillus section Usti, and further ophiobolins were bought from commercial sources. 
Ophiobolin A, B, C and K induced apoptosis in CLL cells with LC50 values of values of 1, 2, 8, 
and 4 nM, respectively, with a possible narrow therapeutic window. The remaining ophiobolins 
were inactive. Eight other bioactive extracts were addressed and the compounds responsible for 
the activity towards CLL cells were identified from six of the extracts. The known compounds: 
penicillic acid, viridicatumtoxin, calbistrin A, brefeldin A, emestrin A, and neosolaniol 
monoacetate all displayed activity towards CLL cells though they all showed general cytotoxic in 
the assay. In the remaining two extracts the bioactive compounds were tentatively identified as 
cycloaspeptide E and a compound belonging to the statin family of compounds though these 
results are inconclusive. 
 
A second aim of this PhD project has been to discover novel bioactive NPs using a target-
guided approach based on MS and NMR. In one project a target-guided approach based on MS 
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lead to isolation of two new cytochalasins, sclerotionigrin A and B and the known proxiphomin 
from the fungal species Aspergillus sclerotieoniger. The compounds are moderately cytotoxic 
towards CLL. In a second approach three novel bioactive micropeptins produced by 
cyanobacteria were discovered through target-guided isolation based on NMR. The micropeptins 
displayed inhibitory activity towards serine proteases: chymotrypsin and elastase with IC50 values 
between 5.9 and 28.0 µM. 
 
In conclusion, this PhD study adds to the knowledge of bioactive NPs produced by 
filamentous fungi, and in particular activity towards CLL cells. The results obtained here have 
been based on the use of a combined bio-guided and analytical dereplication approach. This PhD 
study also includes a review of 50 compounds or compound families with anticancer activity 
primarily produced by Aspergillus, Penicillium and Talaromyces. 
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 Sammenfatning 
Filamentøse svampe og andre mikroorganismer har en utrolig evne til at synteserne strukturelt 
komplekse, forskellige og unikke små organiske molekyler. Mange er bioaktive stoffer som f.eks. 
mykotoksiner, antifungale og anticancer aktive stoffer er blevet afrapporteret i litteraturen gennem 
de sidste 100 år. Der bliver stadig opdaget nye naturstoffer (NPs) og med en stigning i selektive 
biologiske assay udviser tidligere beskrevne stoffer ofte nye bioaktiviteter, hvilket retfærdiggør 
deres tilstedeværelse in nye screeningstiltag. 
 
Screening og opdagelse af stoffer med aktivitet mod kronisk lymfatisk leukæmi (CLL) celler 
er vigtigt fordi CLL anses som en uhelbredelig sygdom. Opdagelse af nye kemiske stoffer der 
målretter CLL celler er kompliceret fordi CLL celler in vitro hurtigt underlægges apoptose når de 
fjernes fra deres naturlig mikromiljø, selvom de in vivo har en høj overlevelsesevne. 
Overlevelsesevnen for CLL celler kan heldigvis bibeholdes in vitro ved hjælp af kultivering 
sammen med stromal celler hvorved in vivo forhold imiteres. Dette har ført til udviklingen af et 
co-kultiverings assay der er velegnet til screening af NPs. 
 
Hovedformålet af dette studie har været at opdage svampe NPs med aktivitet mod CLL celler 
in vitro. Vi baserede vores screening på en kombineret analytisk og bio-guided fremgangsmåde 
med LC-DAD-HRMS baseret dereplikering, ’explorative solid-phase-extraction (E-SPE)’ og en 
co-kultiverings platform bestående af CLL og stromale celler. 
 
Aktiviteten blev undersøgt på enkelte stoffer i syv af de mest aktive ekstrakter i et screenings 
setup der inkluderede 289 svampeekstrakter. Den nye ophiobolin U blev isoleret sammen med de 
kendte ophiobolin C, H, K og 6-epiophiobolin G, K, N fra tre stammer in Aspergillus sektion 
Usti. Yderligere ophioboliner blev købt kommercielt. Ophiobolin A, B, C og K inducerede 
apoptose in CLL celler med LC50 værdierne 1. 2, 8 og 4 nM med et muligt men snævert 
terapeutisk vindue. De resterende ophioboliner var inaktive. Otte andre bioaktive ekstrakter blev 
adresseret og stofferne der var ansvarlig for aktiviteten mod CLL celler blev identificeret i seks af 
ekstrakterne. De kendte stoffer: penicillinsyre, viridicatumtoxin, calbistrin A, brefeldin A, 
emestrin A, og neosolaniol monoacetate viste alle aktivitet mod CLL celler dog var de alle 
generelt cytotoksiske i assayet. I de to tilbageværende ekstrakter blev de bioaktive stof 
midlertidigt identificeret til at være cycloaspeptid E og et stof fra statin familien, dog var disse 
resultater ikke fyldestgørende. 
 
Et andet mål i dette Ph.d. projekt har været at opdage nye biotaktive NPs ved hjælp af en 
’target-guided’ fremgangsmåde baseret på hhv. MS og NMR. I et projekt var den ’target-guided’ 
fremgangsmåde baseret på MS hvilket ledte til isolering af to nye cytochalasiner, sclerotionigrin 
DTU Systems Biology 
Chemical Biology of Microbial Anticancer Natural Products 
VI 
 
A and B og den kendte proxiphomin fra svampen Aspergillus sclerotieoniger. Stofferne er 
moderat cytotoxiske mod CLL. I en anden fremgangsmåde blev tre nye bioaktive micropeptiner, 
produceret af cyanobakterier, opdaget gennem ’target-guided’ isolering beseret på NMR. De tre 
micropeptiner viste inhiberende aktivitet mod serin proteaserne chymotrypsin og elastase med 
IC50 værdier mellem 5.9 og 28.0 µM. 
 
Dette Ph.d. studie bidrager til vores viden omkring bioaktive NPs produceret af filamentøse 
svampe og særligt med aktivitet mod CLL celler. Resultaterne opnået her har været baseret på 
brugen af en kombineret bio-guided og analytisk fremgangsmåde. Dette Ph.d. studie inkluderer 
også et review af 50 stoffer eller stofklasser med anticancer aktivitet primært produceret af 
Aspergillus, Penicillium og Talaromyces. 
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DMSO Dimethyl Sulfoxide 
DTU Technical University of Denmark 
DTU Systems Biology Department of Systems Biology 
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HRMS High Resolution Mass Spectrometry 
HSQC Heteronuclear Single Quantum Coherence 
Hty Homotyrosine 
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Ile Isoleucine 
LC Liquid Chromatography 
LC50 Median Lethal Concentration 
Leu Leucine 
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MEA Malt Extract Agar 
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MeOH Methanol 
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MS Mass Spectrometry 
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NMe-Tyr N-Methylated-Tyrosine 
nM Nano Molar 
NMR Nuclear Magnetic Resonance 
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NPs Natural Products 
NRP Non-Ribosomal Peptide 
ORD-CD Optical Rotatory Dispersion-Circular Dichroism 
OSMAC One Strain – Many Compounds 
PBMC Peripheral Blood Mononuclear Cells 
Phe Phenylalanine 
PP Protein Phosphatase 
qTOF Quadrupole Time Of Flight 
ROESY Rotating Frame Nuclear Overhauser Effect Spectroscopy 
RP Reverse Phase 
SAR Structure-Activity Relationship 
SAX Strong Anion-Exchanger 
SCX Strong Cation-Exchanger 
SGGPNA Suc-Gly-Gly-p-Nitroanilide 
Thr Threonine 
TOCSY Total Correlation Spectroscopy 
Trp Tryptophan 
Tyr Tyrosine 
UHPLC Ultra-High-Performance Liquid Chromatography 
UV Ultra Violet 
Val Valine 
YES Yeast Extract Sucrose 
µM Micro Molar 
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 Background 
Cancer is characterized by American Cancer Society as an “uncontrolled growth and spread of 
abnormal cells” [1]. Different treatments, such as surgery, radiation, hormone therapy, biological 
therapy, and chemotherapy are used in the struggle against cancer [1]. The use of 
chemotherapeutics goes back to the early 20th century, where it was discovered by ‘accident’ 
during World War I. Several hundred people were exposed to mustard gas (1,5-dichloro-3-thia-
pentane) and following they showed very low white blood cell counts. This discovery was used in 
cancer research in the hope of finding an agent with a similar effect on certain types of blood 
cancers. This led to the development of the first chemotherapeutic agent, nitrogen mustard. The 
therapeutic effect was unfortunately only temporary [2,3]. From the first chemotherapy agents in 
the 1940’s and up until today, more than 200 anticancer drugs has been approved for clinical use. 
Approx. 40 % of them are natural products (NPs) or derived from NPs [4,5]. 
This PhD thesis is concerned with the screening and discovery of compounds from 
filamentous fungi that act against a specific type of cancer, chronic lymphocytic leukemia (CLL). 
These cells differ from other cancer cells in that they have entered a prolonged non-dividing arrest 
stated in the G0/G1 phase of the cell cycle. This results in a defective apoptotic mechanism and 
allows the CLL cells to escape apoptosis [6,7]. CLL is the most common type of leukemia among 
adults in the Western World, accounting for 30 % of all reported cases [8]. CLL is generally 
considered a heterogeneous disease with a large diversity in clinical behavior between patients. 
When diagnosed, many patients remain asymptomatic for decades when other develops the 
disease rapid and progressive whereupon they die within two to three years after diagnosed [9]. 
The CLL cells tend to accumulate at various locations in the body of patients including the blood, 
lymph nodes, bone marrow, spleen, and liver, thereby they overshadow other blood cells [6]. The 
accumulation of CLL cells is mainly due to suppression of apoptotic cell death, rather than 
increased cell proliferation [10]. In vivo, CLL cells are associated with a survival-inducing 
microenvironment of stromal cells, non-malignant leukocytes, so-called nurse-like cells, as well 
as growth and differentiation factors [11,12]. Removed from their natural microenvironment, the 
CLL cells rapidly undergo apoptosis in vitro even though they in vivo are long-lived cells [13]. 
This dependence of the surrounding microenvironment prolongs the survival of CLL cells 
significantly and has led to the development of a co-culture system containing CLL and human 
bone marrow-derived cells. In the co-culture, the CLL cells were able to survive for several 
months in vitro [14]. The protective effects caused by these bone marrow infiltrating cells in the 
surrounding microenvironment, results in significantly higher resistance to chemotherapeutics. As 
a consequence of the diverse courses of CLL and the heterogeneous clinical response, various 
treatment strategies are demanded [8,15]. Patients with asymptomatic and stable disease courses 
are currently not treated, due to lack of any survival benefits. In these cases treatment will only be 
introduced if symptoms arises [9,16]. Since the 1960’s alkylating agents such as chlorambucil and 
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fludarabine have been used as standard first-line therapy for treatment of CLL. They are still used 
today either as monotherapy or as combination chemotherapies or chemoimmunotherapies 
[17,18]. Terasawa et al. conclude that “no single treatment showed significantly better overall 
survival than any other” [18]. In general, CLL is considered as an incurable condition and applied 
treatment strategies primarily aim at prolonging patient survival. Consequently, there is a great 
need for discovery and development of new chemotherapeutic agents for treatment of CLL 
[16,18,19]. 
A co-culture assay suitable for screening fungal extracts, fractions, and single compounds has 
been established (section 2.1). Altogether, 289 fungal raw extracts from 137 fungal strains were 
screened for apoptosis-inducing activity towards CLL cell in vitro. The extracts that exhibited the 
highest bioactivity were pursued to track the activity into single fractions/compounds by a 
combined analytical and bio-guided approach. This approach builds on ultra-high-performance 
liquid chromatography-diode detector array-high resolution mass spectrometry (UHPLC-DAD-
HRMS)-based dereplication for fast identification of known compounds in the extracts combined 
with the CLL stromal cell co-cultured assay to follow the activity during each purifications step. 
This PhD thesis is organized in 6 chapters, where results and discussion from publications are 
used, though I have clarified and elaborated on the contents. All publications and supplementary 
files including experimental are enclosed in appendix. The first chapter introduces the scope of 
this PhD project starting with known anticancer NPs (paper 1) followed by an overview of the 
applied assays, screenings approach, and analytical NPs chemistry. Chapter 2 outlines the results 
and discussion of nine bioactive crude extracts and covers the whole screening process from 
activity to single compounds by a combined analytical and bio-guided approach (paper 2). 
Chapter 3 focuses on the results and discussion in the discovery process of bioactive ophiobolins 
(paper 2). Chapter 4 describes the structures of two new cytochalasins and their activity towards 
CLL cells (paper 3). Chapter 5 address the isolation and structure elucidation of cyclic peptides 
produced by cyanobacteria and covers the results of my external stay with Professor Shmuel 
Carmeli at Tel Aviv University, Israel (paper 4). Finally, chapter 6 holds the overall discussion, 
perspectives, and concluding remarks that enclose what I have learned during this project. 
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 Chapter 1 
Introduction 
1.1 Anticancer Compounds Produced by Filamentous Fungi 
Fungal NPs represent an amazingly high structural variety and complexity in their chemical 
scaffolds, often rich in stereochemistry, concatenated rings, and reactive functional groups. Many 
hypotheses about the purpose of secondary metabolism in fungi have been suggested over the 
years. One of the more plausible theories for NPs production is the model proposed by Williams 
et al. saying that secondary metabolites serve to improve the overall fitness of the producing 
organism “by acting at specific receptors in competing organisms” [20]. The structural features of 
many NPs provide favorable chemical interactions, making them capable of binding to receptors 
with remarkable affinity and specificity. Many of these compounds are even privileged structures 
where one compound interacts with many different biological receptors and as a result show 
multiple bioactivities [21]. This makes NPs very attractive for drug discovery purposes. The last 
fifty years intensive research in bioactive fungal NPs have, in fact, provided the world with new 
pharmaceuticals in infection diseases, immunopharmacology, organ transplant, cardiovascular 
diseases, cancer etc. [5]. Owe to the complexity of many NPs, synthetic approaches can be 
difficult or even impossible. Thus, we often rely on Nature’s own biosynthetic machinery to 
create these molecules. The major biosynthetic classes in filamentous fungi are polyketides, 
terpenoids, and non-ribosomal peptide (NRP). 
One of the best known anticancer drugs of natural origin is taxol, also known as paclitaxel 
(Figure 1), originally isolated from the bark of yew tree Taxus brevifolia [22]. Clinical 
development of taxol was delayed due to problems with production of sufficient quantities of the 
compound. This problem was solved 20 years later when it was demonstrated that taxol was 
produced by fungi as well [23,24]. Taxol was approved as an anticancer drug against a wide range 
of tumors in the 1990s and is the first billion dollar drug against cancer [25,26]. Today, taxol is 
routinely used to treat ovarian, breast and lung tumors as well as Kaposi’s sarcoma [27]. 
Figure 1. Taxol, the first billion dollar anti-cancer drug developed. 
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The three small antifungal polyketides terrein, brefeldin A, and griseofulvin are examples of 
well-known metabolites that decades after they were discovered were shown to exhibit novel 
anticancer activities. The small antifungal [28] polyketide terrein (Figure 2a) produced by A. 
terreus has been known since 1935 [29]. Almost 80 years later, it was found that terrein inhibits 
breast cancer by induction of apoptosis with a median inhibitory concentration (IC50) value of 1.1 
nM in MCF-7 cell line. That makes terrein 100-fold more potent than taxol against this cell line 
[30].  
Figure 2. Small antifungal polyketides with anticancer activity: (a) Terrein, (b) Brefeldin A, and 
(c) Griseofulvin. 
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Brefeldin A (Figure 2b), another small antifungal [31,32] polyketide was identified as inducer 
of apoptosis in leukemia, colon, prostate, cervical, breast, and lung cancer cell lines almost 40 
years after it was discovered [33–37]. The inhibiting effect of brefeldin A was demonstrated with 
IC50 values between 6.3 and 110 nM [36,37]. In this PhD project the activity of brefeldin A 
towards CLL cells is discussed in section 2.1 (paper 2). 
Another known antifungal [38,39] compound, griseofulvin (Figure 2c), was discovered in 
1939 [40] but first connected to cancer 30 years later [41]. In 2007, it was furthermore shown to 
inhibits centrosomal clustering in human squamous cancer SCC-114 cell line with an IC50 value 
of 35 µM [42,43]. 34 analogs has been synthesized for a structure-activity-relationship (SAR) 
study and the synthetic analog GF-15 increased the inhibitory effect of centrosomal clustering in 
the SCC-114 cells 39-fold with an IC50 value of 0.9 µM [44]. 
 
Cyclic di-peptides called diketopiperazines are some of the more potent anticancer compounds 
and are in general known as cell cycle inhibitors of the G2/M phase [45]. The diketopiperazine 
fumitremorgin C (Figure 3a) was found active against human leukemia P-388 cell line with a 
medial effective dose (ED50) value of 10.3 µM and the analog 12,13-dihydroxyfumitremorgin C 
has antiproliferative effects on human leukemia U-937 and human prostate cancer PC-3 cell lines, 
with IC50 values of 1.8 and 6.6 µM, respectively [46,47].  
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Figure 3. Diketopiperazines with anticancer activity. (a) Fumitremorgin C, (b) Phenylahistin, and 
(c) Emestrin A. 
 
 
Another diketopiperazine, phenylahistin (Figure 3b), that was isolated as a mixture of 
enantiomers [48]. (−)-Phenylahistin was more active than (+)-phenylahistin against dermal, lung, 
ovary, leukemia, breast, and colon cancer cell lines with IC50 between 0.18 and 3.7 µM [49]. A 
synthetic analog, plinabulin displays very potent activity against human prostate carcinoma cell 
line and has now entered phase II clinical trials [50]. Recently, more than 60 synthetic analogs of 
plinabulin have been designed and synthesized. The more active analog with a benzoyl group 
coupled on the phenylalanine (Phe) unit was 10-fold more active than plinabulin with an IC50 
value as low as 1.4 nM [50]. 
Another group of diketopiperazines with anticancer activity contain a poly-sulfide bridge in 
the diketopiperazine ring. The antifungal [51] compound emestrin A (Figure 3c) inhibits human 
leukemia with an IC50 value of 83.5 nM [52]. Eight structural analogs of emestrin A were later 
isolated and found to have strong antiproliferative effects on the human prostate cancer cell line 
with IC50 values down to 9.3 nM for the more potent emestrin C. Furthermore, it was proven that 
the activity decreased when the macro cyclic ring was opened and the polysulfide bridge in the 
diketopiperazine was absent [53]. The activity of emestrin A towards CLL cells are addressed in 
section 2.1 (paper 2). 
 
The ophiobolins are a family of naturally occurring sesterterpenoids, currently constituting  35 
known analogues [54–58]. They all consist of a C25 skeleton with a dicyclopenta[a,d]cyclooctane 
ring system. Some ophiobolins have an extra ring incorporated, for example ophiobolin A (Figure 
4), forming a tetra-cyclic structure [59].  
Figure 4. Ophiobolin A 
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Ophiobolins exhibit a broad spectrum of inhibitory activity against cancer cell lines, including 
lung cancer, breast cancer, colon cancer, melanoma, leukemia and ovarian cell lines with IC50 
values between 0.06 and 0.3 µM [60,61]. In 2012 the novel ophiobolin O was discovered and it 
was found to inhibit breast cancer and leukemia cell lines with IC50 values of 17.9 and 4.7 µM, 
respectively [55,56]. In 2013 the novel 3-anhydro-6-hydroxyophiobolin A was isolated and found 
active against lung cancer and leukemia cell lines with IC50 values of 6.5 and 4.1 µM, respectively 
[57]. This PhD study discusses in detail the activity of the ophiobolins towards CLL cells (chapter 
3, paper 2). 
 
A group of compounds that are biosynthesized by incorporation of amino acids into a core 
polyketide part is the cytochalasins and the chaetoglobosins (paper 1). The cytochalasins contains 
a Phe coupled to the polyketide chain where the chaetoglobosins have an tryptophan (Trp) moiety 
[62,63]. Many of the cytochalasins have shown inhibitory activities towards lung, ovarian, colon 
cancer as well as human leukemia with cytochalasin E (Figure 5a) as one of the most potent 
analogs [64,65]. The activity of three cytochalasins towards CLL cells are discussed in chapter 4 
(paper 3). 
Figure 5. (a) Cytochalasin E and (b) Chaetoglobosin B. 
 
The chaetoglobosins showed activity against cancer cell lines as well. Of the more potent ones 
was chaetoglobosin B (Figure 5b) that inhibited human breast cancer cell line with an IC50 value 
of 3.0 µM [66] and chaetoglobosin D that inhibited breast- and adenocarcinoma cancer cell lines 
with IC50 values between 3.4 and 12.2 µM [66]. Most recently chaetoglobosin A was found to 
induce apoptosis in CLL cells with a median lethal concentrations (LC50) value of 2.8 µM [67]. 
 
1.2 Screening Towards Chronic Lymphocytic Leukemia (CLL) 
Many of the anticancer compounds used in clinical treatment today are general cytotoxic, yet 
they kill cancer cells more efficiently than healthy cells in the body. The activity of these 
compounds is often based on cells that divide very fast such as most cancer cells [68]. Side effects 
arise do to the fact that other cells for example hair follicles and bone marrow divide rapid as well 
and consequently become targets [68]. Many of these chemotherapeutics has been approved in 
cancer treatment despite severe side effects due to the critical and lethal consequences of cancer. 
Even with a high tolerance level of side effects in cancer treatment, most general cytotoxic 
compounds are not compatible with clinical applications and consequently most drug discovery 
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approaches today make a huge effort in development of selective target molecules or ‘magic 
bullets’ [21,43,68,69]. Cytotoxic response towards target cells in an assay may originate from 
large amounts of undesired general cytotoxic compound found in most fungal extract [70–72], 
which may mask the activity of compounds with selective activity present only in lower 
concentrations [73]. One way to address general cytotoxicity and recognize ‘magic bullets’ the 
extracts is through a orthogonal screening approach where fractions/single compounds are 
screened towards an array of targets cells including healthy cells. The bio-guided separation is 
then directed towards fractions that do not target healthy cells and with activity against single cell 
lines. This application is though debatable regarding crude extracts as they might contain both 
general cytotoxic compounds as well as compounds with selective activity. 
Another way of facilitating ‘magic bullets’ is through phenotypic drug discovery where a 
mechanism unique for the cancer cells is targeted [74]. Inhibition of centrosomal clustering 
targeting a special mechanism unique for cancer cells is one example of phenotypic drug 
discovery [43]. 
Bioassay-guided separation of fungal extracts includes screening of various types of samples, 
from very complex mixtures in the crude extracts to the pure compound. This variety of samples 
require a very robust assay that is sensitive from the very low to the high concentrations with a 
minimum of both false negative and false positive samples [75]. Differences in concentrations of 
compounds added to the assay complicate the interpretation of the results since a higher response 
may be observed for a moderate active compound in high concentrations compared to a very 
potent compound in low concentration. 
 
The screening towards CLL cells in this PhD project is based on two complementary 
bioassays, the cell viability assay, which is a rough measurement of the effect on the CLL cells 
and the apoptosis assay, which is a co-cultured assay measuring apoptotic cell death of the cells. 
CLL cells are uncultivable and whole blood samples are obtained directly from patients that 
matched the standard diagnostic criteria for CLL for both assays (paper 2). 
Cell viability is evaluated using CellTiter-Glo® assay providing fast results that show the 
effect on CLL cells in vitro of fractions and single compounds. The CLL cells are only supported 
by conditioned media and not directly by the survival-inducing microenvironment of stromal 
cells. Conditioned media is enriched by soluble factors excreted from the stromal cells whereby 
the CLL cells survive in approximately three days, which is sufficient for this assay [14]. The 
CLL cells are exposed to fractions or single compounds in different concentrations and incubated 
for 24 hours. The results are determined by the luminescence signals generated by the luciferase 
reaction (Figure 6) when ATP is present and corresponds to the extent of living cells (paper 2). 
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Figure 6. The luciferase reaction where luciferin is oxidized in the presence ATP and hereby emits 
light catalyzed by the protein luciferase. Luminescence signals is used as a measure for cell 
viability after CLL cells has been exposed to fractions or single compounds. 
 
Complementary and more profound than the cell viability assay is the apoptotic assay. The 
CLL cells are directly supported by the survival-inducing microenvironment of stromal cells in a 
co-culture platform mimicking in vivo conditions. The co-culture platform allows the cells to 
survive for several months in vitro [14]. The CLL cells are exposed to fractions or single 
compounds in different concentrations and incubated for 48 hours. Apoptotic cell death is 
detected by staining with labeled annexin V that detects early apoptosis and 7-amino-actinomycin 
(7-AAD) that detect dead cells. The cell membrane of normal cell contains a strictly asymmetric 
lipid bilayer. The negatively charged phospholipid, called phosphatidyl serine, is located on the 
inside of the cell and the cell is not possible to stain (Figure 7a). The cell membrane of an 
apoptotic cell is flipped a phosphatidyl serine is exposed, which allows Annexin V to stain the 
cell (Figure 7b) [76]. 
Figure 7. Staining of apoptotic cell with labelled Annexin V. (a) The cell membrane of a normal 
cell is not possible to stain with Annexin V since phosphatidyl serine (edged, purple) is on the 
inside of the cell membrane. (b) When a cell become apoptotic parts of the cell membrane is 
flipped inside out and phosphatidyl serine is hereby translocated from the inner to the outer side 
of the plasma membrane. This flipping allows staining with labeled annexin V due to the exposure 
of phosphatidyl serine (edged, purple) in the apoptotic cell. Figure obtained from Van Engeland et 
al. [76]. 
 (a) (b) 
 
The cell membrane of a cell that die by apoptosis is opened up and DNA is exposed to the 
media and allow staining with 7-AAD that binds directly to DNA and indicate cell death [77]. 
The double-labeling enables discrimination of early apoptotic cells labeled with annexin V solely, 
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and dead cells which are positive for both annexin V and 7-AAD [76–78]. To study the 
progression of and confirm induction of apoptosis, active caspase-3 is stained using BD 
Cytofix/CytopermTM. Active caspase-3 indicates the final steps of apoptosis [77,78]. 
1.3 Screening Approach and Profiling of Natural Products 
Fungal extracts are often complex mixtures of secondary metabolites of unknown chemical 
compositions where the compound(s) responsible for activity is unknown. The goal for the natural 
product chemist is to reduce time from the bioactivity is observed to the identification of the 
active compound(s). Consequently, establishing a suitable strategy is essential to any screening 
program [79]. It is possible to distinguish between bio and targeted guided screening strategies. 
Bio-guided screening relies on discovery of compounds targeting a specific disease or biological 
mechanism. The setup requires high chemodiversity and hereby a high potential of discovering 
novel compounds but also include the risk of overlooking compounds with other activities. The 
targeted-guided screening strategy depends on few extracts tested towards many diseases or 
biological mechanism [73,80]. In this PhD project both bio-guided and target-guided screening 
approaches are applied. The target-guided approach based on MS and NMR, respectively is 
described in chapter 4 and 5 (paper 3 and 4). 
The bio-guided approach was combined with dereplication based on the analysis of the 
spectroscopic data generated from state-of-the-art UHPLC-DAD-HRMS. The bioactivity is 
followed in each step from crude extract to single compound with activity (paper 2). In a 
preliminary screen, the selection of fungi is essential and needs to represent as large a biodiversity 
as possible, with the hope of an equally high chemodiversity (paper 2) [79]. The fungal collection 
at DTU Systems Biology covers a huge biodiversity with approx. 30,000 fungal strains capable of 
producing hundred thousands of compounds. One strategy to increase chemodiversity for rapid 
bio-testing is to select strains representing a wide variety of species with a limited number of 
strains from each species [79,81]. The spectrum of compounds produced by the individual strains 
can further be varied and increased by the ‘one strain – many compounds’ (OSMAC) approach, 
through variation of culture conditions [82]. A large number of fungi cultivated under different 
conditions can be extracted in micro-scale by a very fast procedure leaving enough extract for 
both HPLC-DAD-HRMS and bioassay. Results from the bioassay provide an initial idea of the 
bioactivity of each extract. Extracts with the most potent or selective bioactivities are selected for 
large scale incubation to pursue the observed bioactivity. Small scale prefractionation can be very 
helpful to lower the complexity of the crude extract and to avoid that active compounds are 
overlooked due to masking or concentration issues and. E-SPE applying an array of orthogonal 
separation techniques combined with bioassay has proven to be very powerful in prefractionation 
of fungal extracts [83]. 
Dereplication (section 1.4) is a rapid method for tentative identification of known NPs, based 
on detailed chemical analysis before unnecessary time is spent on rediscovery of already known 
compounds. New strategies and methodologies for fast dereplication have been developed within 
the last decade. The performance of mass spectrometers is continuously improving, including 
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easy access to both positive and negative ionization spectra even during fast UHPLC resulting in 
tentative identification of a potential active candidate. Information obtained from E-SPE (section 
1.5) functions as preliminary chemical characterization and as guidance for the preparative 
isolation of a single compound. 
Isolation is important to verify the activity of the pure compound and, if novel to elucidate the 
structure by nuclear magnetic resonance (NMR) spectroscopy. The absolute configuration of a 
compound can be messured by optical rotation or optical rotatory dispersion-circular dichroism 
(ORD-CD). Alternatively, if a suitable crystal can be obtained, X-ray crystallography can be 
applied for both structure elucidation and absolute configuration. This approach may result in new 
drug hits and following optimization of a drug lead e.g. through semi-synthetic analogs and 
bioavailability considerations etc. 
1.4 MS-based Dereplication 
Fungal extracts are often very complex mixtures of NPs due to mixed biosynthetic origin 
[79,84,85] and UHPLC-DAD-HRMS-based dereplication is an approach that ensures a high 
throughput and reproducibility of complex fungal extracts. This approach is based on the 
monoisotopic mass found in the mass spectra and hereby the elemental composition of a 
compound [86]. This part of the process is prone to error since the mass spectra is easily 
misinterpreted due to strong adduct ions such as the sodiated adduct, [M+Na]+, or the ammoniated 
adduct, [M+NH4]+, which may lead to false identification of the pseudo molecular ion, [M+H]+. 
Adduct patterns can be identified through mass differences between peaks in the mass spectra 
[86]. Mass accuracy and isotope ratio are vital for MS-based dereplication. Currently state-of-the-
art HRMS has a mass accuracy of typically 1-5 ppm and accuracy of isotope ratio of 1-2 %, 
which drastically decreases the number of potential elementary compositions found for each peak. 
The formula(s) generated from the monoisotopic mass is subsequently used as a query in an 
appropriate database for example AntiBase2012 (40,066 compounds), which is a comprehensive 
database for NPs from microorganisms [87]. The high mass accuracy ensure that database 
searches are conducted with the fewest possible candidates [86,88]. The number of compounds 
with a given elementary composition can vary a lot and candidate elimination on the basis of for 
example ultra-violet (UV) chromophore and retention time may be necessary [86]. Small 
molecules in particularly polyketides and alkaloids often contains conjugated double bonds that 
results in more or less unique UV-chromophores. The UV data from target peaks are matched 
against database for tentative identification of NPs [79,89]. The use of UV spectral information is 
often important in the dereplication process for prioritizing between the MS-generated candidates 
[90,91]. The high resolution of each peak in UHPLC chromatograms has made it easier to obtain 
a UV spectrum of practically all compounds even in complicated mixtures such as fungal extract. 
This makes UV detection a readily accessible technique that is relevant in drug discovery [79]. 
The combined information gained from the dereplication process is used to direct the research and 
may function as an early stop-or-go decision to avoid spending time on rediscovering compounds. 
DTU Systems Biology 
Chemical Biology of Microbial Anticancer Natural Products 
11 
 
It is very important to be incisive and balance these early stop-or-go decisions to increase the 
possibility of discovering novel anticancer skeletons. 
 
1.5 Prefractionation by explorative solid phase extraction (E-SPE) 
Prefractionation of complex crude fungal extracts is important to lower the complexity of the 
extract, increasing the relative concentration above the screening threshold, or even unmasking 
selectively active compounds [73,92]. Additionally, prefractionation can provide preliminary 
chemical characterization of interesting compounds in the fractions. E-SPE is one approach of 
prefractionation, which use small pre-packed columns with orthogonal stationary phases such as 
reverse phase (RP), normal phase, size-exclusion, and ion-exchange resins [83,93]. The goal of 
applying different SPE columns is to identify a column where a target molecule is selectively 
absorbed on the resin and unwanted compounds are eluted followed by a second step where the 
concentrated target molecule is eluted. 
Traditionally, RP chromatography has been the favored choice for separation of NPs but co-
eluting interferences of several compounds are often a huge problem due to the complexity in 
fungal extracts. Co-eluting interferences can be reduced or even prevented by choosing 
orthogonal purifications strategies [83]. The use of orthogonal stationary phases makes it possible 
to fully separate compounds with different functionalities even though they would co-elute on 
traditional RP chromatography (section 2.1, paper 2). New insights of the chemical 
functionalities of the NPs in the extract can be gained by this method and guidelines for 
preparative scale isolation strategies may be provided. Furthermore, the small scale E-SPE 
approach provides small scale fractions for bioassay [83]. The E-SPE strategy that builds on ion-
exchanger columns for example strong anion-exchanger (SAX), mixed mode anion-exchanger 
(MAX), and strong cation-exchanger (SCX) (Figure 8) has proven to be very powerful due to the 
relative high percentages of ionizable functional groups in fungal NPs [83]. The mixed mode of 
the Oasis MAX® column possesses both RP and anion-exchange functionalities. The MAX 
column is able to retain both strong and weaker anions compared to the SAX column that only 
retrains strong anions primarily carboxylic acids [83,94].  
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Figure 8. Optimized collection of ion-exchangers (SAX, MAX and SCX) and normal phase (diol 
and amino) SPE columns in the E-SPE setup. The orthogonal stationary phases of the columns 
enables different selectivity of an extract. Figure adapted from Maria Månsson. 
 
The E-SPE setup applied in this project has been developed according to the original paper by 
Månsson et al. [83]. Orthogonal to ion-exchangers are normal phase columns for example with 
diol- or amino-resin, which have been introduced to the protocol instead of size chromatography 
(LH-20) (Figure 9). The amino column has a good ability for retaining more polar compounds as 
well as proton donors for example alcohols and phenols. Compared to the amino, the diol 
stationary phase is very similar regarding separation but with a weaker retention ability compared 
to the amino column [95]. The reason for this adjustment is primarily based on practical 
arguments. LH-20 columns are not commercial available contrary to pre-packed diol and amino 
columns. The requirement of column packing of the LH-20 column is time-consuming and 
complicates the E-SPE setup especially for numerous extracts. Additionally, the pre-packed 
columns are more suitable for automation by for example SPE workstations. The combination of 
the SPE columns in the E-SPE approach offers a combined analytical and biological indication of 
the functionality and polarity of the active compound in a crude extract. The E-SPE approach 
opens the opportunity for comparative dereplication where peaks from inactive fraction are 
eliminated by comparison to chromatographic peaks in the active fractions. This results in a 
reduced number of peaks to be dereplicated compared to the crude extract and hereby time saved 
(paper 2) [83].  
SAX MAX SCX DIOL Amino 
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 Chapter 2 
Discovery of Fungal Secondary 
Metabolites Targeting CLL 
The discovery of NPs with activity towards CLL was based on the great chemodiversity found 
at DTU Systems Biology and the CLL/stromal cell co-culture platform developed at DKFZ. In a 
screening campaign that covered 289 crude fungal extracts the activities in nine of the most active 
extracts were pursue (Figure 9) through dereplication combined with E-SPE and bioassay (paper 
2). The 289 fungal extracts were prepared from cultivation of 137 fungal strains (Table S1 in 
paper 2 supplementary file) on a selection of solid media at variable temperatures in accordance 
with the OSMAC approach [82]. The extracts were prepared by the micro-extraction method 
developed by Smedsgaard [96]. To obtain a representative sample of the fungal colonies the plugs 
were taken across the colony. 61 extracts showed activity towards CLL cells (Table S2 in paper 2 
supplementary file). Nine of the candidates that displayed the highest level of activity were 
selected for further bio-testing. Large-scale extracts were prepared from incubation on the media 
supporting the highest level of bioactivity, and the extracts were prefractionated before further 
testing. 
Figure 9. Screening set-up: 289 fungal extracts (from 137 fungal strains) were tested for cytotoxic 
activity towards CLL cells. From the 61 extracts with activity the nine candidates that displayed 
the highest bioassay activity were selected for further bio testing and single compound isolation in 
a large scale. 
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2.1 Comparative Dereplication Based on Explorative Solid Phase Extraction 
The E-SPE strategy was applied to a series of highly complex extracts, i.e. P. brasilianum 
(IBT 22244), P. decumbens (IBT 11843), P. cluniae (IBT 21051), Aspergillus sp. (Emericella-
like state) (IBT 22838), and Fusarium compactum (IBT 9034). 
 
Penicillium brasilianum 
The extract of P. brasilianum (IBT 22244) was very potent against CLL cells in vitro (≈ 5 
ng/ml) with the active compound retained on both anion-exchangers (SAX and MAX) as well as 
the two normal-phase columns (diol and amino), while unretained on the cation-exchanger (SCX). 
The combined biological and chromatographic information lead to the conclusion that the 
bioactive compound contained a strong anion. The large scale extract was fractionated on a SAX 
column. Comparison of chromatographic peaks from the fraction that contained neutral/basic 
compounds (Figure 10a) and the fraction with acidic compounds (Figure 10b), showed that the 
anion-exchange was extremely selective, removing the majority of inactive compounds from the 
extract. 
Figure 10. E-SPE strategy based on a SAX column to separate co-eluting compounds in the crude 
extract of P. brasilianum. (a) UHPLC chromatograms of the SAX fraction that contained 
neutral/basic compounds. The ion trace of compound I (m/z 462.2387) is marked with red. (b) 
UHPLC chromatogram of the SAX fraction that contained acidic compounds. The ion trace of 
compound IV (m/z 548.1916) is marked with blue. (c) In the crude extract compound I and IV 
were co-eluting on a RP C18 column. 
 
In the initial extract, the two compounds I and IV co-eluted on a C18 RP column (Figure 10c). 
These were easily and quantitatively separated on the SAX column due to the difference in 
charged functionalities. Only three major acidic compounds were left in the bioactive fraction 
(Figure 11a), which significantly simplifying the subsequent dereplication and purification 
process. Based on comparative HRMS analysis, compound II was immediately eliminated due to 
its presence in the inactive neutral/basic fraction. The molecular formula of compounds III and 
IV were established as C15H10O9 (-0.7 ppm) and C30H31NO10 (-0.2 ppm), respectively. These were 
used as queries in AntiBase2012 (Figure 11b) [87]. Compound II had no hits in AntiBase2012 
that contained a strong anion, thus likely being a novel compound. Compound IV had two hits in 
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AntiBase2012. One of the candidates had no strong anion and was consequently eliminated that 
left viridicatumtoxin as the only candidate (Figure 11b). 
Figure 11. Dereplication of the P. brasilianum extract (a) UHPLC chromatogram of the active 
SAX fraction that contained the acidic compounds as well as UV and MS spectra of the potential 
candidates. (b) Hits in Antibase2012. 
 
The identity of viridicatumtoxin as compound IV was confirmed 1) by comparison to the 
retention time and UV spectrum of an in-house standard from our database (1559 standards), 2) 
by the fact that it hold a strong anion, and 3) by having similar 1H NMR chemical shifts as 
published for viridicatumtoxin [97]. Viridicatumtoxin was isolated as one of the most cytotoxic 
compounds tested towards CLL cells in this screening campaign with a LC50 value between 0.7 
and 3.5 nM. Unfortunately, further testing revealed that the activity was not specific, as both CLL 
and stromal cells were targeted. Results from Annexin-V PE apoptosis assay displayed that the 
CLL cells did not die by apoptosis but more probably by necrosis though this suggestion not 
clearly can be distinguished by this assay. 
 
Penicillium decumbens 
One flash fraction (70 % organic) from the P. decumbens (IBT 11843) extract was found 
active towards CLL cells (≈ 200 ng/ml). Further E-SPE analysis showed that the active compound 
 
(b) 
III: Unknown  IV: Viridicatumtoxin 
Query No. of candidates  Query No. of candidates 
C15H10O9 1  C30H31NO10 2 
Strong anion 0  Strong anion 1 
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was retained on SAX and MAX columns indicating the presence of a strong anion. By 
comparative dereplication tentative identifications of calbistrin A (Figure 12a) and B as well as 
their precursor (or decomposition product) versiol (Figure 12c) were established within the 
fraction.  
Figure 12. Structure of (a) Calbistrin A, (b) Calbistrin C, and (c) Versiol. 
 
The MS based dereplication was complicated by the fact that the [M+H]+ ion was absent in the 
mass spectra of calbistrin A and B. The presences of strong adduct- and fragmentation patterns 
consisting of the sodiated, [M+Na]+, and the ammoniated, [M+NH4]+, adducts as well as neutral 
loss of one and two water molecules assisted the establishment of the monoisotopic masses and 
hereby the molecular formulas of calbistrin A and B. The identity of calbistrin A was confirmed 
by comparison of retention time and UV spectrum to an in-house standard as well as the presence 
of a carboxylic acid. The tentative identity of calbistrin B was confirmed by comparison of the 
UV spectrum to that of calbistrin A (Figure 12a). Testing of calbistrin A from our in-house 
metabolite collection showed general cytotoxic activity towards CLL and healthy cells. 
Comparative experiments with calbistrin C (Figure 12b) from the metabolite collection did not 
induce cell death, indicating that the pharmacophore is located in the versiol part (Figure 12c) of 
the molecule. 
 
Penicillium cluniae 
A bioactive flash fraction (activity approx. 100 ng/ml) from a P. cluniae (IBT 21051) extract 
was likewise subjected to E-SPE. Here, the bioactivity profiled revealed that the active compound 
was a medium to apolar compound with no charged functionalities. By comparative dereplication, 
the active compound was tentatively identified as brefeldin A (Figure 13a), which was in 
accordance with the profile revealed by E-SPE. The identity of brefeldin A was confirmed by its 
retention time and UV spectrum compared to an in-house standard. Brefeldin A is a known 
anticancer compound [34,98] and commercially available, thus the activity was easily confirmed 
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in the CLL assay. Unfortunately, the compound displayed general cytotoxic activity towards CLL 
cells (0.39-1.56 µM) and stromal cells in the same concentrations. 
Figure 13. Examples of CLL active compounds discovered by E-SPE and comparative 
dereplication (a) Brefeldin produced by P. cluniae, (b) Emestrin A produced by Aspergillus sp. 
(Emericella-like state), and (c) Neosolaniol monoacetate produced by F. compactum. 
 
 
Aspergillus sp. (Emericella-like state) 
The E-SPE strategy of the bioactive extract (≈ 40 ng/ml) from Aspergillus sp. (Emericella-like 
state, IBT 22838) resulted in retention of the bioactive compound on the amino normal phase SPE 
column. Fast comparative dereplication based on UV spectra and retention times of in-house 
standards as well as comparison of 1H NMR chemical shifts [99] led to an identification of the 
known antifungal and anticancer compound, emestrin A (Figure 13b) [51,52,98]. The pure 
emestrin A isolated form the active fractions showed cytotoxic activity towards CLL cells and 
stromal cells at the same concentration levels. Accordingly, emestrin A is regarded as a generally 
cytotoxic compound with no therapeutic window [100]. No further work was pursued on the 
Aspergillus sp. (Emericella-like state) extract. 
 
Fusarium compactum 
The F. compactum (IBT 9034) extract displayed cytotoxic activity towards CLL cells at 
approximately 200 ng/ml. The bioactive compound from F. compactum was retained on both the 
diol and amino columns in the E-SPE prefractionation experiment. Comparative dereplication 
reviled only one candidate that might be responsible for the activity. The compound was 
tentatively identified as the known trichothecene, neosolaniol monoacetate (Figure 13c). The 
compound was isolated and the 1H NMR data was compared to the literature for final 
identification of neosolaniol monoacetate [101]. Neosolaniol monoacetate was tested in the CLL 
assay and found as a generally cytotoxic, apoptosis inducing compound, why no further work was 
performed on the F. compactum extract.  
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Penicillium jugorum 
The last example of bio-guided isolation based on E-SPE is demonstrated by the P. jugorum 
(IBT 22779) extract. The compound responsible for the activity was found in the fractions eluted 
by 60-70 % organic. Comparative dereplication leads to 4 potential candidates responsible for the 
activity. Further fractionation by the E-SPE approach eliminates compounds possessing anionic 
and cationic functionalities and comparative dereplication left cycloaspeptide E (Figure 14a) as 
the only potential candidate. 
 
Figure 14. Structures of (a) cycloaspeptide E (tentative active), (b) Cycloaspeptide D (inconclusive 
data on activity), and (c) Cycloaspeptide A (tentative inactive) 
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In our in-house metabolite collection we had the analog cycloaspeptide D (Figure 14b). To 
save time on purification of cycloaspeptide E we tested cycloaspeptide D to get an indication of 
the activity of the compound family. The results indicated that cycloaspeptide D induced 
apoptosis in CLL cells with a therapeutic window of activity around 18 µM. The results of 
cycloaspeptide D were considered inconclusive and cycloaspeptide D was regarded inactive due 
to the high concentration. Dereplication of some of the inactive fractions revealed the presence of 
cycloaspeptide A (Figure 14c) indicating that not all cycloaspeptide displayed activity towards 
CLL cells. The structural differences between cycloaspeptide E, D and A are found in the third 
and fourth position. In the third position have cycloaspeptide E and A leucine (Leu) where 
cycloaspeptide D has valine (Val). In the fourth position cycloaspeptide E has N-methylated-
phenylalanine (NMe-Phe) while cycloaspeptide D and A have N-methylated-tyrosine (NMe-Tyr). 
If cycloaspeptide E is the compound responsible for the activity in the crude extract of P. jugorum 
the structural observations indicate that the pharmacophore is present at NMe-Phe moieties. Due 
to the time frame of the work presented herein, cycloaspeptide A in the inactive fraction was not 
discovered until very late in the process and no time was left to cultivate the fungus in large scale 
and isolate cycloaspeptide E. The E-SPE approach with the optimized collection of ion-
exchangers and normal phase SPE columns has turned out to be a good combination to evaluate 
and follow bioactivity of fungal extracts. 
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2.2 MS Based Dereplication of Penicillium pulvillorum 
The extract of P. pulvillorum (IBT 22393) was among the candidates that displayed the highest 
level of activity (≈ 1.25 µg/ml). The first five flash fractions (ranging from 15-40 % organic) were 
tested active against CLL cells in vitro. LC-DAD-HRMS revealed one major component shared 
between these fractions, with an elementary composition of C8H10O4 (-0.7 ppm mass accuracy). 
AntiBase2012 [87] revealed penicillic acid as a likely candidate responsible for the observed 
activity (Figure 15). The tentative identification of penicillic acid was confirmed by comparison 
of the retention time to a standard from our in-house metabolite database as well as comparison of 
1H and 13C NMR chemical shifts to the literature [102].  
Figure 15. Dereplication of penicillic acid from P. pulvillorum mass spectrum of penicillic acid 
[87]. The mass spectrum shows a widespread adduct pattern that besides [M+H]+ contains ions 
that corresponds to neutral loss of water [M+H-H2O]+ and the sodiated adduct [M+Na]+, as well 
as the corresponding dimeric ions [2M+H]+, [2M+H-H2O]+, and [2M+Na]+. 
 
To verify the observed anti-leukemic activity in the extract, penicillic acid was purified and 
tested on CLL cells, resulting in induced cell death in both CLL and stromal (HS-5) cells. No 
further work on this extract was done as penicillic acid is regarded as generally cytotoxic 
compound [102]. 
 
2.3 UV Based Dereplication of Penicillium pinicola 
The P. pinicola (IBT16545) extract was fractionated by RP C18 chromatography and fractions 
9-12 (70-90 % organic) were found active against CLL cells in vitro at concentrations of 
approximately 1 mg/ml. The active fractions were analyzed by LC-DAD-MS and comparative 
dereplication exposed four compounds solely present in the active fractions (Figure 16, compound 
A-D). All other compounds in the active fractions were present in the inactive fractions as well. 
The first compound (A) was tentatively identified as cycloaspeptide A by the pseudomolecular 
ion, [M+H]+, and the sodiated adduct, [M+Na]+, in the mass spectrum. The identity was 
confirmed by compression of retention time and UV spectrum to or in-house metabolite database. 
Due to the fact that cycloaspeptide A was found in inactive fractions from the P. jugorum extract 
(section 2.1) this compound was eliminated as a potential candidate for the observed activity. 
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Figure 16. Dereplication of compounds in the active fraction from the P. pinicola extract. 
Cycloaspeptide A (A), ML-236C (B), Compactin (C), and 4a,5-dihydrocompactin (D). 
 
The remaining three compounds (B, C, D) displayed similar UV chromophores (Figure 16). 
The UV spectra were compared to our in-house metabolite database and recognized as the statins 
family of compounds, primarily known for their ability to inhibit synthesis of cholesterol 
[103,104]. By comparison of the retention times, accurate masses, and UV spectra it was possible 
to identify two of the statins as compactin (C) and 4a,5-dihydrocompactin (D), respectively. The 
remaining statin (B) was not in our in-house database and therefore only tentatively identified as 
the statin ML-236C. 
The statins were connected to the observed activity towards CLL cells due to the high 
abundance in the active fractions. The statin family has previously been connected to CLL due to 
the suggestion that CLL cell proliferation depends on cholesterol synthesis [105]. The synthetic 
analog simvastatin has been included in one clinical study though patients did not significantly 
benefit from this drug [105]. Statins are commercially available, thus to evade time-consuming 
purification we bought and used compactin and simvastatin to explore the activity of the statin 
family towards CLL cells in vitro. In this study neither compactin nor simvastatin exhibited 
activity towards the CLL cells. 
The contradictory results of the statin family being responsible for the observed activity in the 
crude extract are inclusive. A successive E-SPE analysis [83] of the active fraction resulted in the 
loss of activity. This loss of activity may be due to treatment histories of patients, lack of synergy 
effects or instability of the active compound(s). 
Treatment histories of patients might be important for the assay results. It is not possible to 
grow CLL cell lines in vitro due to their general defect to divide and undergo mitosis. 
Consequently, the CLL cells applied in the bioassay are extracted from whole blood samples 
obtained directly from patients diagnosed with CLL. CLL is generally considered a heterogeneous 
disease resulting in various treatment histories for the individual patients. The CLL cells applied 
in the bioassay are therefore very heterogeneous and have a huge influence on the results from the 
bioassay. The subsequent lack of activity observed from the P. pinicola extract might be due to 
the screening of cells from different patients with different treatment histories. On a general level 
this variety of the cells demands a higher number of replicates of the assay to ensure the precision 
of the results. 
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Synergy effects have previously been described for compounds of the statin family where 
lovastatin has synergistic antifungal activity with azoles [106,107]. Similar synergistic effects 
might cause the observed activity towards the CLL cells and the subsequent loss of activity after 
further fractionation. 
Instability and degradation of the active compound could be another potential explanation to 
the lost activity. 
To follow these theories would be very interesting and perhaps lead to the identification of an 
effective treatment towards CLL. The time did not allow further investigation of these topics 
though it might be a convincing route. 
 
2.4 Conclusion 
In conclusion, our combined bio-guided, E-SPE, and dereplication based discovery approach 
has proven to be effective for fast dereplication and discovery of bioactive fungal natural products 
that target CLL cells. Comparative testing of active extracts on CLL cells as well as healthy cells 
allowed the exclusion of compounds with general cytotoxic activity. The optimized collection of 
ion-exchangers and normal phase SPE columns in the E-SPE setup has turned out to be a good 
combination to evaluate and follow bioactivity of fungal extracts. In the eight bioactive extracts 
discussed in this chapter, the compounds responsible for the activity were tentatively identified by 
dereplication, and the activities towards CLL cells were verified by testing the pure compounds in 
six of the extracts. The six active compounds, penicillic acid (P. pulvillorum), viridicatumtoxin 
(P. brasilianum), calbistrin A (P. decumbens), brefeldin A (P. cluniae), emestrin A (Aspergillus 
sp. (Emericella-like state)), and neosolaniol monoacetate (F. compactum), were all known and 
general cytotoxic. These projects were closed as soon as the activities of the compounds were 
confirmed. In general, cytotoxic compounds are only suitable as anti-cancer pharmaceuticals if 
they selectively target the cancer cells and not healthy cells, or at least have a higher impact 
towards the tumor cells. In the two remaining extracts cycloaspeptide E (P. jugorum) and the 
statin family of compounds (P. pinicola) were tentatively identified as candidates for the activity 
observed in the crude extract. 
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 Chapter 3 
Ophiobolins Targeting CLL Cells 
Discovery of ophiobolins (Figure 17) and further activity optimization of the ophiobolins is 
addressed through the chemistry of closely related fungal species to obtain more analogues and 
discuss their pharmacophore (paper 2). 
The bioactive extract from a new species in Aspergillus section Usti (IBT 18591) was more 
selective than the other active extracts from the initial screen and in consequence selected for 
more detailed investigations. MS- and UV-based dereplication led to the tentative identification of 
the ophiobolin family of compounds. Ophiobolin K and 6-epiophiobolin K (Figure 17) [108] were 
isolated and ophiobolin K was found very potent against CLL cells in vitro. 
Figure 17. Structures of ophiobolin A, 3-anhydro-ophiobolin A, 3-anhydro-6-epiophiobolin A, 
ophiobolin B, ophiobolin C, 6-epiophiobolin G, ophiobolin H, 6-epiophiobolin K, ophiobolin K, 6-
epiophiobolin N, and the new ophiobolin U. 
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Investigation of the anti-leukemic activity and pharmacophore of the ophiobolins in the 
CLL/stromal cell co-culture platform were performed with the purpose of isolating a high number 
of naturally occurring analogs as well as identification of novel analogues. Taking advantage of 
the huge biodiversity available in the IBT culture collection [79], we expanded the biodiversity 
and hereby the expected chemodiversity with 12 closely related Aspergilli from the section Usti 
(Table S7 in paper 2 supplementary file) [109]. Cultures of the 12 new strains were extracted in 
micro-scale [96] to explore their potential for producing ophiobolins. A. insuetus (IBT 28266) and 
A. calidoustus (IBT 25726) were identified as potent ophiobolin producers with one likely novel 
and more known ophiobolins analogs compared to the original strain (Figure 18). 
Figure 18. UHPLC chromatograms of (a) the new species in Aspergillus section Usti (IBT 18591) 
producing ophiobolin K and 6-epiophiobolin K, (b) A. insuetus (IBT 28266) producing the novel 
ophiobolin U together with ophiobolin H, K, C as well as 6-epiophiobolin K and N and (c) A. 
calidoustus (IBT 25726) producing ophiobolin K and C as well as 6-epiophiobolin K and G. 
 
3.1 Structure elucidation of the new Ophiobolin U 
The novel ophiobolin U (Figure 19) was isolated together with ophiobolin H [110] (Figure 17) 
and the rare 6-epiophiobolin N [111] (Figure 17) from the A. insuetus extract, while ophiobolin C 
[112] (Figure 17) and 6-epiophiobolin G [111] (Figure 17) were isolated from the A. calidoustus 
extract. 
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Figure 19. Structure and numbering of ophiobolin U. 
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The structure of the novel ophiobolin U was elucidated by 1D and 2D NMR spectroscopy. The 
1H NMR spectrum of ophiobolin U was closely related to that of ophiobolin K with many 
practically identical chemical shifts (Table 1 and 2). The most remarkable difference between 
ophiobolin U and ophiobolin K was found at C5 that shifted 143.9 ppm upfield from δC 217.0 to 
73.1 ppm in the carbon spectrum, indicating the disappearance of a ketone group. C5 had an 
additional heteronuclear single quantum coherence (HSQC) correlation to a proton at δH 4.91 ppm 
(H5). This significant change indicated a reduction of the ketone (C5) in ophiobolin K to a 
secondary alcohol in ophiobolin U. This reduction was confirmed by the correlation spectroscopy 
(COSY) spin system between H1-H2-H6 in ophiobolin K that in ophiobolin U was expanded with 
a vicinal coupling between the protons at δH 3.02 (H6) and 4.91 ppm (H5) and further a vicinal 
couplings between H5 and the diastereotopic protons at δH 1.87 (H4a) and 2.68 ppm(H4b), 
respectively (Figure 20a). 
Figure 20. (a) Important DQF-COSY couplings and (b) important HMBC connectivities in the 
novel compound ophiobolin U. 
 
The spin systems identified in the DQF-COSY spectrum of ophiobolin U were assembled 
through heteronuclear multiple bond correlation (HMBC) correlations, which also enabled the 
identification of the quaternary carbon atoms. The most important HMBC correlations are shown 
in Figure 20b. The COSY spin systems were connected by HMBC connectivities further 
confirming the presence of the eight-membered ring. HMBC connectivities were found from H5 
DTU Systems Biology 
Chemical Biology of Microbial Anticancer Natural Products 
26 
 
to the quaternary carbons at δC 81.9 (C3) and 142.1 ppm (C7), from the diastereotopic protons at 
δH 1.03 (H1a) and 1.58 ppm (H1b) to C3 and the carbon at δC 54.0 ppm (C10), and finally from 
H9 to C7 and the quaternary carbon at δC 44.1 ppm (C11). The reduction at C5 changed the 
chemical environment of the surrounding carbons (C2, C3, C6, C8 and C21) that were more 
deshielded and therefore shifted 1.8 - 6.5 ppm downfield compared to ophiobolin K (Table 1). 
The remaining chemical shifts in ophiobolin U matched the chemical shifts of ophiobolin K 
(Table 1 and 2). 
Table 1. 13C NMR data for ophiobolin U, ophiobolin K, 6-epiophiobolin K, ophiobolin C, 
ophiobolin H, 6-epiophiobolin H, and 6-epiophiobolin G. (*125 MHz in dimethyl sulfoxide 
(DMSO)-d6, †125 MHz in CDCl3, or ‡200 MHz in CDCl3, δC). 
ophiobolin U‡ K* 6-epi-
K* 
C† H‡ 6-epi-
N‡ 
6-epi-
G† 
1 35.2 34.5 41.0 36.0 35.7 45.6 45.8 
2 51.0 49.2 49.6 50.8 50.9 49.3 49.2 
3 81.9 76.2 74.7 76.6 80.2 179.8 178.1 
4 53.4 53.9 54.7 54.6 50.8 130.0 130.2 
5 73.1 217.0 216.1 217.5 116.0 209.6 208.2 
6 50.5 48.3 48.2 48.4 52.8 49.9 50.0 
7 142.1 140.6 141.5 141.5 138.5 140.1 139.9 
8 164.1 157.6 159.9 163.8 123.6 157.3 158.1 
9 25.6 24.3 30.0 24.7 25.0 31.0 30.9 
10 54.0 53.0 43.1 53.4 55.0 43.1 43.8 
11 44.1 43.3 44.9 43.6 43.6 45.0 45.4 
12 42.0 42.2 44.4 42.6 43.0 44.5 44.3 
13 26.7 25.4 27.1 22.8 26.8 27.1 27.8 
14 47.4 46.2 51.4 45.2 47.2 51.1 52.1 
15 35.9 34.4 31.9 32.7 35.5 31.8 32.6 
16 137.7 136.9 136.0 36.8 138.0 37.1 135.7 
17 122.3 121.7 123.3 26.0 121.7 25.6 124.0 
18 120.2 119.9 120.1 124.3 120.4 124.4 120.0 
19 135.9 134.6 135.3 131.0 135.2 131.6 136.6 
20 26.3 25.7 25.2 25.4 25.4 17.4 17.3 
21 198.1 193.1 194.7 195.9 71.5 193.0 193.0 
22 18.6 18.2 22.8 19.0 18.7 23.1 22.9 
23 20.6 19.6 21.1 16.4 20.4 18.6 21.3 
24 18.3 18.0 17.9 17.6 18.2 17.7 18.2 
25 26.7 25.9 26.1 25.6 26.6 25.7 26.5 
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Table 2. 1H NMR data for ophiobolin U, ophiobolin K, 6-epiophiobolin K, ophiobolin C, 
ophiobolin H, 6-epiophiobolin H, and 6-epiophiobolin G. (*500 MHz in DMSO-d6, †500 MHz in 
CDCl3, or ‡ 800 MHz in CDCl3, δH mult. (J (Hz))). 
Ophiobolin U‡ K* 6-epi-K* C† H‡ 6-epi-N‡ 6-epi-G†
1a 1.03 m 1.14 m 1.58 m 1.26 m 1.36 m 1.18 m 1.15 m 
1b 1.58 m 1.58 m 1.65 m 1.81 m 1.42 m 2.04 dd 
(3.7; 13.2) 
2.03 m 
2 2.30 m 2.25 m 1.91 m 2.38 m 2.26 m 2.71 m 2.66 m 
3-OH   6.51 br.s.     
4a 1.87 dd 
(4.1, 15.1) 
2.35 m 2.21 m 2.49 m 2.10 m 6.11 s 6.04 s 
4b 2.68 dd 
(7.9, 15.1) 
2.50 m 2.77 d (16.0) 2.80 m 2.18 m   
5 4.91 dd 
(4.7, 7.9) 
      
6 3.02 d (9.6) 3.22 d (9.8) 3.04 d (10.8) 3.26 m 3.17 d (9.8) 3.54 d (3.7) 3.40 m 
8 6.94 t (8.5) 7.02 t (8.5) 6.96 m 7.21 m 5.64 br.s. 6.86 dd 
(2.0; 6.3) 
6.80 m 
9a 2.24 m 2.04 m 2.27 m 2.31 m 1.70 m 2.25 m 2.20 m 
9b 2.89 dd 
(8.5, 12.5) 
2.69 m 2.65 m 2.45 m 2.50 dd 
(8.6; 13.8) 
2.71 m 2.93 m 
10 1.55 m 1.56 m 2.46 m 1.67 m 1.60 m 2.72 m 2.63 m 
12a 1.38 m 1.33 m 1.38 m 1.41 m 1.40 dd 
(7.6; 11.7) 
1.42 m 1.43 m 
12b  1.35 m 1.44 m 1.44 m 1.57 m 1.51 m 1.52 m 
13a 1.58 m 1.54 m 1.22 m 1.46 m 1.54 m 1.23 m 1.25 m 
13b 1.78 m 1.69 m 1.57 m 1.55 m 1.76 m 1.58 m 1.67 m 
14 2.09 m 2.09 m 1.87 m 2.36 m 2.05 m 1.75 m 1.89 m 
15 2.72 m 2.72 m 2.61 m 1.65 m 2.68 m 1.42 m 2.55 m 
16a 5.21 t (10.0) 5.23 t (9.5) 5.25 t (9.3) 1.18 m 5.20 m 0.99 m 5.11 t (1.3) 
16b    1.24 m  1.45 m  
17a 6.03 m 5.99 m 6.11 m 1.95 m 5.99 m 1.94 m 6.10 m 
17b    2.00 m  2.07 m  
18 6.00 m 6.04 m 6.09 m 5.09 m 5.98 m 5.12 t (7.0) 6.00 m 
20 1.26 s 1.19 s 1.26 s 1.36 s 1.24 s 2.10 s 2.06 s 
21a 9.26 s 9.14 s 9.12 s 9.23 s 4.48 br.s. 9.30 s 9.26 s 
21b     4.59 d (12.2)   
22 0.99 s 0.91 s 0.77 s 0.90 s 0.90 s 0.86 m 0.85 s 
23 0.91 d (6.7) 0.85 d (6.6) 0.92 d (6.6) 0.78 d (6.8) 0.88 d (6.7) 0.91 d (6.4) 0.97 d 
(6.8) 
24 1.74 s 1.68 s 1.70 s 1.61 s 1.73 s 1.61 s 1.76 s 
25 1.82 s 1.76 s 1.79 s 1.69 s 1.80 s 1.69 s 1.83 s 
 
The stereochemistry of the A/B ring system in ophiobolin U (Figure 21) was assigned based 
on NOE correlations and chemical shifts. The A/B-cis ring system was established by the NOE 
correlations found between the protons at δH 2.30 (H2) and 3.02 ppm (H6), as demonstrated in 
Figure 21. The stereochemistry of C5 was tentatively assigned through strong NOE correlations 
of the diastereotopic protons at δH 1.87 (H4a) and 2.68 ppm (H4b). H4a had NOE correlations to 
the protons at δH 1.26 ppm (H20) and H2, while H4b had a NOE correlation to H5, which 
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indicated that the hydroxy group at C5 was cis to H6. Other important NOE correlations are 
shown in Figure 21.  
Figure 21. Important NOE correlations in ophiobolin U. 
 
The A/B-cis conformation was confirmed by chemical shifts. Earlier reports showed that C1 
and C22 in ophiobolins with A/B-cis ring structure are more upfield compared to ophiobolins 
with A/B-trans ring structure [113]. In ophiobolin U and ophiobolin K, the chemical shifts of C1 
and C22 were more upfield compared to 6-epiophiobolin K, which indicate a A/B-cis ring 
structure in ophiobolin U. Other reports have showed that the A/B-cis ring structure in 
ophiobolins causes a small deshielding (0.2 - 0.3 ppm) for H2 and H8 as well as a small shielding 
(0.3 - 0.6 ppm) for H4 [114]. The 1H chemical shifts for ophiobolin U were inconclusive 
regarding conformation of the A/B ring system. The residual stereocenters of ophiobolin U were 
biosynthesized in the same way as in the known ophiobolins due to the stereospecificity of the 
biosynthetic pathway of the ophiobolins [115,116]. 
The stereochemistry of the A/B ring system of the remaining six ophiobolins (ophiobolin K, 6-
epiophiobolin K, 6-epiophiobolin N, 6-epiophiobolin G, ophiobolin H, and ophiobolin C) isolated 
in this study were confirmed by NOE correlations. Together with the general trend that C1 and 
C22 in the ophiobolins with A/B-cis ring structure were more upfield compared to ophiobolins 
with A/B-trans ring structure [111,113]. The shifting of chemical shifts for H2, H4, and H8 for 
the A/B-cis ring system were more ambiguous due to the small deshielding/shielding in chemical 
shifts and inconclusive for the seven ophiobolins. A comparison of the 13C and 1H chemical shifts 
of all the seven ophiobolins are found in table 1 and 2, respectively (full NMR data is found in 
table S10-S16 in paper 2 supplementary file). 
3.2 Ophiobolins Targeting CLL Cells 
Besides the seven purified ophiobolins: ophiobolin A, ophiobolin B, 3-anhydroophiobolin A, 
and 3-anhydro-6-epiophiobolin A (Figure 17) were bought as standards with the aim of obtaining 
a broader understanding of the SAR of the ophiobolin family against CLL cells. Ophiobolin U 
was unstable and therefore not applied in any bioassay, but the remaining ten ophiobolins were 
tested for their cytotoxic activity towards CLL cells. Ophiobolin A, B, C, and K showed the 
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strongest effects with LC50 values between 1 and 8 nM (results compiled in Table 3 and Figure 
22). Ophiobolin A and B displayed cytotoxic effects towards normal lung fibroblasts in 10 nM 
concentration indicating a possible narrow therapeutic window. Ophiobolin C and K displayed no 
effect towards normal lung fibroblasts in concentrations up to 10 nM (Figure 24). Ophiobolin-
treated cells were further stained with PE-labelled Annexin-V and 7-AAD, or antibodies for 
activated caspase-3 prior to flow cytometric analyses. Thereby, apoptosis was identified as the 
mode of killing of CLL cells. 
 
Table 3. Cell viability activity (LC50) of the 10 ophiobolins towards CLL cells. 
Compound LC50
Ophiobolin A 1 nM 
3-anhydro-ophiobolin A Inactive 
3-anhydro-6-epiophiobolin A Inactive 
Ophiobolin B 2 nM 
Ophiobolin C 8 nM 
6-epiophiobolin G Inactive 
Ophiobolin H Inactive 
Ophiobolin K 4 nM 
6-epiophiobolin K Inactive 
6-epiophiobolin H Inactive 
 
Figure 22. Effects of ophiobolin A, B, C, K and 6-epiophiobolin K on CLL cell viability. CLL cells 
were treated for 24 hours with increasing concentrations of the ophiobolins and cell viability was 
analyzed by CellTiter-Glo® assay measuring each data point as duplicate. Relative cell viability 
compared to DMSO control. 
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 Chapter 4 
Sclerotionigrin A, B and Proxiphomin 
Targeting CLL 
An important and diverse group of fungal anticancer compounds that have caught our interest 
are the cytochalasans due to their wide range of biological functions [62]. In particular this 
includes inhibitory activities towards lung, ovarian, and human colon cancer as well as human 
leukemia [64,65]. Recently, it was demonstrated in our group that chaetoglobosin A, produced by 
Penicillium aquamarinum, selectively induce apoptosis in CLL cells with a LC50 value of 2.8 µM 
[67]. On the basis of the expressed chemodiversity of Aspergillus sclerotieoniger (IBT 22905) it 
was selected for target-guided isolation of cytochalasins. Two new cytochalasins sclerotionigrin A 
and B (Figure 26) were isolated from A. sclerotieoniger together with the known cytochalasin 
proxiphomin [118]. 
Figure 26. Structure of sclerotionigrin A (1), B (2) (relative stereo chemistry) and proxiphomin (3) 
(absolute stereo chemistry). 
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The structure of proxiphomin was tentatively identified through UHPLC-DAD-HRMS based 
dereplication of the crude extract. The pseudomolecular ion, [M+H]+, was recognized from the 
mass spectrum due to the presence of the sodiated adduct, [M+Na]+ and the corresponding 
dimeric adducts [2M+H]+ and [2M+Na]+. The molecular formula C29H37NO2 was established with 
an accuracy of 0.8 ppm through the monoisotopic mass of [M+H]+ of m/z 432.2901. The formula 
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was used as a query in Antibase2012 [87] with one resulting hit, proxiphomin. NMR data and 
optical rotation of proxiphomin matched published data [118]. 
Sclerotionigrin A was purified as a yellow powder. The UV spectrum displayed absorption 
maxima at 210 nm. The positive electrospray ionization (ESI+) spectrum showed a distinct adduct 
pattern consisting of [M+H]+, [M+Na]+, [2M+H]+ and [2M+Na]+. The molecular formula 
C29H37NO3 (12 double-bond equivalents) was gained from HRMS of [M+H]+ (m/z 448.2843) with 
an accuracy of 2.3 ppm. 
The 1H NMR spectra revealed the presence of one amide proton, 15 methines (five which were 
vinylic and five aromatic), six methylene, and three methyls (Table 4). The DQF-COSY spectrum 
of sclerotionigrin A defined three spin systems. The linking between COSY spin systems and 
assignments of the remaining signals and quaternary carbons were accomplished through detailed 
analysis of HMBC experimental data (Figure 27). 
Figure 27. Important HMBC correlations connecting the three COSY spin systems (marked in 
bold) in sclerotionigrin A. The remaining HMBC correlations are found in table 4. 
 
The HMBC correlations from the protons at δH 1.65 ppm (H10) and 7.26 (H27 and H29) to a 
quaternary carbon at δC 137.8 (C25), together with HMBC correlations from the protons at δH 
7.14 (H26 and H30) to the carbon at δC 42.6 (C10) linked two of the spin systems belonging to the 
Phe moiety in sclerotionigrin A. The amide proton at δH 8.00 ppm (H2) displayed HMBC 
correlations to the carbons at δC 54.2 (C3) and 170.6 ppm (C1). Combination of these HMBC 
correlations established the Phe moiety of sclerotionigrin A, which was incorporated on the 
polyketide part of the molecule. 
The polyketide part of sclerotionigrin A, was established through a large COSY spin system 
(from H7 to H22), equal to that seen for proxiphomin. Furthermore a COSY coupling was found 
between the proton at δH 2.57 ppm (H5) and a methyl group at 0.68 ppm (C11). This part was 
coupled to the PK part by a week COSY coupling between H5 and H7 identified as a w-coupling. 
The COSY spin system could furthermore be connected via HMBC correlations to the above 
mentioned Phe moiety as well as the PK part. The protons at δH 1.65 (H12) correlated to the 
carbons at δC 33.6 (C5) and 123.6 ppm (C7) where proton at δH 0.68 (H11) correlated to the 
carbons at δC 49.1 (C4) and 140.0 ppm (C6). The proton at 2.53 ppm (H4) correlated to C5, C6 
and the quaternary carbon at δC 85.4 ppm (C9). 
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Table 4. NMR data for sclerotionigrin A.† 
No. δH (integral, mult., J [Hz]) δC  HMBC NOESY 
1 - 170.6 - - 
2 8.00 (1H, s) - 1, 3, 4, 9 3, 10 
3 3.09 (1H, td, 5.8, 3.1) 54.2 - 2, 4, 10, 11, 12, 26/30 
4 2.53 (1H, dd, 4.2, 3.1) 49.1 3, 5, 6, 9 3, 10, 11, 26/30 
5 2.57 (1H, m) 33.6 - 7, 8, 11 
6 - 140.0 - - 
7 5.25 (1H, m) 123.6 - 5,8, 12 
8 3.15 (1H, m) 45.8 - 5, 7, 13, 14 
9 - 85.4 - - 
10 2.82 (2H, dd, 5.8, 2.2) 42.6 3, 4, 25, 26/30 3, 4, 26/30 
11 0.68 (3H, d, 7.1) 12.8 4, 5, 6 3, 4, 5, 12, 26/30  
12 1.65 (3H, s) 19.4 5, 6, 7 3, 7, 11 
13 5.85 (1H, ddd, 14.8, 10.0, 1.2) 128.9 15 8, 15 
14 5.22 (1H, m) 132.6 8 8, 15’, 16 
15 1.60 (1H, d, 13.5) 40.7 13, 14, 16 13, 15’ 
15’ 2.07 (1H, dd, 13.5, 2.1) 40.7 - 14, 15, 16, 20’, 24 
16 1.36 (1H, m) 31.9 - 14, 15’, 19’ 
17 0.61 (1H, m) 33.8 - 17’, 18’, 24 
17’ 1.66 (1H, m) 33.8 - 17 
18 1.14 (1H, m) 25.9 - 18’ 
18’ 1.53 (1H, m) 25.9 - 17, 18 
19 1.29 (1H, m) 25.3 - 24 
19’ 1.68 (1H, m) 25.3 - 16, 21 
20 2.23 (1H, m) 33.1 - 20’, 21 
20’ 2.29 (1H, m) 33.1 - 15’, 20, 22 
21 6.96 (1H, ddd, 15.5, 8.6, 6.8) 151.7 23 19’, 20, 22 
22 5.65 (1H, d, 15.5) 120.6 20, 23 20’, 21 
23 - 163.5 - - 
24 0.84 (3H, d, 6.3) 20.0 15, 16, 17 15’, 17, 19 
25 - 137.8 - - 
26‡ 7.14 (1H, d, 7.5) 129.5 10, 26/30 28 3, 4, 10, 11 
27‡ 7.26 (1H, t, 7.4) 128.0 25, 29 - 
28 7.18 (1H, t, 7.5) 126.1 26, 30 - 
29‡ 7.26 (1H, t, 7.5) 128.0 25, 27 - 
30‡ 7.14 (1H, d, 7.5) 129.5 10, 26/30, 28 3, 4, 10, 11 
† 1H NMR data were obtained  at 500 MHz in DMSO-d6 and 13C data were obtained at 125 MHz in DMSO-d6. 13C-
NMR chemical shifts determined from HSQC and HMBC experiments. ‡It was not possible to distinguish between no. 
26 and 30 as well as no. 27 and 29. 
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Finally the polyketide chain was closed via an ester bond assigned from HMBC correlations 
from the vinylic protons at δH 5.65 (H22) and 6.96 ppm (H21) to the carbonyl carbon at δC 163.5 
ppm (C23) supported by the high chemical shift of the quaternary carbon at δC 85.4 ppm (C9) 
indicating that C9 is bound to oxygen, similar to what is seen in several other cytochalasins [62]. 
This structure accounted for all the degree of unsaturation required by the formula allowing the 
assignment of sclerotionigrin A. 
The size of the vicinal coupling constants (3JHH) for H13/H14 and H21/H22 were rather large 
(14.8 and 15.5 Hz respectively) suggestion trans stereogeometry. NOESY experiments enabled 
determination of the relative stereochemistry for most of the stereogenic centers of sclerotionigrin 
A to be very similar to those of proxiphomin. NOE connectivities were found between the proton 
at δH 3.09 ppm (H3), δH 2.53 (H4) and the methyl at δH 0.68 ppm (H11) placing these protons at 
the same side of the central ring system. Other NOE connectivities were observed between the 
protons at δH 2.57 ppm (H5), 5.25 (H7) and 3.15 (H8), whereas no NOE connectivities could be 
seen to H3, H4 or H11, strongly indicating the positioning of H5, H7 and H8 on the opposite side 
of the central ring system compared to H3, H4 and H11. The stereocenters at C9 and C16 could 
not be assigned through NOESY correlations, however being biosynthesized by the same fungus 
we propose that the stereochemistry at these centers are identical to those of proxiphomin. 
Especially we note that the extra oxidation between C9 and C23 in other cytochalasans never 
leads to a change in stereochemistry at C9.7,15 We do however note that the optical rotation of 
sclerotionigrin A and B are positive as opposed to that of proxiphomin and other similar 
cytochalasans,15 indicating a possible difference in stereochemistry. Further experiments, e.g. X-
ray crystallography or circular dichroism (CD) are needed to clarify the absolute stereochemistry 
of sclerotionigrin A. 
Sclerotionigrin B, was isolated as a yellow powder, and displayed UV absorption maxima at 
212 nm and the ESI+ MS adducts [M+H]+, [M+Na]+, [2M+H]+ and [2M+Na]+. The molecular 
formula of sclerotionigrin B, C29H37NO4 was deduced from the monoisotopic mass obtained from 
the [M+H]+ ion (m/z 464.2797) with the accuracy of 1.2 ppm. Examination of the NMR spectra of 
sclerotionigrin B displayed a high similarity compared to sclerotionigrin A. Comparison of the 
NMR spectra of sclerotionigrin A and B (Table 4 and 5) revealed that the difference between 
them is located in position five, six and seven. 
The Phe moiety in sclerotionigrin B was identified through a connection of the two COSY spin 
systems linked by HMBC correlations as demonstrated for sclerotionigrin A. The COSY spin 
system of the polyketide chain terminated with a proton at δH 3.68 ppm (H7), indicating a binding 
to a hydroxy group instead of the vinyllic methine group. This was also evident from the carbon 
chemical shift moving to δC 69.1 ppm (C7). 
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Table 5. NMR data for sclerotionigrin B.† 
No. δH (integral, mult., J [Hz]) δC  HMBC NOESY 
1 - 171.2 - - 
2 8.34 (1H, s) - 3, 4, 9 3, 10’ 
3 3.39 (1H, m) 57.7 1, 4, 5, 9  
4 3.32 (1H, m) 47.1 1, 5, 6, 9  
5 - 123.9 - - 
6 - 134.2 - - 
7 3.68 (1H, d, 9.7) 69.1 - 8, 12, 13 
8 3.05 (1H, t, 10.0) 48.3 1, 4, 7, 9, 13, 14 7, 13, 14 
9 - 83.6 - - 
10 2.55 (1H, dd, 13.0, 10.1) 42.5 3, 4, 25, 26/30 3, 10’, 26/30 
10’ 2.92 (1H, dd, 13.0, 5.0) 42.5 3, 4, 25, 26/30 2, 3, 10, 26/30 
11 1.16 (3H, s) 16.7 4, 5, 6 3, 26/30 
12 1.52 (3H, s) 14.3 5, 6, 7 7 
13 6.03 (1H, dd, 15.0, 11.3) 128.4 8, 15/15’ 4, 7, 8, 14, 15 
14 5.00 (1H, ddd, 15.0, 10.8, 3.4) 132.7 8, 15/15’ 8, 13, 15, 15’ 
15 1.58 (1H, dd, 24.3, 11.1) 41.6 16 13, 14, 15’, 16, 17’ 
15’ 2.00 (1H, br. d., 11.6) 41.6 - 14, 15, 16, 24 
16 1.13 (1H, m) 32.5 - 15, 15’, 17’, 18, 24 
17 0.52 (1H, dd, 19.4, 11.0) 34.5 - 17’ 
17’ 1.67 (1H, m) 34.5 24 15, 16, 17, 18, 24 
18 0.86 (1H, m) 26.1 - 16, 17’, 18’ 
18’ 1.68 (1H, m) 26.1 20 18, 19, 21 
19 1.30 (1H, dd, 21.5, 10.2) 25.4 - 18’, 19’ 
19’ 1.73 (1H, m) 25.4 - 19 
20 2.11 (1H, dd, 20.8, 10.9) 33.4 - 20’, 22 
20’ 2.41 (1H, dd, 12.7, 4.6) 33.4 - 20, 21 
21 6.89 (1H, ddd, 15.7, 10.8, 5.0)  151.4 20, 23 18’, 20’, 22 
22 5.79 (1H, d, 16.1) 121.3 20, 23 20, 21 
23 - 163.8 - - 
24 0.83 (3H, d, 6.6) 19.9 15, 16, 17 15’, 16, 17’ 
25 - 137.4 - - 
26‡ 7.08 (1H, d, 7.1) 128.9 10, 28, 30 3, 4, 10, 10’, 11, 27/29 
27‡ 7.31 (1H, t, 7.5) 128.2 25, 29 26/30, 28 
28 7.23 (1H, t, 7.4) 126.3 26, 30 27/29 
29‡ 7.31(1H, t, 7.5) 128.2 25, 27 26/30, 28 
30‡ 7.08 (1H, d, 7.1) 128.9 10, 26, 28 3, 4, 10, 10’,11, 27/29 
† 1H NMR data were obtained  at 500 MHz in DMSO-d6 and 13C data were obtained at 125 MHz in DMSO-d6. 13C-
NMR chemical shifts determined from HSQC and HMBC experiments. ‡It was not possible to distinguish between no. 
26 and 30 as well as no. 27 and 29. 
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HMBC correlations from the three protons of the methyl group at δH 1.52 ppm (H12) to the 
carbons at δC 123.9 (C5), 134.2 (C6) and C7, combined with correlations from the protons at δH 
1.16 ppm (H11) to the carbons at δC 47.1 (C4) and 123.9 ppm (C5) and 134.2 (C6) linked the Phe 
moiety to the spin system in the polyketide chain (Figure 28). The remaining chemical shifts in 
sclerotionigrin B matched the chemical shifts of sclerotionigrin A (Table 4 and 5) and the 
structure of sclerotionigrin B was established. 
Figure 28. Important HMBC correlations establishing the quaternary carbon C6 and C7 2. The 
remaining HMBC correlations are found in (Table 5. Inidividual COSY spin systems are marked 
in bold. 
 
As the optical rotation of sclerotionigrin B was similar to the optical rotation of sclerotionigrin 
A, the two compounds most likely have the same relative stereochemistry, which was confirmed 
by NOE connectivities. The absolute stereochemistry of sclerotionigrin B has not yet been solved. 
Biological testing of the cytotoxicity of compounds sclerotionigrin A, B and proxiphomin 
towards CLL cells in vitro were performed using a CellTiter-Glo® assay (paper 2). Proxiphomin 
displayed the strongest effects with estimated LC50 values of ca 48 µM. Where no effect was 
found towards healthy B-cells below 100 µM. Sclerotionigrin A and B only showed minor 
activities at concentrations below 100 µM (Figure S18, paper 3). Improvement of the anti-
leukemic activity of cytochalasins can further be addressed through biocombinatorial engineering 
using a synthetic biology approach. The goal of such study could be to identify the gene cluster 
responsible for production of cytochalasins and express it in a model organism like A. nidulans. 
Subsequently incorporate a gene coding for an alternative amino acids into the cytochalasin gene 
cluster. This approach may enable design of cytochalasin analogs and SAR investigations of the 
anti-leukemic activity and could be an alternative to traditional preparation of semi-synthetic 
analogues. 
Conclusion 
In summary the two new cytochalasins, sclerotionigrin A and B have been isolated from A. 
sclerotieoniger together with the known proxiphomin casting new insights into the chemistry of 
this species. The latter compound displayed the strongest cytotoxic effect towards CLL. 
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 Chapter 5 
Micropeptins with Inhibitory Activity 
Towards Proteases 
This chapter covers isolation of serine proteases inhibitors produced by cyanobacteria and are 
the result obtained during my external stay at Tel Aviv University. Serine proteases are often 
associated with the mechanisms that causes diseases such as AIDS, Alzheimer’s and cancer etc. 
[119]. Inhibition of various proteases can slow down or even stop disease progression [120]. 
Cyanobacteria genera including Microcystis that form natural blooms are prolific producers of 
potent protease inhibitors [121]. The protease inhibitors are usually members of five discrete 
families: micropeptins [122], aerugenosins [123], microginins [124], anabaenopeptins [125] and 
microviridins [126]. Cyanobactrial blooms usually contain one or several of these groups 
covering cyclic and linear modified peptides. Modification of proteinogenic amino acids, by 
cyanobacteria, results in new amino acid mimics, i.e. amino hydroxy piperidone (Ahp), amino 
methoxy piperidone (Amp), hydroxycyclohexenyl alanine (HcAla), hydroxy methylproline 
(HMP), or NMe-Tyr to name only a few incorporated into the micropeptins. The acid residue 
sequence of the micropeptins is highly variable, as can be figured from the 139 members of the 
family [127]. Some of the positions present high tendency for acid variation while others vary 
only between two closely related acids. The more conservative positions in micropeptins are the 
first, fourth and sixth position mostly represented by isoleucine (Ile)/Val, Aph/Amp, and 
threonine (Thr)/HMP, respectively. The lactone ring of the micropeptins is formed by 
introduction of an ester bond between Thr/HMP and Ile/Val [128–130]. The side chain of the 
micropeptins is also highly variable in the length (0 to 3, most frequently 2 amino acids) and acid 
composition. The side chain is always terminated by either hydroxy acid or a short chain fatty 
acid (1 to 8 carbons). 
It has been proposed that the Aph moiety is biosynthesized from the amino acids glutamine 
(Gln) or glutamic acid (Glu) by cyclisation of the δ-carbon and the nitrogen form the neighboring 
amino acid [131]. Another special amino acid is HcAla most probably is derived from L-
arogenate, the precursor of tyrosine (Tyr) and Phe. It is presumably biosynthesized by reduction 
and decarboxylation of L-arogenate (Figure 29), in analogy with the biosynthesis of the proline 
mimicking amino acid, Choi, in the aeruginosins [132]. The biosynthetic pathway of Aph and 
HcAla has not yet been studied. 
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Figure 29. Possible biosynthetic route from L-arogenate to HcAla. 
 
Absolute configuration of the amino acids in peptides can be achieved either by a direct 
approach using chiral HPLC columns or by an indirect approach using pre-column derivatization 
and reverse phase chromatography [133]. It is often easy to obtain a good separation and the 
columns are more rugged and cheaper when using the indirect method compared to the direct. The 
indirect pre-column derivatization with Marfey’s reagent is often the favored choice for small 
peptides and the method applied in this project. Marfey’s reagent contain a chiral center in the L-
alanine part of the molecule. In the derivatization the amino acids is incorporated by nucleophilic 
substitution (Figure 30) [133,134]. 
 
Figure 30. Marfey's derivatization of single amino acids for determination of absolute 
configuration. Figure adapted from Hymer et al. [133]. 
It is possible to separate L- and D-diastereomers by reverse phase chromatography. The separation 
is often ascribed to intramolecular hydrogen bonds between the carboxyamide and the carboxylic 
acid in the L,L diastereomer. In the L,D-diastereomer only weak or none hydrogen bonds are 
formed [133,134]. The mixture of hydrolyzed and derivatized amino acids is spiked with L and D 
amino acid standards for the final resolution of the stereo chemistry of the individual amino acid. 
5.1 Isolation and Structural Elucidation of Micropeptins 
The extracts of a Microcystis sp. bloom material collected in September 2009 at Kabul 
Reservoir, Israel was studied. Three new micropeptins KR1030, KR1002, and KR998 (Figure 32) 
were discovered together and the known microcyclamide GL546A (Appendix) [135]. The 
structure elucidation and the biological activity of the compounds are discussed below. 
 
 
Figure 31. Structure of the three novel micropeptins: KR1030 (1), KR1002 (2) and KR998 (3).  
DTU Systems Biology 
Chemical Biology of Microbial Anticancer Natural Products 
41 
 
 
Micropeptin KR1030, presented an ESI+ MS pseudo-molecular [M+Na]+ ion at m/z 
1053.5288, corresponding to the molecular formula C53H74N8NaO13 and 21 degrees of 
unsaturation. Examination of the NMR spectra of micropeptin KR1030, in DMSO-d6, revealed its 
peptide nature; i.e., nine carboxyamide carbons in the 13C NMR spectrum and five amide doublet 
protons in the 1H NMR spectrum. Some characteristic signals suggested that it was a micropeptin 
type compound [136]. Taking into account the NMe-aromatic amino acid and the N,N-
disubstituted-amino acid of the micropeptins, suggested that this micropeptin was assembled from 
seven amino acid moieties. In addition, a hydroxy group of secondary alcohol group, resonating at 
δH 4.61 ppm (d) and the hydroxy proton of Ahp at δH 5.99 ppm were evident in the 1H NMR 
spectrum. 
Additionally this analysis revealed two short fragments in agreement with one N,N-
disubstituted aromatic amino acid (N,N-Phe), one a para substituted phenol rings (Tyr), and an 
extended spin system that didn’t fit any proteogenic amino acid. The amide proton of this non-
proteogenic amino acid (H 8.40 ppm) had a COSY coupling to its -methine proton at H 4.23 
ppm. Using the COSY and TOCSY correlations (paper 4 supplementary) the -methine proton 
was connected to a methylene, which in turn was connected to a methine, which was part of a 4-
hydroxycyclohex-2-enyl moiety. This amino acid moiety was thus established as the rare HcAla 
(Figure 32) previously identified in only four cases in micropeptins [137–140]. 
 
 
 
 
 
1Val 
2NMeTyr
3N,N-disubstituted-Phe
4Aph
5HcAla
6Thr 7Gln 
HA 
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Figure 32. Structure of the rare non-proteogenic amino acid HcAla. 
OH
H2N
O
OH
 
Assuming a twisted boat conformation for the cyclohexenyl moiety in HcAla, the pseudoaxial 
H8 (H8pax) and H9 (H9pax) were identified by their shift to higher field. NOE correlation of H9pax 
with H7 and of H8pax with H4, as well as, the rest of the NOE’s of this spin system shown in 
Figure 33, established both as pseudoaxial, and the relative configuration of the hydroxy 
cyclohexenyl moiety as 4S*,7R*. Although the NOE pattern of H2, 3a, 3b and 4 pointed to a 
restricted rotation (Figure 33) it was not possible to assume the relative configuration of positions 
2 and 4. 
Figure 33. NOE correlations instrumental for detemining the relative configuration of the 
hydroxycyclohexenyl alanine moiety. 
 
 
Table 6. NMR data of micropeptin KR1030 in DMSO-d6.a 
Position δC, mult.b δH, mult., J (Hz) LR H-C correlationsc NOE correlationsd 
Val-1 172.2 s       
2 55.8 d 4.73 m Val-1, NMeTyr-1 Val-3,4,5 
3 31.0 d 2.07 m   Val-4,5,NH, Thr-3 
4 19.5 q 0.84 d 6.5 Val-2,3,5 Val-2,3,NH, NMeTyr-NMe  
5 17.3 q 0.71 d 6.9 Val2,3,4 Val-2,3,NH, Ahp-6-OH, NMeTyr-
NMe 
NH   7.36 d 9.6 NMeTyr-1 Val-4,5, NMeTyr-2,NMe, Ahp-6-OH 
NMeTyr-1 169.3 s      
2 61.0 d 4.85 dd 12.0, 2.2 NMeTyr-1 Val-NH, NMeTyr-3b,5,5’,NMe, Phe-
2 
3 33.0 t 2.70 dd 14.0, 12.0 
3.08 dd 14.0, 2.2 
NMeTyr-5,5’ 
NMeTyr-5,5’ 
NMeTyr-3b,5,5’ 
NMeTyr-2,3a,5,5’,,6,6’ 
4 127.7 s       
5,5’ 130.6 dx2 6.98 dx2 8.2 NMeTyr-3,5,5’,7 NMeTyr-2,3a,3b,6,6’,NMe, Phe-2 
6,6’ 115.5 dx2 6.74 dx2 8.2 NMeTyr-4,5,5’,7 NMeTyr-5,5’,7-OH, Phe-6,6’ 
7 156.4 d       
7-OH  9.33 s NMeTyr-6,6’,7 NMeTyr-5,5’,6,6’ 
NMe 30.5 q 2.75 s NMeTyr-2, Phe-1 Val-4,5,NH, NMeTyr-2,5,5’,6,6’, 
Ahp-6-OH 
Phe-1 170.5 s     
2 50.4 d 4.72 m Ahp-2 NMeTyr-2, Phe-3a,5,5’ 
H
OH
H
H
H
H
H
H
H
HO
H
NH
H
4
7
95
2
NOE
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Table 6. Cont.
Position δC, mult.b δH, mult., J (Hz) LR H-C correlationsc NOE correlationsd 
3 35.5 t 1.78 dd 14.0, 3.8 
2.85 dd 14.0, 12.3 
Phe-5,5’ 
Phe-2,5,5’ 
NMeTyr-6,6’, Phe-2,3b,5,5’,  
Phe-3a,5,5’, Ahp-6 
4 136.9 s        
5,5’ 129.6 dx2 6.82 dx2 7.1 Phe-5’,5,6,7 Phe-2,3a,3b,6,6’, Ahp-4a,6 
6,6’ 127.9 dx2 7.17 tx2 7.1 Phe-4,6’,6 NMeTyr-6,6’, Phe-5,5’ 
7 126.4 d 7.13 t 7.1 Phe-5  
Ahp-2 169.0 s     
3 48.6 d 3.61 m Ahp-2 Phe-5,5’, Ahp-4a,NH 
4 21.8 t 1.54 m 
2.39 dq 3.0, 12.3 
 Ahp-3,4b,5 
Ahp-4a,5a,6-OH,NH 
5 29.4 t  1.66 m 
1.52 m 
  Ahp-4b,6,6-OH 
6 73.9 d 5.05 dt 1.8,3.2   Phe-3b,5,5’, Ahp-5a,5b,6-OH  
6-OH   5.99 d 3.2   Val-4’,5,NH, Ahp-5a,6, NMeTyr-
NMe 
NH   7.08 d 9.1  HcAla-1 Ahp-3,4b, AcAla-2,NH, Thr-3 
HcAla-1 170.1 s    
2 49.6 d 4.23 brdd 10.6,8.8  Ahp-NH, HcAla-3b  
3 36.4 t 1.40 brt 10.6 
1.69 m 
 HcAla-3b,4,5,6,NH 
HcAla-2,3a 
4 31.7 d 1.92 m  HcAla-3a,5,6,8pax,NH 
5 132.2 d 5.37 m HcAla-7 HcAla-3a,4,6,7 
6 132.9 d 5.55 brd 10.3 HcAla-8 HcAla-3a,4,5,7,7-OH 
7 65.3 d 3.95 m  HcAla-6,7,7-OH,8peq,9pax 
7-OH  4.61 d 5.3 HcAla-6,7,8 HcAla-6,7,8pax 
8pax 
  peq 
31.5 t 1.20 m  
1.79 m  
 HcAla-4,7-OH,8peq,9peq 
HcAla-7,8pax,9pax 
9pax 
  peq 
26.0 t 0.95 td 12.7,3.0  
1.66 m  
 
HcAla-4 
HcAla-7,8peq,9peq 
HcAla-8pax,9peq 
NH  8.40 d 8.8 Thr-1 Ahp-NH, HcAla-3a,4, Thr-2 
Thr-1 169.5 s     
2 54.9 d 4.55 d 9.1 Thr-1 HcAla-NH, Thr-3,4 
3 71.8 d 5.37 m Val-1 HcAla-NH, Thr-2,4, Val-3  
4 17.6 q 1.17 d 6.6 Thr-2,3 Thr-2,3, Gln-2 
NH  7.96 d 9.1 Gln-1 Thr-4, Gln-2 
Gln-1 172.8 s    
2 52.2 d 4.38 dt 6.0,8.0 Gln-1 Thr-4,NH, Gln-3a,3b,NH, HA-4 
3 27.9 t 1.69 m 
1.84 m 
Gln-2,4 Gln-2,3b,NH  
Gln-2,3a,NH 
4 31.8 t 2.07 m 
2.08 m 
Gln-5 
Gln-5 
 
5 174.0 s    
5-NH2 (a) 
(b) 
 6.73 s 
7.21 s 
Gln-4 
Gln-5 
 
Gln-4 
NH  7.98 d 8.0 HA-1 Gln-2,3a 
HA-1 172.5 s    
2 35.2 7 2.08 m HA-1,4 HA-3 
3 25.1 t 1.49 m HA-1,4 HA-2 
4 31.5 t 1.20 m HA-1,3,5  
5 22.0 t 1.23 m HA-3,4,6  
6 14.0 q 0.84 t 7.0 HA-5   
a500 MHz for 1H, 125 MHz for 13C. bMultiplicity and assignment from HSQC experiment. cDetermined from 
HMBC experiment, nJCH=8 Hz, recycle time 1s. dSelected NOE’s from a ROESY experiment. 
Analysis of the COSY, total correlation spectroscopy (TOCSY), and HSQC 2D NMR 
experiments, (see Table 6) allowed the assignment of Val, Thr, Gln, and Ahp moieties.  
The complete structure of the micropeptin was achieved by analysis of the long range (LR) 
correlations of the 1H–13C HMBC experiment (see Table 6). This procedure established the 
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structures of Val, NMeTyr, N,N-disubstituted-Phe, Ahp, HcAla, 3-O-substituted-Thr, Gln, and 
hexanoic acid (HA) residues. 
The sequence of the amino acids of micropeptin KR1030 was assigned on the basis of HMBC 
and rotating frame nuclear Overhauser effect spectroscopy (ROESY) correlations as illustrated in 
Figure 35. 
Figure 34. HMBC correlations (blue) and ROESY correlation (green) linking the amino acids and 
HA in micropeptin KR1030. 
 
The absolute configuration of most of the amino acids in micropeptin KR1030 was established 
through hydrolysis to release single amino acids and derivatization with Marfey’s reagent [134], 
followed by HPLC analysis. This demonstrated the L-configuration of Val, NMe-Tyr, Phe, Thr, 
and Glu residues. Micropeptin KR1030 contains the special amino acids Aph. The carboxyamide 
in Ahp was reduced to a secondary alcohol with Jones oxidation [141] prior to hydrolysis (Figure 
35) and reaction with Marfey’s reagent. Hereby the 3S-configuration for the Ahp residue was 
determined. An attempt to determine the absolute configuration of C2 in HcAla by advances 
Marfey’s procedure failed most probably due to its decomposition during hydrolysis. 
Figure 35. Jones oxidation that liberates L-Glu from Ahp and hydrolysis to release the amino acid. 
 
The configuration of C6 of the Ahp was determined as R on the basis of the J-values of H6, 
1.8 and 3.2 Hz, with pseudo-equatorial-H5 and pseudo-axial-H5, respectively. This points to an 
equatorial orientation of H6. The chemical shift of the pseudo-axial-H4, H 2.39 dq (3.0,12.3), 
which is down-field shifted by the axial 6-hydroxy-group. The trans diaxial relationship with H3 
and the NOE correlation between H4pax with the 6-OH. Based on these findings the structure of 
micropeptin KR1030 was established. 
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Examination of the NMR spectra of micropeptin KR1002 revealed that the 1H and 13C NMR 
spectra are similar to those of micropeptin KR1030. The molecular formula of micropeptin 
KR1002, C51H70N8O13, was deduced from the high-resolution ESI+-MS measurements of its 
sodiated molecular adduct ion at m/z 1025.4958. Comparison of the NMR data of micropeptin 
KR1030 and micropeptin KR1002 (Table 6 and 7) revealed that the difference between them is 
located in the fatty acid at the N-termini of these cyclic depsipeptides. Two methylene carbons 
(C 31.5 and 25.1 ppm) of the aliphatic residue and four proton signals (H ~1.20 ppm) were 
present in the spectra of micropeptin KR1030 were missing from the spectra of micropeptin 
KR1002. This suggests that the HA residue, in micropeptin KR1030, is replaced by a butyric acid 
(BA) residue, in micropeptin KR1002. Full assignment of micropeptin KR1002 was achieved by 
interpretation of the COSY, TOCSY, ROESY, HSQC and HMBC 2D NMR correlations (see 
Table 7), revealing the composition and sequence of acid residues of micropeptin KR1002 as, 
Val, NMeTyr, N,N-disubstituted-Phe, Ahp, HcAla, Thr, Gln and BA.  
Table 7. NMR data of micropeptin KR1002 in DMSO-d6.a 
Position δC, 
mult.b 
δH, mult., J (Hz) LR H-C 
correlationsc 
NOE correlationsd 
Val-1 172.6 s      
2 55.6 d 4.73 dd 9.8,4.2 Val-5 Val-3,4,NH, NMeTyr-2 
3 30.9 d 2.07 m   Val-2,4,5 
4 19.3 q 0.86 d 6.7 Val-2,3,5 Val-3, NMeTyr-NMe 
5 17.1 q 0.71 d 6.7 Val-2,3,4 Val-3,NH, NMeTyr-NMe, Ahp-
6-OH 
NH   7.38 d 9.8  NMeTyr-1 Val-2,3, NMeTyr-2,NMe 
NMeTyr-1 168.9 s      
2 60.9 d 4.89 dd 11.5,2.0 NMeTyr-1 Val-2, NMeTyr-3b,5,5’,NMe 
3 32.8 t 2.71 dd 13.2, 11.5 
3.09 dd 13.2, 2.0 
NMeTyr-5,5’ 
NMeTyr-4,5,5’ 
Val-NH, NMeTyr-3b,5,5’,6,6’ 
NMeTyr-2,3a,5,5’ 
4 127.5 s      
5,5’ 130.4 dx2 6.99 dx2 8.2 NMeTyr-3,5’,5,7 NMeTyr-2,3a,3b, Phe-2 
6,6’ 115.3 dx2 6.76 dx2 8.2 NMeTyr-4,6’,6,7 NMeTyr-3a,7-OH, Phe-3a 
7 156.2 s       
7-OH  9.33 NMeTyr-6’,6,7 NMeTyr-6,6’ 
NMe 30.3 q 2.75 s NMeTyr-2 Val-4,5,NH, NMeTyr-2,5,5’ 
Phe-1 170.3 s    
2 50.2 d 4.75 dd 11.9,3.9 Phe-1 NMeTyr-5,5’, Phe-3a,5,5’ 
3 38.5 t 1.79 m  
2.85 dd 11.9,14.0 
Phe-5,5’ 
Phe-5,5’ 
Phe-2,3b,5,5’, NMeTyr-6,6’ 
Phe-3,5,5’, Ahp-6 
4 136.7 s    
5,5’ 129.4 dx2 6.82 dx2 7.1 Phe-3,5’,6,7 Phe-2,3a,3b, Ahp-4a 
6,6’ 127.7 dx2 7.17 tx2 7.1 Phe-4,5,6 HcAla-OH  
7 126.2 d 7.13 t 7.1 Phe-5 Ahp-3 
Ahp-2 169.3 s      
3 48.5 d 3.60 ddd 
7.1,9.1,12.7 
  Ahp-4a,NH, Phe-7 
4 21.6 t 1.55 m 
2.39 brq 12.7 
 Ahp-3,4b,6, Phe-6,6’ 
Ahp-4a,NH,6-OH 
5 29.6 t  1.67 m 
1.55 m 
  Ahp-6-OH, HcAla--5 
6 73.7 d 5.05 brs   Phe-3b, Ahp-4,5,6-OH  
6-OH   5.99 d 2.5   Ahp-4b,5,6, Val-5,NH, HcAla-
NH 
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Table 7. Cont. 
Position δC, 
mult.b 
δH, mult., J (Hz) LR H-C 
correlationsc 
NOE correlationsd 
NH   7.08 d 9.1 HcAla-1 Ahp-3,4b, HcAla-2,9,NH 
HcAla-1 170.0 s     
2 49.4 d 4.23 brdd 11.4,7.4  Ahp-NH, HcAla-3b,4 
3 36.4 t 1.40 dt 3.7,11.4 
1.71 m 
 HcAla-3b,4,5,6 
HcAla-2,3a 
4 31.6 d 1.92 m  HcAla-2,3a,5,6,8pax,NH 
5 132.0 d 5.37 brd 10.2  HcAla-3a,4,6,7 
6 132.7 d 5.55 dd 10.2,1.0 HcAla-4 HcAla-3a,4,5,7,7-OH 
7 65.1 d 3.94 brm  HcAla-5,6,7-OH,8peq,9pax 
8 peq 
   pax 
31.6 t 1.79 m 
1.20 m 
 HcAla-7,7-OH,8pax,9pax 
HcAla-4,8peq,9peq,7-OH 
9 peq 
   pax 
25.8 t 1.70 m 
0.93 brq 11.3 
 HcAla-4,8pax,9pax 
HcAla-7,8peq,9peq 
7-OH  4.61 d 5.4 HcAla-6,7,8 HcAla-6,7,8peq,8pax 
NH  8.40 d 8.4  Ahp-NH, HcAla-3a,4, Thr-2,3 
Thr-1 169.1 s    
2 54.9 d 4.55 brd 9.1 Thr-1, Gln-1 HcAla-NH, Thr-4 
3 71.7 d 5.39 q 6.5 Thr-4 HcAla-NH, Thr-4  
4 17.6 q 1.17 d 6.5 Thr-2,3 HcAla-7-OH, Thr-2,3,NH 
NH  7.91 d 9.0 Gln-1 HcAla-NH, Thr-4 
Gln-1 172.2 s     
2 52.0 d 4.38 m Gln-1 Thr-NH, Gln-3a,3b,4b 
3 27.7 t 1.69 m 
1.84 m 
Gln-4 Gln-2,3b,NH, BA-3 
Gln-3a,NH 
4 31.6 t 2.11 m Gln-5 Gln-2,NH,5-NH2 
5 173.9 s    
5-NH2(a) 
(b) 
 6.72 s 
7.21 s 
Gln-4  
Gln-4 
NH  7.99 d 7.5 BA-1 Gln-3a,4 
BA-1 172.0 s    
2 37.0 t 2.09 m BA-1,3,4 Gln-2 
3 18.9 t 1.51 m BA-1,2,4 Gln-3a 
4 13.6 q 0.84 t 7.3 BA-2,3 Val-2 
a400 MHz for 1H, 100 MHz for 13C. bMultiplicity and assignment from HSQC experiment. cDetermined from 
HMBC experiment, nJCH=8 Hz, recycle time 1s. dSelected NOE’s from a ROESY experiment. 
Acid hydrolysis of micropeptin KR1002 and derivatization with Marfey’s reagent [134], as 
described above for micropeptin KR1030 followed by HPLC analysis, demonstrated the L-
configurations for all of the amino acid residues except of HcAla. The absolute configuration of 
the Ahp residue was determined in the same way as for micropeptin KR1030. Based on these 
findings the structure of micropeptin KR1002 was established. 
 
Micropeptin KR998 presented an ESI+-MS pseudo-molecular [M+Na]+ ion at m/z 1021.4666, 
corresponding to the molecular formula C51H66N8O13 and 23 degrees of unsaturation. 
Comparison of the degree of unsaturation of micropeptin KR998 with those of micropeptin 
KR1002, revealed two additional ones in micropeptin KR998. The 1H and 13C NMR spectra of 
micropeptin KR998 were comparable with those of micropeptin KR1002, but revealed some 
differences as well. 
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In the aromatic region of the 1H NMR spectrum of micropeptin KR998, two additional doublet 
signals at δH 6.89 and 6.56 ppm (2H each) with a J coupling constant of 8.2 Hz. Furthermore did a 
singlet at δH 9.07 ppm occur as well as two additional benzyl protons (H 3.11 and 2.50 ppm) in 
the aliphatic region. The signals corresponding to the HcAla in micropeptin KR1002 were 
missing. 
In the 13C NMR spectrum of micropeptin KR998 four new aromatic signals (C 128.3, 129.8, 
115.2 and 155.7 ppm), of a para-substituted phenol moiety were observed. As in the 1H NMR 
spectrum the signals of HcAla observed in micropeptin KR1002 were missing (Table 7 and Table 
8). The data summarized above and the molecular formula of micropeptin KR998 relative to that 
of micropeptin KR1002 suggested that in micropeptin KR998 a Tyr moiety substitute the HcAla 
of micropeptin KR1002. The rest of the structures of these compounds are identical. Full 
assignment of the tyrosine moiety and the rest of the moieties that compose micropeptin KR998 
as well as their sequence were achieved using COSY, TOCSY, ROESY, HSQC and HMBC 2D 
NMR correlations (Table 8). 
Table 8. NMR data of micropeptin KR998 in DMSO-d6.a 
Position δC, mult.b δH, mult., J (Hz) LR H-C correlationsc NOE correlationsd 
Val-1 172.1 s      
2 55.9 d 4.66 dd 9.5,4.3 Val-1,3,5 Val-3,4,5,NH, Gln-NH2 
3 31.0 d 2.02 m Val-2,4,5 Val-2,4,5,NH, Thr-2 
4 19.4 q 0.85 d 5.7 Val-2,3,5 Val-2,3,NH, NMeTyr-
NMe 
5 17.3 q 0.70 d 6.7 Val-2,3,4 Val -2,3,NH, NMeTyr-
NMe, Ahp-6-OH 
NH   7.37 d 9.5 NMeTyr-1 Val-2,3,4,5, NMeTyr-
2,NMe, Ahp-6-OH 
NMeTyr-1 169.0 s      
2 61.0 d 4.89 brd 11.4 NMeTyr-1,NMe Val-NH, NMeTyr-3b,5,5’ 
3 33.0 t 2.71 dd 13.4,11.4 
3.08 brd 13.4 
NMeTyr-2,5,5’ 
NMeTyr-4,5,5’ 
NMeTyr-3b,6,6’ 
NMeTyr-2,3a,5,5’ 
4 127.7 s       
5,5’ 130.6 dx2 6.99 dx2 8.0 NMeTyr-3,5’,5,6,6’,7 NMeTyr-2,3b,NMe, Phe-
2,3a 
6,6’ 11.5.5 dx2 6.77 dx2 8.0 NMeTyr-4,6,6’,7 NMeTyr-NMe,OH, Phe-3a 
7 156.4 s       
NMe 30.5 q 2.75 s NMeTyr-2, Phe-1 NMePhe-5,5’,7, Val-
4,5,NH 
Phe-1 170.5 s     
2 50.4 d 4.74 dd 11.3,3.6 Phe-1 NMeTyr-5,5’, Phe-3a,5,5’ 
3 35.5 t 1.78 m  
2.86 dd 11.7,13.8 
Phe-5,5’ NMeTyr-5,5’,6,6’, Phe-
2,3b,5,5’ 
Phe-3a,5,5’, Ahp-6 
4 136.9 s        
5,5’ 129.6 dx2 6.83 dx2 7.1 Phe-3,5’,5,7 Phe-2,3a,3b, Ahp-3,5a,6 
6,6’ 127.9 dx2 7.18 tx2 7.1 Phe-4,5,5’,6’,6 Ahp-3 
7 126.4 d 7.14 t 7.1 Phe-5,5’  
Ahp-2 169.0 s      
3 49.0 d 3.60 ddd 11.6,8.2,6.0  Ahp-2,4 Phe-5,5’, Ahp-4a,NH 
4 21.7 t 1.62 m 
2.40 brq 12.4 
  Ahp-3,4b 
Ahp-4a,5b,NH 
5 29.4 t  1.68 m 
1.57 m 
   Ahp-6,6-OH 
Ahp-4b 
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Table 8. Cont. 
Position δC, mult.b δH, mult., J (Hz) LR H-C correlationsc NOE correlationsd 
6 73.9 d 5.05 brs   Phe-3b,5,5’, Ahp-5a,5b  
6-OH   5.99 d 2.1   Ahp-5b,6, Val-5,NH  
NH   7.07 d 10.2   Ahp-3,4b, Tyr-2,NH 
Tyr-1 169.7 s     
2 53.6 d 4.35 ddd 3.8,9.0,13.0   Ahp-NH, Tyr-
3a,3b,5,5’,NH 
3 35.1 t 2.50 dd 13.0,14.7 
3.11 dd 3.8,14.7 
Tyr-2,4,5 Tyr-2,3b,5,5’ 
Tyr-2,3a,NH 
4 128.3 s       
5,5’ 129.8 dx2 6.89 dx2 8.2 Tyr-3,5,5’,6,6’,7 Tyr-2,3a,NH  
6,6’ 115.2 dx2 6.56 dx2 8.2 Tyr-4,6’,6,7 Tyr-5,5’,7-OH 
7 155.7 s    
7-OH  9.07 s Tyr-6,6’ Tyr-6,6’ 
NH  8.45 d 9.0 Thr-1 Ahp-NH, Tyr-2,3a,5,5’, 
Thr-2,3 
Thr-1 169.0 s     
2 554.4 d 4.45 brd 9.4 Thr-1,4, Gln-1 Tyr-NH, Thr-4,NH, Ahp-
NH 
3 72.2 d 5.37 q 6.5 Thr-4, Val-1 Ahp-NH, Tyr-NH, Thr-4  
4 17.7 q 1.10 d 6.5 Thr-2,3 Thr-2,3,NH 
NH  7.69 d d 9.4 Gln-1 Thr-2,3,4, Gln-2,3b 
Gln-1 172.3 s     
2 52.2 d 4.30 dt 5.3,8.3 Gln-3 Thr-NH, Gln-3a,3b,4,NH 
3 27.5 t 1.70 m 
1.80 m 
Gln-2,4,5 
Gln-1,2,4,5 
Gln-2,NH 
Thr-NH, Gln-2 
4 31.7 t 2.05 m Gln-2,3,5 Gln-2,NH,5-NH2(a,b) 
5 174.3 s     
5-NH2a 
          b   
 6.81 s 
7.24 s 
Gln-4,5 
Gln-5 
Gln-4 
Gln-4 
NH  7.98 d 7.8 BA-1 Gln-2,a3,4 
BA-1 172.4 s      
2 37.4 t 2.10 m BA-1,3,4  
3 18.9 t 1.50 tq 7.3,7.3 BA-1,2,4  
4 13.8 q 0.85 t 7.2 BA-2,3  
a500 MHz for 1H, 125 MHz for 13C. bMultiplicity and assignment from HSQC experiment. cDetermined from 
HMBC experiment, nJCH=8 Hz, recycle time 1s. dSelected NOE’s from a ROESY experiment. 
 
Marfay’s analysis as described above established the absolute configuration of all amino acids 
including C3 of Ahp as L in micropeptin KR998. The absolute configuration of C6 of the Ahp 
residue was determined in the same way as for micropeptin KR1030. Based on these findings the 
structure of micropeptin KR998 was established. 
 
5.2 Biological Activity of Micropeptins 
The crude cyanobacteria extract exhibited significant inhibition of the serine protease 
chymotrypsin with a concentration of 1 mg/ml. Purification of the three micropeptins from the 
extract revealed that they were responsible for the inhibition of chymotrypsin. The inhibitory 
activity of the three micropeptins was determined for serine protease: chymotrypsin, elastase and 
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trypsin. Chymotrypsin was inhibited with IC50 values between 5.9 and 18.8 M. Elastase was 
inhibited by micropeptin KR1030 and micropeptin KR1002 with IC50 values of 28.0 M each. 
Micropeptin KR998 did not inhibit elastase at a concentration up to 50 M. The three 
micropeptins did not inhibit trypsin at a concentration up to 45.5 M. Additionally, the three 
micropeptins were tested towards CLL cells though without activity at concentrations up to 72 
nM. The results of biological activity induced by the three micropeptins are compiled in Table 9. 
 
Table 9. The inhibitory activity [IC50] of micropeptin KR1030, KR1002, and KR998 screened 
towards serine protease chymotrypsin, elastase and trypsin as well as CLL cells. 
 Chymotrypsin Elastase Trypsin CLL 
Micropeptin KR1030 13.9 µM 28.0 µM Inactive Inactive 
Micropeptin KR1002 18.8 µM 28.0 µM Inactive Inactive 
Micropeptin KR998 5.9 µM Inactive Inactive Inactive 
 
The nature of the fifth position from the C-termini of the micropeptins has been reported to be 
display selectivity between trypsin and chymotrypsin types of enzyme inhibition. Selective 
trypsin inhibition is induced by basic amino acids where selective chymotrypsin inhibition is 
induced by lipophilic or aromatic amino acids [119,127]. The inhibitory activity of micropeptins 
towards chymotrypsin observed in this study was in accordance with the lipophilic nature of the 
amino acids next to the Ahp moiety, which usually are potent chymotrypsin inhibitors [119,127]. 
One of the most potent proteases inhibitor reported among the micropeptins with IC50 values in 
picomolar and low nanomolar range is Cyanopeptolin 1020 [142]. Cyanopeptolin 1020 differ 
from micropeptin KR1030, KR1002, and KR998 in the fifth position and in the side chain. This 
indicates some very important binding sites in these positions of micropeptins in serine proteases. 
The conformation of the micropeptins is important for the inhibition of proteases. The NOE 
correlations between the hydroxy proton in Ahp and protons in Val indicate a U-shaped 
conformation where Ahp and Val are close in space. This conformation of micropeptins is found 
in a X-ray crystal structure of micropeptin A9072A/bovine trypsin complex and has been 
associated to inhibiting activity of micropeptins [143]. 
 
5.3 Conclusion 
This study describes the isolation of micropeptin KR1030, KR1002, and KR998 together with 
the known microcyclamide GL546A from a water bloom material of the cyanobacterium 
Microcystis sp. The three new micropeptins displayed inhibitory activity towards chymotrypsin 
with IC50 values between 5.9 and 18.8 µM. The awareness of proteases influence on development 
of cancer is increasing and protease inhibitors develop as an interesting new class of anticancer 
agents [119,144]. The presence of non-proteogenic amino acids (Ahp and HcAla) in the three new 
micropeptins allows the expansion of the library of micropeptins that are biosynthesized by 
cyanobacteria. Non-proteogenic amino acids in peptides might be incorporated to avoid 
recognition by proteolytic enzymes or enable recognition by receptors in the immune system.  
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 Chapter 6 
Overall Discussion and Perspectives 
Fungal extracts usually contain multiple bioactive compounds with high structural complexity. 
Historically, NPs have been a very important source in drug discovery yet untapped biodiversity 
[145] and knowledge from full genomes sequences [146] indicates that new compounds are still 
to be discovered within even well-characterized fungal species (paper 1) [70]. The aim of this 
PhD project has been to uncover unknown NPs that target CLL cells or other biological targets 
and additionally to identify novel bioactivities in previously described compounds. During the 
course of this PhD 11 compounds have been identified with activity towards CLL cells. Four of 
the compounds, ophiobolin A, B, C and K, induced apoptosis in CLL cells with LC50 values 
between 1 and 8 nM and a narrow therapeutic window. Additionally proxiphomin displayed 
cytotoxic effect towards CLL cells with a LC50 value of ca 20 µM. 
SAR study has indicated the pharmacophore of the ophiobolins. One new ophiobolin U was 
isolated and the structure fully characterized by 1D and 2D NMR and an initial. The work has 
added to the strategy for effective dereplication that allows quickly identification of known 
compounds in an active extract. The results obtained have been presented in in the four previous 
chapters of this thesis and peer-reviewed papers. 
 
The challenge of avoiding rediscovering of compounds forces the NPs chemist to focus on the 
screening setup such as preliminary selection of producing organism, prefractionation, and early 
dereplication. The search for novel bioactive compounds often starts with a preliminary screen set 
up covering a huge biodiversity. The design of the preliminary screen affects the results of the 
entire campaign. In our preliminary screen 289 fungal extracts from 138 fungal strains were 
screened. Many of the strains were newly described and with unexplored chemodiversity. To 
maximize the chemical spectrum of compounds produced by the strains cultivated in accordance 
with the OSMAC approach were applied. The most potent strains were chosen for further 
investigation of the activity towards CLL.  
 
Six of the eleven compounds targeting CLL cells, which have been discovered in this project, 
are penicillic acid, viridicatumtoxin, calbistrin A, brefeldin A, emestrin A, and neosolaniol 
monoacetate. All of them displayed cytotoxic activity towards CLL and healthy cells in the same 
concentration (paper 2). In the past, compounds like these might have been developed as a drug 
lead to obtain analogs that kills cancer cells more efficiently than healthy cells. One example of a 
cytotoxic compound that was approved for clinical use in cancer treatment despite the fact that 
severe side effects are induced in patients is taxol. Today, approval of new drugs is more 
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restricted and request tumor-specific targets to meet the demand for next generation 
chemotherapeutics. Accordingly, a general cytotoxic hit is not sufficient as pharmaceutical 
anymore. 
 
A strategy to reveal completely new chemical scaffolds may be to stimulate the microbe to 
express silent gene clusters [146,147]. Methods to achieve this undiscovered chemodiversity have 
been developed, including co-culture, epigenetic modification experiments, and metabolic 
engineering [148]. In these experiments, novel bioactive compounds can be produced due to 
either activation of silent biosynthetic pathways or due to up-regulations of the production of 
certain compounds [149,150]. In co-cultures, chemical signals between organisms can provoke 
activation or up-regulation of biosynthetic pathways [148,151]. One example of a previously 
unexpressed biosynthetic pathway is the libertellenones. Libertellenones A-D were produced by a 
fungal Libertella sp. strain in a co-culture with a marine bacterium. Libertellenones A-D were 
isolated from the co-culture and displayed anti-cancer activity towards colon cancer [152]. 
Chemical epigenetic modification is another approach to stimulate production of NPs not 
expressed under standard laboratory conditions. Epigenetic modifications can give access to pools 
of novel NPs scaffolds produced in their native host. One example is the report of chaetophenol 
C-E, three novel polycyclic skeleton produced by the fungus Chaetomium indicum, directly 
associated to epi-genetic modification [153]. 
Metabolic engineering can be another route to discover novel bioactive NPs through genome 
mining and following expression of silent genes in stable mutants [154,155]. This was done by 
accurate prediction of the gene cluster of the NRP nidulanin A and following expression through 
a stable mutant [156]. Metabolic engineering can be a challenging task that requires knowledge of 
the full genome sequence and the target gene cluster. Making mutant libraries is often very time 
consuming and still there is no guarantee for correct expression of a target compound [155].  
If I should setup a new large screening campaign I would consider including both co-culture 
and epigenetic experiments in the pre-screen to provoke production of novel chemical scaffolds. 
Co-culture and epigenetic experiments are both suitable for high through-put screening as they are 
fast, low-cost approaches that readily can be implanted in most labs without high expenses for 
new equipment [155,157] Molecular biology is a more expensive and inaccessible approach as it 
demand time-consuming preparation of mutant strains, making it less suitable for high through-
put screening. Nevertheless, metabolic engineering can, with advantage, be included in later 
stages of the discovery process to gain a higher and more stable expression of target metabolites. 
A high yield of a compound is needed to resupply for synthesize of analogs, e.g. for SAR 
studies. Alternatively design of analogs can be conducted through synthetic biology where new 
analogs are produced directly in the living model organism. The advantage of this approach 
compared to semi-synthetic derivatization is that the relative complex structures, often found in 
NPs, easier can be produced through genetic biosynthesis. 
 
In this current PhD study, all extracts in the preliminary screen were small-scale crude 
extracts. By solely screening crude extracts it is hard to distinguish between selective activity and 
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general cytotoxicity even if the extracts are screened towards healthy cells as well. This is due to 
various bioactive compounds in the crude extract and consequently, it is not possible to know if 
all active compounds likewise have activity towards healthy cells. Prefractionation at the 
preliminary screening can be beneficial and might increase the efficiency of the assay compared 
to screening of crude extracts. By the screening of fractions with lower complexity in an 
orthogonal screenings setup consisting of both target cells and healthy cells it may be possible to 
distinguish between fractions containing selective active compounds and general cytotoxic 
compounds, thus giving a more realistic hit rate. E-SPE has been the method of choice for 
prefractionation in this project, yet first at a later stage in the screening. These fractions could 
have provided the needed reduction in complexity for the initial screen. Even with all the benefits 
gained by prefractionation it is still worth to combine the preliminary screen with crude extracts 
as well. Sometimes activity is lost in a prefractionation due to disruption of potential synergisms, 
the active compounds may be trapped on the column, or be instable. To distinguish between these 
possibilities it would be valuable to recombine a small amount from each fraction and include this 
in the screening as well. One example of lost activity by fractionation is the P. pinicola extract 
containing the statins (section 2.3). 
 
Dereplication is a very powerful tool to tentatively identify known compounds in a crude 
extract to save time isolate and structure elucidate already known compounds [86]. Dereplication 
can be introduced in many stages of the drug discovery process. Based on my experience in this 
PhD study, dereplication should be introduced very early in the drug discovery process where it 
functions as an early stop-or-go message and continually through the whole discovery process. 
Comparative dereplication of small-scale E-SPE fractions often provides a strong indication of the 
candidate responsible for the activity. If the potential candidate is a known compound or potential 
analog of a known compound, I think that the project needs to be closed before any scale up. This 
very conservative approach entails that more time is spent in the preliminary screen including 
prefractionation and a highly increased number of samples for prescreening. This might have 
caused rejection of the majority of the 61 active fungal extracts in this project. The problem by 
this conservative decision-making can be that none or only very few extracts satisfy the 
requirements for scale up. Nevertheless, I believe that this approach increase the possibility of 
discovering novel bioactive scaffolds from the extracts that are scaled up. 
 
The performance of mass spectrometers is continuously improving, including easy access to 
both positive and negative ionization spectra even during fast UHPLC. Integration of these 
massive amounts of data; however, might represent a major challenge in the near future. In order 
to manage fast dereplication of the massive data flow generated, multivariate data analysis 
becomes a necessary tool. Recent initiatives of e.g. molecular networking based on MSMS 
fragmentation libraries [158] and bioassay results might in the future enable fast dereplication. 
The implantation of such a setup might focus a targeted screening procedure and speed up the 
process from observed activity to identification of compound.  
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During my external stay with Professor Shmuel Carmeli at Tel Aviv University, I got the 
opportunity to work with NPs produced by cyanobacteria with the focus of discovering novel 
bioactive peptides (paper 4). Here, the discovery process was a target-guided isolation based on 
NMR spectroscopy where the method of choice at DTU Systems Biology is bio-guided combined 
with UV and MS techniques. The project based on NMR provided three new micropeptins that 
inhibited chymotrypsin. 
To select the most ideal separations strategy it is very important to consider the aim and type 
of the project. The approach with NMR as reference point is based on selection of fractions for 
further separation that contain a specific target compound or compound family for further 
purification [159], primarily based on 1D 1H NMR experiments for fast and non-destructive 
structural information. Target-guided separation based on LC-HRMS supports the separation 
strategy by providing information on the number of compounds in a fraction and molecular 
formula. 
NMR spectroscopy has a high signal richness and consequently the 1H NMR spectra from 
crude extract and fractions tend to be filled with overlapping signals especially in the more 
shielded region at chemical shifts below 3 ppm [160]. Among compounds reported from 
cyanobacteria so far, there seems to be a prevalence of small peptides [161]. The characteristic 
chemical shifts of peptides originating from the more deshielded amide-(NH) and α-protons (Hα). 
NH chemical shifts are mostly recognized as doublets between δNH 7.0 and 9.0 ppm where Hα 
chemical shifts are found more upfield between δHα 3.5 and 5.0 ppm [162]. These chemical shifts 
are easy to identify and NMR-based isolation targeting peptides is accordingly a favored method 
of choice. Fractions that contain secondary metabolites with no deshielded proton are not suited 
for NMR-based separation. For example fungal extracts that often contain a high amount of 
polyketides with low proton density or terpenoids that contain many shielded protons. 
LC-HRMS is very sensitive method and with the access to both positive and negative 
ionization spectra most small molecules are detectable even in very low amounts. This very 
beneficial quality decreases the chance of overlooking interesting molecules although some of the 
compounds detected are inaccessible for preparative purification. NMR is more insensitive, 
especially regarding mixtures, and target-guided separation based on NMR mainly leads to 
compounds present in high amounts with the risk of overlook interesting compounds. Target-
guided separation based on neither NMR- nor LC-HRMS provides any security that the 
compounds isolated are bioactive and solely these approaches can lead to discovery of inactive 
compounds. Consequently both approaches need to be combined with bio-guided isolation when 
the aim of a project is to discover compounds with a given bioactivity. Bio-guided isolation is, 
depended on the bioassay, often a very sensitive approach allowing discovery of bioactive 
compounds present only in small amounts. The sensitivity of many assays holds a duality for the 
NPs chemist as low-amount compounds are more unexplored but also more inaccessible. The 
disadvantage of solely bio-guided separation is the continual challenge of rediscovery of 
compounds. Furthermore bio-guided separation is limited by the choice of bioassay since NPs 
with other bioactivities are overlooked. None of these approaches are appropriate alone and needs 
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to be combined to increase the effectiveness of isolation and identification of novel biological 
interesting compounds. 
 
NPs drug discovery today balance between promise and reality. The promise related to NPs as 
an enormous reservoir of novel chemistry with biological activities. The opportunities is abundant 
due to the huge unexplored diversity in the fungal kingdom (paper 1) [145]. Yet, the reality is 
that only 13 commercial NPs has been approved as pharmaceuticals between 2000 and 2010 [4]. 
In recent years, the pharmaceutical industry has assigned a lower priority to discovery of 
bioactive small molecules [163,164]. 
The development and approval of a new drug cost approx. US$ 1,778 million [165], which is 
unrealistic to conduct within academia [82]. The high cost combined with the low priority from 
the pharmaceutical industry makes it important for the NPs chemist to give relevance to a 
compound for ultimately enter into clinical trials. This requires strong collaboration within 
academia where interdisciplinary clusters between NPs chemistry, synthetic chemistry, biology, 
molecular biology, fermentation etc. are needed. Before a hit in the discovery process is 
interesting as a drug lead suitable for the pharmaceutical industry, the compound need to fulfill 
some of the items listed below [166]. 
 A specific and selective activity 
 Target a novel biological mechanism 
 Reasonably bioavailability 
 
Specific and selective activity: As demonstrated in this PhD project many compounds display 
anti-cancer activity as well as antifungal activity (paper 1 and 2). This observation might be a 
consequence of general cytotoxic molecules maybe because they target eukaryote cells in general. 
General cytotoxicity is a huge problem in development of pharmaceuticals because it often results 
in severe side effects for the patients. Consequently, a bioactive compound must be superior 
potent with a therapeutic window or the first agent of its class before it can advance into the 
discovery pipeline in the pharmaceutical industry. 
Target a novel biological mechanism: To be relevant for the pharmaceutical industry it is 
important that the compound target a novel biological mechanism [167]. Pharmaceuticals 
developed today only target 483 out of the estimated 3,000-10,000 therapeutic targets leaving a 
huge potential for novel pharmaceuticals [168]. The molecular and cellular mechanisms can be 
investigated within academia through for example fluorescent probes. The bioactive NPs are 
labeled with a single fluorescent dye through a linker resulting in a fluorescent probe. It is 
important the linker do not revoke the binding of the NPs to the cellular receptor [169]. The 
fluorescent probe is subsequently incubated with the cancer cells. It is possible to visualize the 
therapeutic mode of action of the bioactive NPs through LED fluorescence microscopy [170,171]. 
This approach provide valuable information but can be complicated to execute due to the lack of 
selective mono-functionalization reactions and that bioactive NPs often are isolated in limited 
quantities [169]. 
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Reasonably bioavailability. The awareness of the importance of bioavailability has increased 
in NPs chemistry and is important to consider already at an early stage in the drug discovery 
[172]. Lipinski's 'rule-of-five' [173] can be a measurement for oral bioavailability. The use of 
Lipinski's 'rule-of-five' in NPs is a highly discussed topic among NPs chemists from the pure 
rejection of the concept to a narrowing of the rules. The basis of the rejection is that the ‘rule-of-
five’ can be counter-productive due to an overemphasizing of bioavailability that exclude 
interesting bioactive NPs [172]. The narrowing of the rules is a more conservative opinion leaving 
room for developed development of synthetic analogs that satisfy the ‘rule-of-five’. The 
discussion of Lipinski's 'rule-of-five' moving in a grey area where the rejection of the rules allows 
more compounds to be developed but probably fewer compounds that are approved for clinical 
use. In contrast, many potential leads might be excluded too early in the process. 
 
In the discussion on the gap between academia and the pharmaceutical industry it is important 
to address our role as universities, which may include discovery of novel scaffolds to inspire the 
pharmaceutical industry or develop new methods. For academia to discover novel bioactive 
compounds and make them relevant for the industry requires: a strong cross-disciplinary 
cooperation in academia, the right contact to industry, understand the marked, and funding for 
industrial cooperation. Nevertheless, the final development of new drugs, including clinical trials 
and approval, must lie with the industry. This synergism can lead to discovery of novel 
pharmaceutical in the future. 
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 Concluding Remarks 
Filamentous fungi have an amazing ability to synthesize incredible structural diverse 
molecules. In this PhD study we pursued bioactive NPs targeting CLL cells through a combined 
approach of LC-DAD-HRMS-based dereplication, E-SPE, and a co-culture platform of CLL and 
stromal cells. A screening campaign of 289 crude fungal extracts resulted in identification of 11 
compounds with activity towards CLL cells. Four of the compounds, ophiobolin A, B, C and K, 
induced apoptosis in CLL cells with LC50 values between 1 and 8 nM and a narrow therapeutic 
window. Proxiphomin displayed cytotoxic activity towards CLL cells with a LC50 value of 20 
µM. The remaining six compounds responsible for the activity towards CLL cells were regarded 
as general cytotoxic compounds.  
These low hit-rate of finding novel bioactive compounds in this project indicate that bioactive 
compounds produced by the genera Penicillium and Aspergillus are already well studied. New 
methods might be needed to achieve the goal of discovering new scaffolds. Strategies including 
co-culture cultivation, epigenetic modification, and molecular biology can provoke expression of 
some of the often more than 50 % silent gene clusters present in filamentous fungi, thereby 
enhancing the chance to discover novel scaffolds and biosynthetic pathways. Alternatively, 
isolation of microorganisms originating from more underexplored habitats e.g. the deep sea may 
demonstrate to be rich sources of novel bioactive NPs. 
The work performed in this PhD study has demonstrated that the combined use of E-SPE and 
comparative dereplication assist fast identification of bioactive NPs. This approach can be 
sharpened with the aim of decrease rediscovery of general cytotoxic compounds. This might be 
done by introduction of prefractionation and dereplication combined with an orthogonal screening 
already at the preliminary stage. By this approach projects needs to be closed before large scale 
incubation, if comparative dereplication indicates a known compound as the potential candidate 
for activity. Future research in dereplication supported by molecular networking based on MSMS 
fragmentation libraries and bioassay results might add to discovery of bioactive compounds. A 
conservative approach like this requires more time spend with preliminary screening and no 
guarantee for success within the time period of one PhD project. Though this approach a more 
solid foundation might be provided for discovery of novel scaffolds in the extracts selected for 
large scale incubation.  
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Abstract: This review covers important anticancer and antifungal compounds reported 
from filamentous fungi and in particular from Aspergillus, Penicillium and Talaromyces. 
The taxonomy of these fungi is not trivial, so a focus of this review has been to report the 
correct identity of the producing organisms based on substantial previous in-house 
chemotaxonomic studies. 
Keywords: anticancer; polyketides; non-ribosomal peptides; terpenoids; fungi;  
natural products; taxonomy 
 
1. Introduction 
Filamentous fungi such as Aspergillus, Penicillium and Talaromyces are some of the most incredible 
chemical factories known today. Accordingly, numerous bioactives such as mycotoxins, antifungal and 
anticancer agents have been reported in the literature within the last more than 100 years [1]. Despite this 
many new compounds revealing remarkable new bioactivities are still being discovered, including 
well-known metabolites such as griseofulvin [2–5]. This, combined with the fact that large 
combinatorial libraries have not provided the anticipated number of new chemical entities explains 
why the field of natural products is currently assuming new prominence. Thus, natural products are 
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still used as scaffolds for synthetic organic chemistry, although nowadays primarily for designing 
smaller and more focused diversity oriented synthesis-derived libraries [6]. 
It has been estimated that approximately 1.5 million or likely as many as 3 million fungal species 
exist on Earth, of which only around 100,000 species have been described so far [7]. A multitude of 
new species are likely to be discovered from diverse habitats, such as tropical forest plants and soils, 
associated to insects and in the marine environment. In addition to untapped biodiversity recent 
sequencing of complete fungal genomes has revealed that many gene clusters are silent, suggesting the 
possibility for many more compounds [8]. Despite several efforts to stimulate such pathways using 
epigenetic modifiers [9,10], it is evident that we still do not know the full biosynthetic potential even 
of well studied model organisms such as Aspergillus nidulans, altogether strongly indicating Nature’s 
potential as source of new promising bioactive small molecule scaffolds. 
The renewed interest in natural product discovery is further enhanced with the new strategies  
and methodologies for fast dereplication that have been developed within the last decade.  
Thus chromatographic and spectroscopic methods are combined with database searching in for 
example Antibase, which is a comprehensive database for natural products from microorganisms [11]. 
The performance of mass spectrometers is continuously improving, including easy access to both positive 
and negative ionization spectra even during fast ultra-high-performance liquid chromatography (UHPLC). 
Altogether the use of accurate mass measurements for dereplication of unknown compounds reduces 
the number of predicted elemental compositions, ensuring that database searches are conducted with 
the fewest possible candidates [12]. The use of UV spectral information is often important in the 
dereplication process for prioritizing between the MS-generated candidates, as well as for UV-guided 
discovery of novel compounds [13,14]. 
This article reviews anticancer and often also antifungal natural products primarily produced by 
Aspergillus, Penicillium and Talaromyces. For practical reasons the compounds have been grouped 
into major biosynthetic classes, according to the biosynthetic origin of the core part of the structures, 
despite that many compounds are actually of mixed biosynthetic origin (e.g., prenylated). This review 
is broader in scope than other recent reviews only focusing on endophytes [15,16], and a strong focus 
has been on giving the correct identity of the species reported in the literature, where many may 
previously have been misidentified or names have been changed according to the 2011 Amsterdam 
Declaration on Fungal Nomenclature [17]. 
2. Polyketide-Derived Anticancer Compounds 
Polyketides represents one of the major classes of natural products of which many are biological 
active [1]. Today much is known about the enzymes involved in the biosynthesis of a huge diversity of 
both non-reduced (aromatic), partly reduced and highly reduced polyketides [8]. 
Some famous fungal polyketides with anticancer activity belong to the statin family. The statins are 
well known cholesterol synthesis inhibitors that are used in clinical treatment of hypercholesterolemia 
and cardiovascular diseases [18–21]. Moreover, members the statin family are known to have 
antifungal properties against Aspergillus spp. and Candida spp. [18,22–24]. The statin family includes 
a long list of both natural and synthetic compounds, for example the naturally derived compactin, 
lovastatin and pravastatin. The statin structure is based on a dicyclohexene ring system connected to a 
Molecules 2013, 18 11340 
 
 
dicyclohexene ring system connected to a side chain with a closed lactone ring or an open acid form [21]. 
The compactins are primarily produced by P. solitum and P. hirsutum [20,25] (first misidentified as  
P. brevicompactum [18] and a fungus identified as P. citrinum [19]). Another group of statins that has an 
extra methyl group attached on the dicyclohexene ring system are produced by A. terreus [26] and 
Monascus spp. [27]. Several in vitro activities of the statins have been published throughout the years. 
Reports showed that compactin (Figure 1a) inhibited acute myeloid leukemia (AML) cells with a full 
inhibitory concentration (IC100) of 2.6 µM [28]. The analogs lovastatin (Figure 1b) and simvastatin 
(Figure 1c) have been shown to be even more potent. 
Figure 1. Statins: (a) Compactin, (b) Lovastatin and (c) Simvastatin. 
 
Lovastatin and the synthetic simvastatin selectively inhibited colony growth of primary AML cells 
with 75%–95% effectiveness. No effect was seen on normal bone marrow [29]. The more recent 
reported activities includes reduction of proliferation by lovastatin in four lung cancer cell lines with 
median inhibitory concentration (IC50) values between 1.5 and 30 µM [30]. In 2010 it was shown that 
lovastatin induced apoptosis in ten ovarian cancer cell lines tested, with IC50 values between 2 and  
39 µM [31], and recently lovastatin was found to inhibit breast cancer MCF-7, liver cancer HepG2, 
and cervical cancer HeLa cell lines with IC50 values of 0.7, 1.1 and 0.6 µg/mL, respectively [32]. 
Simvastatin inhibited two lung cancer, three melanoma, and four breast cancer cell lines with IC50 
values between 0.8 and 5.4 µM and induced apoptosis with reduced tumor growth in hepatic cancer 
cells [33,34]. Encouraged by these results simvastatin has entered clinical trials as an anticancer drug [35]. 
The three small polyketides terrein, brefeldin A, and asperlin are examples of well-known 
metabolites that a couple of decades after they were discovered were shown to exhibit novel anticancer 
activities. The small antifungal [36] polyketide terrein (Figure 2a) produced by A. terreus has been 
known since 1935 [37]. Almost 80 years later it was found that terrein inhibits breast cancer by 
induction of apoptosis with an IC50 value of 1.1 nM in MCF-7 cell line. That makes terrein 100-fold 
more potent than taxol against this cell line. Additionally terrein was found active against pancreatic 
and liver cancer cell lines PANC-1 (IC50 9.8 µM) and HepG2 (IC50 66.8 µM) [38]. 
Figure 2. Small polyketides: (a) Terrein, (b) Brefeldin A, and (c) Asperlin. 
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Brefeldin A (Figure 2b), another small antifungal [39,40] polyketide isolated in 1958 from  
P. brefeldianum [41] was identified almost 40 years later as inducer of apoptosis in leukemia (HL-60 
and K-582), colon (HT-29), prostate (DU-145), cervical (KB and HeLa), breast (MCF-7 and BC-1), 
and lung (SPC-A-1 and NCI-H187) cancer cell lines [42–45]. The inhibiting effect of brefeldin A was 
demonstrated with IC50 values 35.7 nM (HL-60), 32 nM (KB), 6.4 nM (HeLa), 7.1 nM (MCF-7),  
40 nM (BC-1), 6.3 nM (SPC-A-1), and 110 nM (NCI-H187) [44,45]. 
Asperlin (Figure 2c) was isolated from A. nidulans in 1966 [46]. In 2011 it was discovered that 
asperlin reduces cell proliferation and induce G2/M cell cycle arrest in the human cervical carcinoma 
HeLa cell line [47]. 
Filamentous fungi are known to produce anticancer polyketides with different spiro ring structures. 
One of the more well-known is the antifungal [48,49] compound griseofulvin (Figure 3a) from  
P. griseofulvum [50]. Griseofulvin was introduced commercially in 1965 and first considered for 
cancer treatment in 1973 [49,51]. Later it was shown to induce cell proliferation and mitosis in the 
human cervical cancer cell line HeLa with an IC50 value of 20 µM, as well as it inhibits centrosomal 
clustering in human squamous cancer SCC-114 cell line with an IC50 value of 35 µM [2,3].  
The synthetic analog GF-15 increased the inhibitory effect of centrosomal clustering in SCC-114 cells  
25-fold with an IC50 value of 0.9 µM [5]. It was further shown that combined treatment of griseofulvin 
and the cancer chemotherapeutic agent nocodazole in vivo improved the effect of nocodazole and 
arrested tumor growth in mice infected with COLO 205 tumors [4]. 
Other examples of fungal anticancer polyketides with spiro ring structures are sequoiamonascin A 
(Figure 3b) and B from A. parasiticus [52]. Sequoiamonascin A demonstrated selective cytotoxicity 
against six leukemia cell lines and two melanoma cell lines with a median growth inhibitory (GI50) 
log10 value of -6.00 [52]. Furthermore, sequoiamonascin A shows cytotoxic activity against breast 
cancer MCF-7, lung cancer NCI-H460 and central nervous system (CNS) cancer SF-268 cell lines 
where cell growth can be reduced to 1%–2% when treated with 10 µM sequoiamonascin A [52]. 
Figure 3. Spiro compounds: (a) Griseofulvin, and (b) Sequoiamonascin A. 
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A group of fungal γ-pyrones were found to have activity against cancer. An example of these is the 
antifungal [48,49] 3-O-methylfunicone (Figure 4a) produced by T. pinophilus (originally published as 
P. pinophlium) [1,48]. It induced apoptosis and affects cell proliferation in various cancer cell lines 
including HeLa, MCF-7, A-375P and A-375M [50–53]. Another structurally related compound is 
penisimplicissin (Figure 4b) isolated from T. pinophilus (originally published as P. simplicissimum) [54]. 
It displayed selective cytotoxicity towards leukemia HL-60 and CCRF-CEM cell lines with log10 GI50 
−6.7 and −5.8, respectively [55]. 
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Figure 4. γ-Pyrones: (a) 3-O-Methylfunicone and (b) Penisimplicissin. 
 
A group of more than 20 closely related azaphilones, namely the antifungal [56] chaetomugilin family, 
has been isolated within the last five years from marine fish-derived Chaetomium globosum [57–64].  
The chaetomugilins C, I, P and 11-epichaetomugilin I (Figure 5) showed significant inhibition of two 
human leukemia P-388, HL-60 and one murine leukemia L-1210, as well as human cervical cancer cell 
line, KB with 11-epichaetomugilin I as the more potent with IC50 values of 0.7 µM (P-388), 1.0 µM 
(HL-60), 1.6 µM (L-1210), and 1.2 µM (KB) [62]. 
Figure 5. 11-Epichaetomugilin I. 
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The fungal metabolite norsolorinic acid (Figure 6a) with a tricyclic structure is produced by  
A. parasiticus and A. nidulans [65–68]. Norsolorinic acid selectively induced cell cycle arrest in G0/G1 
phase of the cell cycle and consequently induced apoptosis in human bladder cancer T-24 and human 
breast cancer MCF-7 with IC50 values of 10.5 and 12.7 µM, respectively [67,68]. 
Figure 6. (a) Norsolorinic acid and (b) Austocystin D. 
 
Austocystin D (Figure 6b) was isolated from A. pseudoustus [69] in 1974 (originally misidentified 
as A. ustus [70]). Austocystin D was shown to selectively inhibit growth of human colon carcinoma 
LS174T cells in mice and tumor cell lines that overexpress the multidrug resistance-associated protein [71]. 
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Additionally, austocystin D inhibited a number of cancer cell lines: SR (leukemia, GI50 16 nM),  
U-87 (brain, GI50 4946 nM), MCF-7 (breast, GI50 < 1 nM), MDA-MB-231 (breast, GI50 549 nM),  
PC-3 (prostate, GI50 3 nM), SW-620 (colon, GI50 27 nM), HCT-15 (colon, GI50 42 nM), and MX-2 
(uterine, GI50 3358 nM) [72]. Although, displaying diverse activities towards many types of cancer 
lines, austocystin D never entered clinical trials due to a low safety window [71]. 
The two epimers chloctanspirone A and B (Figure 7a) are probably produced by P. chrysogenum or 
P. rubens [73,74] (originally published incorrectly as P. terrestre [75]). Chloctanspirone A and B were 
the first chlorinated sorbicillinoids isolated from a natural source and the first to be identified with 
their very unique ring structure. Chloctanspirone A was the more active analog and inhibited human 
leukemia HL-60 and lung cancer cell line A-549 cell lines with IC50 values of 9.2 and 39.7 µM, 
respectively [76]. Chloctanspirone B however, only showed moderately or no activity against the same 
cell lines. Interestingly, the two precursors terrestrols K and L (Figure 7b) that contain the epicenter, 
which dissociates chloctanspirone A from B were inactive. This points to the conclusion that the 
cyclohexenone moiety has an impact on the activity though it is not the pharmacophore [76]. 
Figure 7. (a) Chloctanspirone A, B and (b) Precursors terrestrols K, L. 
 
A group of around 20 p-terphenyls were isolated from A. candidus and found to be cytotoxic against 
the human cervical cancer cell line HeLa [77]. Thirty years later a new group of prenylated-p-terphenyls, 
called prenylterphenyllins (Figure 8a), terprenins (Figure 8b), and prenylcandidusins (Figure 8c) were 
isolated from A. candidus and A. taichungensis [78,79]. The activity of these compounds were studied 
against lung cancer cell line A-549, human leukemia cell lines HL-60 and P-388, and human 
epidermoid cancer cell lines KB3-1 [78,79]. Prenylterphenyllin A was found to be the more active 
against A-549 and HL-60 with IC50 values of 8.3 and 1.5 µM, respectively [79], whereas  
4′′-deoxyisoterprenin displayed higher activity towards KB3-1 with an IC50 value of 6.2 µM [78], and 
finally prenylcandidusin B showed higher activity against P-388 with an IC50 value of 1.6 µM [79]. 
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Figure 8. Prenylterphenyllins: (a) Prenylterphenyllin A, (b) 4′′-Deoxyisoterprenin,  
and (c) Prenylcandidusin B. 
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In 2011 five new di- and tricitrinols were added to the known citrinin family from P. citrinum [80]. 
All five of them showed cytotoxic activity against human leukemia HL-60, colon cancer HCT-116, 
and cervical cancer KB cell lines. The more potent was tricitrinol B (Figure 9), with IC50 values of 3.2, 
4.8 and 3.9 µM, respectively [80]. 
Figure 9. Tricitrinol B. 
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The class of perylenequinones has been used for centuries in Chinese herbal medicine, but fungal 
production of several perylenequinones has likewise been reported [81]. The calphostins were isolated 
from Cladosporium cladosporioides and shown to inhibit cervical cancer HeLa-S3 and breast cancer 
MCF-7 cell lines. Most potent was calphostin C (Figure 10a) with IC50 values of 0.23 and 0.18 µM, 
respectively [82]. Furthermore, calphostin C induced apoptosis in acute lymphoblastic leukemia [83]. 
The hypocrellins, another branch, of the perylenequinone family was isolated from Hypocrella 
bambusae, originally published incorrectly as Shira bambusicola [84,85]. Hypocrellin D was one of 
the more potent analogs and inhibited liver (Bel-7721) and lung (A-549 and Anip-973) cancer cell 
lines, with IC50 values, 1.8, 8.8, 38.4 µg/ml, respectively [85]. Additionally, the hypocrellins had a 
photodynamic effect on a wide range of tumor cell lines. Due to their insolubility in water several 
analogs have been synthesized to improve the pharmacokinetics and drug delivery. Two of the more 
successful analogs were carboxylate salt derivatives of hypocrellin B (Figure 10b) with increased 
water solubility and activity against human breast cancer MCF-7 when photodynamic therapy was 
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used [81,86]. In 2012 a new group of perylenequinones called the phaeosphaerins were isolated from 
Phaeosphaeria sp. with phaeosphaerin B (Figure 10c) as the more potent against prostate PC-3,  
DU-145, LNCaP cancer cell lines with IC50 values of 2.4 µM, 9.5 µM and 2.7 µM, respectively [87]. 
Figure 10. Perylenequinones: (a) Calphostin C, (b) Hypocrellin B and (c) Phaeosphaerin B. 
 
3. Nitrogen-Containing Anticancer Compounds 
Fungal nitrogen containing compounds represent another large group of natural products, of which 
many have famous bioactivities. In general these types of compounds incorporate amino acid building 
blocks into often complex heteroaromatic compounds such as diketopiperazines, quinazolines and 
benzodiazepines [1]. Often these compounds are referred to as alkaloids, due to their basic nature, 
when containing primary, secondary or tertiary amine functionalities. However, compounds only 
containing amide bonds, that are essentially neutral, are often also referred to as alkaloids. In recent 
years it has become clear that many nitrogen containing compounds are biosynthesized by 
multifunctional enzymes (non-ribosomal peptide synthases, NRPS) with modular arrangements 
comparable to that seen for some polyketide synthases. In such contexts these compounds are usually 
referred to as non-ribosomal peptides (NRPs) even though they are also called alkaloids [88]. In the 
following section no attempt has been made to differentiate between the different naming of the 
numerous amino acid-derived metabolites. 
The antifungal [89] xanthocillin X (Figure 11) was first isolated from Dichotomomyces albus 
ascribed to D. cejpii [90], but is produced by P. chrysogenum as well [1]. In 1968 xanthocillin X was 
found active against a Ehrlich ascites carcinoma-mouse strain with median lethal dose (LD50) of  
40 mg/kg [91]. Approximately 40 years later it was shown that xanthocillin X inhibited leukemia  
K-562, human cervical cancer HeLa, breast cancer MCF-7 and MDA-MB-231, liver cancer HepG2, 
lung cancer NCI-H460, and prostate cancer DU-145 cell lines with IC50 values between 0.4 and  
12 µg/ml [89,92]. Two structural analogs named BU-4704 and xanthocillin X di-methoxy were found 
more potent than xanthocillin X. Instead of the two hydroxy groups BU-4704 contains a methoxy and 
a sulfonic acid group and xanthocillin X di-methoxy contains two methoxy groups. BU-4704 inhibited 
human colon HCT-116 and murine melanoma B16-F10 with IC50 values of 0.6 and 4.3 µg/mL, 
respectively [93]. Xanthocillin X di-methoxy inhibited HepG2, MCF-7 and KB cancer cell lines with 
IC50 values of 0.18, 0.38 and 0.44 µg/mL, respectively [94]. 
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Figure 11. Xanthocillin X. 
 
Asperphenamate (Figure 12) was first isolated from A. flavipes [95] and later found to be produced 
by several of Penicillium spp. as well [96]. Asperphenamate displayed moderate cytotoxic activity 
against several cancer cell lines [97]. Due to the low activity and a low water solubility 
asperphenamate was used as a lead for synthetic structurally isomers. It was found that the (R,S) 
stereoisomers were more potent than the (S,R) stereoisomers [98]. The more active asperphenamate 
derivate was N-benzoyl-O-(N′-(1-benzyloxycarbonyl-4-piperidiylcarbonyl)-D-phenylalanyl)-D-phenyl- 
alaninol (BBP). BBP was approx. 20-fold more active than asperphenamate against breast cancer 
(MCF-7, T47D and MDA-MB231), hepatic (BEL-4702), lung (A-549), and cervical (HeLa) cancer as 
well as leukemia (HL-60) cell lines, with IC50 values between 3.0 and 18.3 µM [99]. 
Figure 12. Asperphenamate. 
 
Cyclic di-peptides called diketopiperazines are in general known as cell cycle inhibitors of the 
G2/M phase [100]. Tryptophan/proline diketopiperazines covers the compound groups 
fumitremorgins, stephacidins, notoamides, tryprostatins, etc. This group of compounds is produced by 
a long range of Aspergilli [101–110]. The fumitremorgins are produced by A. fumigatus and  
A. fischeri [101–103,111]. Fumitremorgin C (Figure 13a) was found active against human leukemia  
P-388 with an ED50 value of 3.9 µg/mL and the analog 12,13-dihydroxyfumitremorgin C has 
antiproliferative effects on human leukemia U-937 and human prostate cancer PC-3, with IC50 values 
of 1.8 and 6.6 µM, respectively [111,112]. Furthermore fumitremorgin C was specifically and potently 
cytotoxic against multi-drug resistant breast- and colon cancer [113,114]. 
Two other tryptophan/proline diketopiperazines are stephacidin A (Figure 13b) and B produced by 
A. ochraceus and A. westerdijkiae [106,107]. Stephacidin B is the dimeric form of stephacidin A and 
was approximate 10-fold more potent. Stephacidin B exhibited inhibitory effect on prostate, ovarian, 
colon, breast and lung cancer cell lines with IC50 values between 0.06 and 0.4 µM [106]. 
The notoamides (Figure 13c) produced by A. amoenus are close analogs to the stephacidins, but 
with a spiro ring structure [115]. Contrary to the stephacidins the notoamides only showed low to 
moderate inhibition of two leukemic cell lines with IC50 values 22–52 µg/mL [116]. 
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Figure 13. Tryptophan/proline diketopiperazines: (a) Fumitremorgin C, (b) Stephacidin A, 
(c) Notoamide A, (d) 18-Oxotryprostatin A and (e) Spirotryprostatin E. 
 
Finally, the tryprostatins (Figure 13d) and spirotryprostatins (Figure 13e) isolated from A. fumigatus 
where found active against lung (NCI-H-522 and A-549), breast (MCF-7) and prostate (PC-3) cancer 
as well as leukemia (HL-60 and MOLT-4). The more potent analogs were Ds1-tryprostatin B with GI50 
values of 15.8 µM (NCI-H-522), 15.9 µM (MCF-7), and 11.9 µM (PC-3) and 18-oxotryprostatin A 
with an IC50 value of 1.3 µM (A-549) [108,110]. Spirotryprostatin E was the more potent of the 
spirotryprostatins, with IC50 values of 3.1 µM (MOLT-4), 2.3 µM (HL-60) and 3.1 µM (A-549) [109]. 
Other diketopiperazines originating from histidine are phenylahistin (Figure 14a) and aurantiamine 
(Figure 14b). Phenylahistin was first isolated from A. ustus in 1997 as a mixture of enantiomers [117]. 
(−)-Phenylahistin was more active than (+)-phenylahistin against dermal (A-431), lung (A-549), ovary 
(HeLa), leukemia (K-562 and P-388), breast (MCF-7), CNS (TE-671) and colon (WiDr) cancer cell 
lines with IC50 between 0.18 and 3.7 µM [118]. A synthetic analog plinabulin (NPI-2358) displays very 
potent activity against human prostate carcinoma cell line DU-145 and has now entered phase II 
clinical trials [119]. Recently, more than 60 synthetic analogs of plinabulin have been designed and 
synthesized. The more active analog with a benzoyl group coupled on the phenylalanine unit was  
10-fold more active than plinabulin with an IC50 value of 1.4 nM [119]. The activity of phenylahistin 
was also compared to the diketopiperazine aurantiamine and other synthetic analogues [120], 
originally isolated by Larsen et al. [121]. 
Figure 14. (a) Phenylahistin and (b) Aurantiamine. 
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Another group of diketopiperazines with anticancer activity contain a di-sulfide bridge in the 
diketopiperazine ring. One of them the antifungal, immunosuppressive and antimicrobial compound 
gliotoxin (Figure 15a) that was isolated from A. fumigatus, and D. cejpii [122–124]. Already in 1947 
the anticancer activity of gliotoxin was suggested and in 2004 it was found that gliotoxin was a very 
potent inhibitor of six breast cancer cell lines with IC50 values between 38 and 985 nM [125,126]. In 
2012, gliotoxin was found active against human leukemia U-937 and human prostate cancer PC-3 cell 
lines with IC50 values of 0.2 and 0.4 µM, respectively [112]. 
Figure 15. Diketopiperazines with a di-sulfide bridge: (a) Gliotoxin, (b) Emestrin A and 
(c) Acetylapoaranotin. 
 
Another diketopiperazine with a di-sulfide bridge is the antifungal [127] compound emestrin A 
(Figure 15b) that was isolated from Emericella striata, now called A. striatus [128]. Emestrin A 
inhibits human leukemia (HL-60) with an IC50 value of 83.5 nM [129]. Eight structural analogs of 
emestrin A were isolated from Cladorrhinum sp. and found to have strong antiproliferative effects on 
the human prostate DU-145 cancer cell line with an IC50 value of 9.3 nM for the more potent emestrin 
C. Furthermore, it was proven that the activity decreased when the macro cyclic ring was opened and 
the polysulfide bridge in the diketopiperazine was absent [130]. 
Recently, a new diketopiperazine with a di-sulfide bridge named acetylapoaranotin (Figure 15c) 
produced by a marine Aspergillus sp. was discovered and found active against colon (HCT-116), 
gastric (AGS), lung (A-549), and breast (MCF-7) cancer cell lines with IC50 values of 13.8, 12, 2 and 
10 µM, respectively [131]. 
The peptide leucinostatin A (Figure 16) was first isolated in 1973 from Purpureocillium lilacinum 
(originally published as Penicillium lilacinum or Paecilomyces lilacinus) [132,133]. It was found 
active against a number of fungi and Gram-positive bacteria, as well as Ehrlich solid carcinoma of 
mice with an ED50 value of 1.6 mg/kg [132,134]. Furthermore leucinostatin A inhibited a long range of 
breast, melanoma, lung, ovary, colon and laryngeal cancers as well as eight leukemia cell lines with 
IC50 values between 4 nM and 12 µM [132,135,136]. Leucinostatin A inhibited growth of prostate 
cancer DU-145 cells in vitro and in vivo [137]. A natural analog leucinostatin A β di-O-glycoside 
displayed active against breast cancer BT-20 cell line, though not as potent as leucinostatin A [138]. 
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Figure 16. Leucinostatin A. 
 
4. Terpenoid-Derived Anticancer Compounds 
Terpenoids form a third large and structurally diverse biosynthetic family of natural products 
derived from C5 isoprene units. Until now active anticancer terpenoids mostly belong to the  
sesqui- or diterpenoids [15]. 
Taxol, also known as paclitaxel (Figure 17), is one of the best known anticancer drugs produced by 
fungi, though it originally was isolated from the bark of yew tree Taxus brevifolia [139]. Clinical 
development of taxol was delayed due to problems with production of large enough quantities of the 
compound. This problem was solved 20 years later when it was demonstrated that taxol was also 
produced by the fungus Taxomyces andreanea [140] and later including P. raistrickii [141]. 
Figure 17. Taxol. 
 
Taxol was approved as anticancer drug against a wide range of tumors in the 1990s and is the first 
billion dollar drug against cancer [142,143]. Taxol functions by inducing cell cycle arrest in G2/M 
phase as well as apoptosis through a unique mode-of-action by promotion and stabilization of tubulin 
polymerization [144]. Today, taxol is routinely used to treat ovarian, breast and lung tumors as well as 
Kaposi’s sarcoma [145]. Besides its anticancer activity taxol displays antifungal activity as well [146]. 
Many sesquiterpenes have been found active against cancer. Two of these are the drimane 
sesquiterpenes fudecadione A and B (Figure 18a) that were isolated in 2011 from Penicillium sp. BCC 
17468. Fudecadione A was found active against human lung cancer NCI-H187, human breast cancer 
MCF-7, and human oral epidermoid carcinoma KB cell lines, with IC50 values of 24.9, 12.6 and  
22.6 µM, respectively. Fudecadione B, on the other hand, was inactive against all three cancer call 
lines [147]. The activity of the two compounds suggests that the pharmacophore is located around the 
carbon at position 13, where fudecadione B is more branched [147]. 
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Figure 18. (a) Fudecadione A, (b) Terrecyclic acid A and (c) a novel unnamed  
chloro-trinoreremophilane sesquiterpene. 
 
Another active sesquiterpene is the antifungal terrecyclic acid A (Figure 18b), which was isolated 
from A. terreus in 1986 [148]. Terrecyclic acid A exhibit cytotoxic activity against human lung cancer 
NCI-H460, human breast cancer MCF-7, and human CNS cancer SF-268 cell lines with IC50 values of 
10.6, 24.1 and 14.7 µM, respectively, and against leukemia in mice P-388 with LD50 values of  
63–125 mg/kg [148,149]. 
In 2013 a novel and as yet unnamed chlorotrinoreremophilane sesquiterpene (Figure 18c) was isolated 
from Penicillium sp. PR19N-1 [150]. This novel sesquiterpene exhibited cytotoxic activity against human 
leukemia HL-60 and lung cancer A-549 cell lines with IC50 values of 11.8 and 12.2 µM, respectively [150]. 
A large group of mycotoxins called the trichothecenes cover more than 150 analogs and are mainly 
produced by a number of Fusarium spp. [151]. All the trichothecenes contain a sesquiterpenoid ring 
structure with an epoxide. The epoxide is often responsible for the cytotoxic activity by binding to the 
60S ribosomal subunit in eukaryote cells thereby inhibiting protein synthesis [152,153]. Many of the 
trichothecenes exhibit cytotoxic activity against both fungi and cancer cell lines [154–156]. One of the 
more potent is AETD (Figure 19a) that inhibits HL-60, U-937, HeLa, MCF-7 and Hep-G2 cell lines 
with IC50 values of 10, 22, 45, 53 and 170 nM [157]. Other bioactive groups are the roridins where a 
macrocyclic ring is connected to the sesquiterpenoid unit. One of the more active compounds of this 
group is 12′-hydroxyroridin E (Figure 19b), which inhibits leukemia L-1210 with an IC50 value of  
0.2 µM [158]. Another trichothecene called anguidine even entered clinical trials against cancer,  
but did not progress beyond phase II due to a lack of therapeutic efficacy [152,159]. 
Figure 19. Trichothecenes (a) AETD and (b) 12′-Hydroxyroridin E. 
 
Wentilactone A and B (Figure 20a) were isolated from A. wentii in 1980 [160]. In 2012 it was 
reported that wentilactone B induced apoptosis and inhibited proliferation in human hepatoma cancer 
cell line SMMC-7721, with an IC50 value of 19 µM [161]. 
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Figure 20. (a) Wentilactone B and (b) Wortmannin. 
 
The antifungal compound wortmannin (Figure 20b) is produced by T. wortmannii originally 
published as P. wortmannii [162] or a related species. Wortmannin inhibit the activity of leukemia  
HL-60 and K-562 cell lines with IC50 values of 30 and 25 nM, respectively [163,164], including the breast 
cancer MCF-7 cell line that was inhibited by 51.3% after 48 h with a concentration of 25 nM [165].  
In human pancreatic cancer cells lines PK1 and PK8 wortmannin induces apoptosis both in vitro and  
in vivo [166,167]. Finally, wortmannin has been shown to inhibit proliferation in lung cancer cell lines 
KNS-62 and Colo-699 both in vitro and in vivo, with IC50 values between 100 and 200 nM [168]. 
The ophiobolins are sesterterpenes mainly isolated from the fungal genus Bipolaris [169,170], but 
are also found in Aspergillus [171], Sarocladium [172,173], and Drechslera [174]. Isolation of 
ophiobolins from Aspergillus spp. misidentified as A. ustus were later ascribed to the three different 
species: A. calidoustus, A. insuetus, and A. keveii from the Aspergillus section Usti [69]. Ophiobolin A 
(Figure 21) exhibit inhibitory activity against cancer cell lines includes lung cancer A-549, colon 
cancer HT-29, melanoma Mel-20, leukemia P-388, and ovarian cancer OVCAR-3 with IC50 values of 
0.1, 0.1, 0.1, 0.06 and 0.3 µM, respectively [175,176]. In 2012 the novel ophiobolin O was discovered and 
it was found to inhibit breast cancer MCF-7 and leukemia P-388 cell lines with IC50 values of 17.9 and 
4.7 µM, respectively [177,178]. Most recently in 2013 the novel 3-anhydro-6-hydroxyophiobolin A 
was isolated and found active against lung cancer (HepG2) and leukemia (K-562) cell lines with  
IC50 values of 6.5 and 4.1 µM, respectively [179]. Besides anticancer activity the ophiobolin family 
show antifungal activity against a wide range of fungi [180,181]. 
Figure 21. Ophiobolin A. 
 
5. Anticancer Natural Products of Mixed or Unresolved Biosynthetic Origin 
Filamentous fungi are capable of producing secondary metabolites of mixed biosynthetic origin. 
This includes both compounds such as meroterpenoids that comprise a huge class of compounds that 
integrate a polyketide part with a terpenoid part [182], in addition to the cytochalasins [183] and 
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chaetoglobosins that are biosynthesized by incorporation of amino acids into a core polyketide part. 
The cytochalasins contains a phenylalanine coupled to the polyketide chain where the chaetoglobosins 
have an tryptophan moiety [183,184]. Both the cytochalasins and the chaetoglobosins exhibit 
antifungal activities against a broad range fungal species [56,185,186]. The cytochalasins are produced 
by many fungal genera including Aspergillus, Hypoxylon, Metarrhizium, Zygosporium, Hypocrella and 
Phoma [90,187–190]. Many of the cytochalasins have shown inhibitory activities towards lung cancer 
A-549. One of the more potent is cytochalasin E (Figure 22a) which inhibited human ovarian  
A-2780S, human colon HCT-116 and SW-620, and lung A-549 cancer as well as human leukemia  
P-388 with IC100 values of 0.02, 1.0, and 0.2 µg/ml and IC50 values of 0.006 and 0.09 µM,  
respectively [191,192]. 
Figure 22. (a) Cytochalasin E and (b) Chaetoglobosin B. 
 
The chaetoglobosins were originally isolated from Chaetomium globosum in 1973 [184]. Several 
chaetoglobosins have been isolated over the years from P. discolor and P. expansum among others [1] 
and many of them showed activity against cancer cell lines. Of the more potent ones was 
chaetoglobosin B (Figure 22b) that inhibited human breast BC cancer cell line with an IC50 value of 
3.0 µM [193] and chaetoglobosin D that inhibited adenocarcinoma KKU-100 and KKU-OCA17 
cancer cell lines with IC50 values of 3.4 and 12.2 µM, respectively [193]. Chaetoglobosin U showed 
activity as well against KB tumor cell line with an IC50 value of 16.0 µM [194], and chaetoglobosin X 
with activity against murine hepatic cancer H-22 cell line with an IC50 value of 7.5 µM [195]. 
Another group of compounds with mixed a biosynthetic pathway are the pseurotins (Figure 23) 
containing phenylalanine coupled to a polyketide and with a spiro ring structure. The pseurotins were 
first isolated from the bacteria Pseudeurotium ovalis and later from the fungus A. fumigatus [196,197]. 
In 2012 four pseurotin analogs were proven active against a human breast cancer cell line MCF-7 with 
the more active pseurotin D inhibiting MCF-7 with an IC50 value of 15.6 µM [198]. 
Figure 23. Pseurotin A. 
 
The γ-pyridone alkaloids, penicidone A–C (Figure 24a) were isolated from an endophytic 
Talaromyces sp. The biosynthesis of penicidones probably happens through the polyketide pathway 
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similar to penisimplicissin (Figure 24b), but with a unique introduction of nitrogen [199]. The 
penicidones were showed to be active against human colon cancer SW1116, human AML (K-562), 
and human cervical cancer (KB and HeLa) cell lines with penicidone B being the more potent analog. 
Penicidone B inhibited the four cancer cell lines with IC50 values of 54.2 µM (SW1116), 21.1 µM  
(K-562), 29.6 µM (KB), and 35.2 µM (HeLa) [199]. Two other γ-pyridone alkaloids called 
penicinoline (Figure 24b) and methylpenicinoline were isolated from an endophytic Penicillium sp. 
and Auxarthron reticulatum in 2010 and 2011, respectively [200,201]. Penicinoline and  
methylpenicinoline were shown to inhibit the lung cancer HepG2 cell line with IC50 values of 13.2 and 
11.3 µM, respectively [202]. 
Figure 24. (a) Penicidone B and (b) Penicinoline. 
 
Communesins are fungal metabolites produced in P. marinum, P. expansum, P. buchwaldii and  
P. rivulorum [96,203–205]. The group is of highly mixed biosynthetic origin with structures 
combining a nitrogen-containing part, a polyketide chain and isoprene. Communesin B (Figure 25) 
displays the highest activity of them all against leukemia P-338, U-937, THP-1, NAMALWA,  
MOLT-3 and SUP-B15 cell lines with ED50 values of 0.5, 10.4, 11.4, 9.9, 8.1 and 7.2 µg/mL, 
respectively [206,207]. 
Figure 25. Communesin B. 
 
The antibiotic compound fumagillin (Figure 26a) has been one of the more potent and interesting 
compounds associated with anticancer activity produced by fungi. Fumagillin, classified as a 
meroterpenoid, was first isolated from A. fumigatus in 1951 [208] and further produced by  
P. scabrosum [209]. The antitumor activity of fumagillin is caused by its potent angiogenesis-inhibiting 
effect. Unfortunately, fumagillin had some unpleasant side effects and consequentially investigations 
into structural analogs have been conducted [210]. The synthetic fumagillin analog TNP-470 (Figure 26b) 
contains an amine and chlorine in the side chain, which led to a highly increased  
angiogenesis—inhibiting effect. Furthermore, TNP-470 is less toxic to normal cells compared to 
fumagillin [210,211]. In vitro and in vivo tests showed that TNP-470 inhibited tumor growth in 
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prostate (PC-3) and breast cancer (MDA-MB-231). TNP-470 entered preclinical trails in 1992 and 
phase I and II in 2000 but did not progress into phase III, due to a very short systemic half-live and 
observed neurotoxicity in patients [212–214]. Recently, in 2013, a novel natural fumagillin analog 
namely ligerin (Figure 26c) was isolated from a marine-derived Penicillium sp.[215]. Ligerin inhibited 
lung cancer POS1 cell line with an IC50 value of 117 nM [215]. 
Figure 26. (a) Fumagillin, (b) Synthetic analog TNP-470 and (c) Ligerin. 
 
A strain so far identified as Talaromyces purpurogenus (earlier P. purpurogenum) is known to produce 
another group of meroterpenoids namely purpurogemutantin (Figure 27a), purpurogemutantidin  
(Figure 27b), and the known antifungal macrophorin A (Figure 27c) [216,217]. All three compounds 
inhibit human leukemia K-562 and HL-60, human cervical cancer HeLa, human gastric 
adenocarcinoma BGC-823 and human breast cancer MCF-7 cell lines. Purpurogemutantidin (Figure 27a) 
was the more potent, with IC50 values of 0.9, 2.4, 16.6, 31.0, and 26.3 µM, respectively. The only 
exception is macrophorin A that displayed higher activity towards the HL-60 cell line with an IC50 
value of 0.9 µM [216]. 
Figure 27. (a) Purpurogemutantin, (b) Purpurogemutantidin and (c) Macrophorin A. 
 
Botryodiplodin (PSX-1), a small antifungal [218] compound of unresolved biosynthetic origin 
(Figure 28), was isolated from T. stipitatus (originally named P. stipitatum) [219] and exhibits activity 
against Ehrlich ascites carcinoma, leukemia L-5178, Sarcoma 37, and cervical cancer Hela cell lines 
with a median effective dose (ED50) values of approximately 1 µg/mL [219,220]. 
Figure 28. Botryodiplodin (PSX-1). 
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The atpenins A4, A5 and B (Figure 29) of unresolved biosynthetic pathway were first isolated from 
P. atramentosum in 1988 and shown to possess antifungal activities [221]. Twenty years later the first 
three atpenins were isolated again from the same fungi along with two new analogs, NBRI23477 A 
and B [222]. The activities of the five atpenins were examined individually against human prostate 
cancer cell line DU-145 and in a stromal co-cultured assay. Growth of the DU-145 cells was inhibited 
more effectively in the co-cultured setup, with atpenin A5 being the more potent analog with an IC50 
value of 0.02 µg/mL [222]. All the reviewed compounds are summarized in Table 1 with their 
individual organisms of origin, biosynthetic pathways, target cancer cells, IC50 (if available), and 
whether the compounds exhibit antifungal activity too. 
Figure 29. Atpenin A5. 
 
Table 1. List of fungal anticancer natural products primarily produced by Aspergillus, 
Penicillium and Talaromyces summarizing producing organisms, biosynthetic origin, target 
cancer cells, IC50 (if available), and if the compounds exhibit antifungal activity. 
Species (original 
published) Compound Type Target cell IC50 Anti-fungal (+/−) 
T. pinophilus [1] 
(P. pinophilum [48]) 
3-O-methylfunicone 
[50–53] 
Polyketide HeLa - + [48,49] 
MCF-7 - 
A-375P - 
A-375M - 
A. nidulans [46] Asperlin [47] Polyketide HeLa - − 
A. flavus [95] 
Penicillium spp. [96] 
Asperphenamate NPR - - − 
A. flavus [95] 
Penicillium spp. [96] 
BBP [99] NPR MCF-7 3.0 µM 
T47D 4.7 µM 
MDA-MB231 5.2 µM 
BEL-4702 12.7 µM 
A-549 15.1 µM 
HeLa 17.0 µM 
HL-60 18.3 µM 
Aspergillus sp. [131] Acetylapoaranotin 
[131] 
NPR HCT-116 13.8 µM − 
AGS 12 µM 
A-549 2 µM 
MCF-7 10 µM 
P. atramentosum [222] Atpenin A5 [222] Unresolved 
biosynthetic 
origin 
DU-145  
(co-culture) 
0.02 µg/mL + [221] 
A. puniceus [69] 
A. turkensis [69] 
A. pseudoustus [69] 
A. ustus [70] 
Austocystin D [71,72] Polyketide SR 16 nM (GI50) − 
U-87 4946 nM (GI50) 
MCF-7 <1 nM (GI50) 
MDA-MB-231 549 nM (GI50) 
PC-3 3 nM (GI50) 
SW-620 27 nM (GI50) 
HCT-15 42 nM (GI50) 
MX-2 3358 nM (GI50) 
P. brevicompactum [20] 
P. paneum [223] 
T. stipitatus [1] 
(P. stipitatum [220]) 
Botryodiplodin 
[219,220] 
Unresolved 
biosynthetic 
origin 
EAC 0.6 µg/mL (ED50) + [218] 
L-5178 0.8 µg/mL (ED50) 
Sarcoma 37 1.5 µg/mL (ED50) 
HeLa 2.0 µg/mL (ED50) 
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Table 1. Cont. 
Species (original 
published) Compound Type Target cell IC50 Anti-fungal (+/−) 
P. brefeldianum [39] Brefeldin A [42–45] Polyketide HL-60 35.7 nM + [39,40] 
KB 32 nM 
HeLa 6.4 nM 
MCF-7 7.1 nM 
SPC-A-1 3.6 nM 
BC-1 40 nM 
NCI-H187 110 nM 
Cladosporium 
cladosporioides [82] 
Calphostin C [82,83] Polyketide HeLa S3 0.2–8.5 µM − MCF-7 0.2–2.7 µM 
ALL - 
Chaetomium globosum 
[184] 
P. discolor [1] 
P. expansum [1] 
Chaetoglobosin B 
[193] 
Mixed 
biosynthetic 
origin 
BC 3.0 µM 
+ [56,186] 
Chaetomium globosum 
[184] 
P. discolor [1] 
P. expansum [1] 
Chaetoglobosin D 
[193] 
Mixed 
biosynthetic 
origin 
KKU-100 3.4 µM 
KKU-OCA17 12.2 µM 
Chaetomium globosum 
[184] 
P. discolor [1] 
P. expansum [1] 
Chaetoglobosin U 
[194] 
Mixed 
biosynthetic 
origin 
KB 16.0 µM 
Chaetomium globosum 
[184] 
P. discolor [1] 
P. expansum [1] 
Chaetoglobosin X 
[195] 
Mixed 
biosynthetic 
origin 
H-22 7.5 µM 
Chaetomium globosum [57–
61,63,64] 
T. pinophilus [1] 
11-epichaetomugilin I 
[62] 
Polyketide P-388 0.7 pM 
+ [56] HL-60 1.0 pM 
L-1210 1.6 pM 
KB 1.2 pM 
P. chrysogenum [74] 
P. rubens [73] 
(P. terrestre [76]) 
Chloctanspirone A 
[76] 
Polyketide HL-60 9.2 µM − A-549 39.7 µM 
P. buchwaldii [96] 
P. marinum [1] 
P. expansum [204] 
P. rivulorum [205] 
Communesin B 
[206,207] 
Mixed 
biosynthetic 
origin 
P-388 0.5 µg/mL (ED50) − U-937 10.4 µg/mL (ED50) 
THP-1 11.4 µg/mL (ED50) 
NAMALWA 9.9 µg/mL (ED50) 
MOLT-3 8.1 µg/mL (ED50) 
SUP-B15 7.2 µg/mL (ED50) 
Mariannaea elegans 
(Spicaria elegans [192]) 
A. clavatus [190] 
A. rhizopodus [90] 
Hypoxylon terricola [187] 
Cytochalasin E 
[191,192] 
Mixed 
biosynthetic 
origin 
A-2780 0.02 µg/mL (IC100) + [185] HCT-116 1.0 µg/mL (IC100) 
SW-620 0.2 µg/mL (IC100) 
A-549 0.006 µM 
P-388 0.09 µM 
A. striatus (Emericella 
striata [128]) 
Cladorrhinum sp. 
Emestrin A [129] NPR HL-60 83.5 nM 
+ [127] 
A. striatus (Emericella 
striata [128]) 
Cladorrhinum sp. 
Emestrin C [130] NPR DU-145 9.3 nM 
Penicillium sp. BCC 17468 
[147] 
Fudecadione A [147] Terpene MCF-7 12.6 µg/mL − KB 22.3 µg/mL 
NCI-H187 24.9 µg/mL 
A. fumigatus [208] 
P. scabrosum [209] 
Fumagillin [210] Mixed 
biosynthetic 
origin 
Angiogenesis 
inhibitor 
- − 
 TNP-470 [210–214] Synthetic PC-3 - 
MDA-MB-231 - 
Penicillium sp. [215] Linerin [215] Mixed 
biosynthetic 
origin 
POS1 117 nM 
 
Molecules 2013, 18 11357 
 
 
Table 1. Cont. 
Species (original 
published) Compound Type Target cell IC50 Anti-fungal (+/−) 
A. fumigatus [101,102] 
A. fischeri [103] 
Fumitremorgin C 
[111,113,114] 
NPR P-388 3.9 µg/mL 
(ED50) 
+ [224] 
A. fumigatus [101,102] 
A. fischeri [103] 
12,13-
dehydroxyfumitremor
gin C [112] 
NPR U-937 1.8 µM 
PC-3 6.6 µM 
A. fumigatus [122] 
D. cejpii [123] 
Gliotoxin 
[112,125,126] 
NPR MCF-7 985 nM + [124] 
T47D 365 nM 
BT-474 102 nM 
ZR75-1 158 nM 
MDA MB231 38 nM 
MDA MB435 87 nM 
U-937 0.2 µM 
PC-3 0.4 µM 
P. griseofulvum [225] Griseofulvin  
[2–4,226,227] 
Polyketide HeLa 20 µM + [226,228] 
SCC-114 35 µM 
 GF-15 [5] Synthetic SCC-114 0.9 µM 
Hypocrella bambusae 
(Shiraia bambusicola 
[84,85]) 
Hypocrellin D [85] Polyketide Bel-7721 1.8 µg/mL + [229] 
A-549 8.8 µg/mL 
Anip-973 38.4 µg/mL 
 Synthetic analog [86] Synthetic MCF-7 (PDT) - 
Purpureocillium 
lilacinum[133] 
(P. lilacinum [132]) 
Leucinostatin A 
[132,135–138] 
NPR Ehrlich 1.6 mg/kg (LD50) + [132,134] 
L-1210 410.3 nM (IC100) 
BT-20 2.3 nM 
MCF-7 4 nM 
G-361 7 nM 
HT-144 6 nM 
A-549 16 nM 
A-427 59 nM 
SK-MES-1 12 µM 
Caov-3 17 nM 
Caov-4 53 nM 
SKOV-3 1,236 nM 
HT-29 119 nM 
LoVo 114 nM 
HEp-2 40 nM 
HL-60 12 nM 
HSB-2 5 nM 
K-562 6 nM 
KG-1 46 nM 
RPMI-1788 158 nM 
SKW-6.4 6 nM 
U-937 319 nM 
Raji 11 nM 
A. parasiticus [65,66] 
A. nidulans [67,68] 
Norsolorinic acid 
[67,68] 
Polyketide T-24 10.5 µM − 
MCF-7 12.7 µM 
A. amoenus [115] Notoamides [116,230] NPR HeLa/L-1210 22–52 µg/mL − 
Bipolaris sp.[169,170] 
A. calidoustus [69] 
A. insuetus [69] 
A. keveii [69] 
(A. ustus [171]) 
Sarocladium oryzae [173] 
(Cephalosporium caerulens 
[172]) 
D. maydis [174] 
D. sorghicola [174] 
Ophiobolin A 
[175,176] 
Terpene A-549 0.1 µM + [180,181] 
HT-29 0.1 µM 
Mel-20 0.1 µM 
P-388 0.06 µM 
OVCAR-3 0.3 µM 
Bipolaris oryzae [179] 3-anhydro-6-
hydroxyophiobolin A 
[179] 
Terpene HepG2 6.5 µM 
K-562 4.1 µM 
Aspergillus section Usti [69] 
(A. ustus [177]) 
Ophiobolin O 
[177,178] 
Terpene MFC-7 17.9 µM 
P-388 4.7 µM 
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Compound Type Target cell IC50 Anti-fungal (+/−) 
Talaromyces sp. 
(Penicillium sp.) [199] 
Penicidone B [199] Mixed 
biosynthetic 
origin 
SW1116 54.2 µM − 
K-562 21.1 µM 
KB 29.6 µM 
HeLa 35.2 µM 
Penicillium sp. [200] 
Auxarthron reticulatum 
[201] 
Penicinoline [202] Mixed 
biosynthetic 
origin 
HepG2 13.2 µM − 
Penicillium sp. [200] 
Auxarthron reticulatum 
[201] 
Methyl-penicinoline 
[202] 
Mixed 
biosynthetic 
origin 
HepG2 11.3 µM 
T. pinophilus [1] 
(P. simplicissimum [54]) 
Penisimplicissin [55] Polyketide HL-60 −6.7 (log10 GI50) − 
CCRF-CEM −5.8 (log10 GI50) 
Phaeosphaeria sp. [87] Phaeosphaerin B [87] Polyketide PC-3 2.4 µM − 
DU-145 9.5 µM 
LNCaP 2.7 µM 
A. ustus [117] Phenylahistin [118] NPR A-431 0.22 µM − 
A-549 0.30 µM 
HeLa 0.20 µM 
K-562 0.19 µM 
P-388 0.33 µM 
MCF-7 3.7 µM 
TE-671 0.18 µM 
A. taichungensis [79] Prenylterphenyllin A 
[79] 
Polyketide A-549 8.3 µM − 
HL-60 1.5 µM 
A. candidus [77,78] 4”-deoxyisoterprenin 
[78] 
Polyketide KB3-1 6.2 µM 
A. taichungensis [79] Prenylcandidusin B 
[79] 
Polyketide P-388 1.6 µM 
Pseudeurotium ovalis [196] 
A. fumigatus [197] 
Pseurotin D [198] Mixed 
biosynthetic 
origin 
MFC-7 15.6 µM − 
T. purpurogenus mutant 
BD-1-6 [1] 
(P. purpurogenum [216]) 
Purpurogemutantidin 
[216] 
Mixed 
biosynthetic 
origin 
K-562 0.9 µM + [217] 
HeLa 16.6 µM 
BGC-823 31.0 µM 
MCF-7 26.3 µM 
T. purpurogenus mutant 
BD-1-6 [1] 
(P. purpurogenum [216]) 
Macrophorin A [216] Mixed 
biosynthetic 
origin 
HL-60 0.9 µM 
A. parasiticus [231] Sequoiamonascin A 
[231] 
Polyketide MCF-7 1% − 
NCI-H460 1% 
SF-268 2% 
 Percent cell 
growth compared 
to untreated cells 
at 10 µM 
P. solitum [20,25] 
(P. brevicompactum [18]) 
P. hirsutum [20] 
(P. citrinum [19]) 
Compactin [28] Polyketide AML 2.6 µM (IC100) + [18] 
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published) Compound Type Target cell IC50 Anti-fungal (+/−) 
A. terreus [26] 
Monascus sp.[27] 
Lovastatin [29–32] Polyketide OVHS-1 39 µM 
+ [22–24] Calu-1 3 µM 
H-460 3 µM 
A-549 10 µM 
H-441 30 µM 
Ovca-432 2 µM 
A-2780 3 µM 
Hey 3 µM 
Ovca-429 5 µM 
HOC-7 10 µM 
DOV-13 11 µM 
Skov-3 21 µM 
A-2780-ADR 21 µM 
A-2780-CIS 22 µM 
MCF-7 1.7 µM 
HepG2 2.7 µM 
HeLa 1.5 µM 
AML - 
 Simvastatin 
[1,20,29,33,34] 
Synthetic DLRP 0.9 µM 
+ [23,24] H-1299 1.3 µM 
HT-144 1.0 µM 
MI-14 0.8 µM 
SK-MEL-28 0.8 µM 
BT-474A 4.2 µM 
SKBR-3 2.2 µM 
MDA-MB-453 5.4 µM 
BT-20 1.7 µM 
AML - 
A. ochraceus [106] 
A. westerdijkiae [107] 
Stephacidin B [106] NPR PC-3 0.4 µM − 
LNCaP 0.06 µM 
A-2780 0.3 µM 
A-2780/DDP 0.4 µM 
A-2780/Tax 0.3 µM 
HCT-116 0.5 µM 
HCT-116/mdr+ 0.5 µM 
HCT-116/topo 0.4 µM 
MCF-7 0.3 µM 
SKBR-3 0.3 µM 
LX-1 0.4 µM 
Taxomyces andreanea [140] 
P. raistrickii [141] 
Taxol [139,142–145] Terpene Clinical use: 
Ovarian tumors 
Breast tumors 
Lung tumors 
Kaposi’s sarcoma 
- + [146] 
A. terreus [148] Terrecyclic acid A 
[148,149,232] 
Terpene NCI-H460 10.6 µM + [148] 
MCF-7 24.1 µM 
SF-268 14.7 µM 
P-388 63–125 mg/kg 
(LD50) 
A. terreus [37] Terrein [38] Polyketide MCF-7 1.1 nM + [36] 
PANC-1 9.8 µM 
HepG2 66.8 µM 
Fusarium spp. [151] 
Isaria japonica [157] 
4-Acetyl-12,13-epoxy-
9-trichothecene- 3,15-
diol (AETD) [157] 
Terpene HL-60 10 nM + [154] 
U-937 22 nM 
HeLa 45 nM 
MCF-7 53 nM 
Hep-G2 170 nM 
Fusarium spp. [151] 
Myrothecium roridum [158] 
12’hydroxyroridin E 
[158] 
Terpene L-1210 0.2 µM 
BC-1 0.9 µM 
NCI-H187 1.5 µM 
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P. citrinum [80] Tricitrinol B [80] Polyketide HL-60 3.2 µM − 
HCT-116 4.8 µM 
KB 3.9 µM 
A. fumigatus 
[104,105,108,109] 
Ds2-tryprostatin B 
[108] 
NPR NCI-H-522 15.8 µM (GI50) − 
MCF-7 15.9 µM (GI50) 
PC-3 11.9 µM (GI50) 
A. fumigatus 
[104,105,108,109] 
18-oxotryprostatin A 
[110] 
NPR A-549 1.3 µM 
A. fumigatus 
[104,105,108,109] 
Spirotryprostatin E 
[109] 
NPR MOLT-4 3.1 µM 
HL-60 2.3 µM 
A-549 3.1 µM 
Penicillium sp. [150] Unnamed chloro-
trinoreremophilane 
sesquiterpene [150] 
Terpene HL-60 11.8 µM − 
A-549 12.2 µM 
A. wentii [160] Wentilactones [161] Terpene SMMC-7721 19 µM + [233] 
T. wortmannii [1] 
(P. wortmannii [162]) 
Or similar species. 
Wortmannin  
[163–168] 
Terpene HL-60 30 nM + [162] 
K-562 25 nM 
KNS-62 100–200 nM 
Colo-699 100–200 nM 
P. chrysogenum [1] 
D. cejpii [90] 
(D. albus[90]) 
Xanthocillin X 
[89,91,92] 
NPR Ehrlich ascites 
carcinoma-mouse 
strain 
40 mg/kg (LD50) + [89] 
K-562 0.4 µg/mL 
HeLa 1.2 µg/mL 
MCF-7 12 µg/mL 
HepG2 7 µg/mL 
NCI-H460 10 µg/mL 
Du-145 8 µg/mL 
MDA-MB-231 8 µg/mL 
Aspergillus sp. [93] BU-4704 [93] NPR HCT-116 0.6 µg/mL 
B16-F10 4.3 µg/mL 
P. chrysogenum [1] Xanthocillin X  
di-methoxy [94] 
NPR HepG2 0.2 µg/mL 
MCF-7 0.4 µg/mL 
KB 0.4 µg/mL 
6. Conclusions  
In this article we have reviewed 50 compounds or compound families with anticancer and often also 
antifungal activities, primarily produced by Aspergillus, Penicillium and Talaromyces. Mycologists 
predict that less than 10% of all fungal species have been isolated so far, indicating a huge potential for 
further discovery of novel bioactive chemical scaffolds, if these fungi can be cultured in the laboratory. 
New strategies such as the application of epigenetic modifiers may help to uncover the full 
biosynthetic potential of fungi and other microorganisms. Development and improvement of screening 
methods and assays will further assist revealing new bioactivities of already known compounds. 
Additionally, ongoing progress in fast dereplication, including improvement of the performance of 
mass spectrometers and high resolution of UHPLC chromatograms, will ensure that database searches 
will lead to fewer possible candidates thereby advancing the drug discovery process. Altogether the 
future seems promising for discovery of many more bioactive small molecules to be used either as 
scaffolds for: (i) diversity oriented synthesis, or (ii) as a starting point for cloning and engineering of 
whole biosynthetic gene clusters towards novel engineered bioactive natural products. 
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Abstract: The purpose of this study was to identify and characterize fungal natural 
products (NPs) with in vitro bioactivity towards leukemia cells. We based our screening on 
a combined analytical and bio-guided approach of LC-DAD-HRMS dereplication, 
explorative solid-phase extraction (E-SPE), and a co-culture platform of CLL and stromal 
cells. A total of 289 fungal extracts were screened and we tracked the activity to single 
compounds in seven of the most active extracts. The novel ophiobolin U was isolated 
together with the known ophiobolins C, H, K as well as 6-epiophiobolins G, K and N from 
three fungal strains in the Aspergillus section Usti. Ophiobolins A, B, C and K displayed 
bioactivity towards leukemia cells with induction of apoptosis at nanomolar concentrations. 
The remaining ophiobolins were mainly inactive or only slightly active at micromolar 
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concentrations. Dereplication of those ophiobolin derivatives possessing different activity 
in combination with structural analysis allowed a correlation of the chemical structure and 
conformation with the extent of bioactivity, identifying the hydroxy group at C3 and an 
aldehyde at C21, as well as the A/B-cis ring structure, as indispensible for the strong 
activity of the ophiobolins. The known compounds penicillic acid, viridicatumtoxin, 
calbistrin A, brefeldin A, emestrin A, and neosolaniol monoacetate were identified from 
the extracts and also found generally cytotoxic. 
Keywords: natural products; ophiobolin U; dereplication; explorative solid phase 
extraction (E-SPE); filamentous fungi; cytotoxic; cancer; leukemia 
 
1. Introduction 
Screening and discovery of compounds that act against chronic lymphocytic leukemia (CLL) cells 
are crucial since CLL is considered as an incurable disease and currently applied treatment strategies 
primarily aim at prolonging patient survival [1,2]. Filamentous fungi have proven to be an incredible 
source of diverse bioactive compounds. The continuous improvements of analytical instruments and 
new approaches for fast dereplication have resulted in an increased interest in natural products 
discovery [3–5]. CLL is the most common type of leukemia among adults in the Western World. Even 
though most patients initially show a good response to therapy, relapse of disease is very frequent, 
with a subsequent increase in chemoresistance [6]. Consequently, there is a great need for discovery 
and development of new agents. Treatment strategies used today are based on small-molecule 
alkylating agents such as chlorambucil and fludarabine. These agents are often used in combination 
with monoclonal antibodies, or more recently inhibitors that target essential signaling pathways in 
CLL [7,8]. In contrast to other cancer cells, the majority of CLL cells is non-proliferating, arrested in 
G0/G1 phase of the cell cycle and accumulates in the patients due to apoptosis resistance [1]. In vivo, 
CLL cells are associated with a survival-inducing microenvironment of stromal cells, non-malignant 
leukocytes, so-called nurse-like cells, as well as growth and differentiation factors [9,10]. Removed 
from their natural microenvironment, the CLL cells rapidly undergo apoptosis in vitro, even though 
they are long-living cells in vivo [11]. However, viability of CLL cells can be maintained in vitro by 
co-cultivation with stromal cells, for example the bone marrow-derived cell line HS-5 [12,13]. Such 
co-cultures mimic the microenvironment of CLL cells in vivo, they are ideally suited for screening of 
natural products (NPs) [14]. We have already demonstrated that fungal NPs are a proper source for 
discovering compounds with activity towards CLL cells in vitro. This was done by identification of 
chaetoglobosin A from P. aquamarinum. Chaetoglobosin A induced apoptosis in CLL cells more 
selectively compared to healthy cells with a median lethal dose (LC50) of 2.8 µM [15]. 
Novel secondary metabolites produced by filamentous fungi such as Penicillium and Aspergillus 
are being discovered continuously [4,16]. With the increase in target-based specific biological assays, 
previously described compounds might display novel bioactivities [17,18], justifying their presence in 
novel screening efforts. Testing all known as well as novel NPs against all disease targets is an 
impracticable approach, why setting up a suitable strategy is essential to any screening program [19]. 
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Targeted screening strategies in NPs-based drug discovery rely on identifying compounds targeting a 
specific disease or biological mechanism. In such screening campaigns, the selection of fungi is 
essential and needs to represent as wide a biodiversity as possible, with the hope of an equally high 
chemodiversity [19]. One strategy to increase chemodiversity for rapid bio-testing is to select strains 
representing a wide variety of species with a limited number of strains from each species [19,20]. The 
spectrum of compounds produced by the individual strains can further be diversified or maximized by 
the ‘one strain-many compounds’ (OSMAC) approach, through variation of culture conditions [16]. 
Dereplication is the tentative identification of known NPs in complex mixtures, before unnecessary 
time is spent on isolating already known compounds. One dereplication approach is based on liquid 
chromatography-diode array detection-high resolution mass spectrometry (LC-DAD-HRMS) and 
database searching, which ensures a high throughput and reproducibility [3]. Subsequent to 
dereplication a separation strategy for preparative isolation of NPs is necessary. Here a small scale 
preliminary chemical characterization focusing on identification of functional groups is helpful.  
Co-eluting interferences often experienced in traditional reverse phase (RP) chromatography can be 
reduced or even completely removed by choosing orthogonal purifications strategies [21]. One 
approach for prefractionation is explorative solid-phase-extraction (E-SPE) [21] that relies on  
ion-exchanger columns such as strong anion-exchanger (SAX), mixed mode anion-exchanger (MAX), 
and strong cation-exchanger (SCX). This method has proven to be very powerful for separating fungal 
NPs due to the relative high percentages of ionizable functional groups [21].  
In this current paper we describe our screening efforts of discovering fungal NPs with bio-activity 
in a co-culture platform of chronic lymphocytic leukemia (CLL) cells and stromal cells and their 
retesting in CLL cells cultures in conditioned media of stromal cells [12]. The fungal NPs were 
tentatively identified by LC-DAD-HRMS based dereplication and extracts were fractionated in order 
to assign the activity to single compounds [3]. Confidence in this identification was improved by using 
an E-SPE strategy based on an array of orthogonal separation techniques [19,21]. Thereby among 
others, ophiobolins were identified and further structural studies were performed by dereplicating 
different ophiobolin dervatives leading to the identification of chemical moieties and conformations 
that are indispensable for strong bioactivity. Ophiobolins lacking these moieties possessed either low 
or no bioactivity. 
2. Results and Discussion 
A total of 289 fungal extracts were prepared from cultivation of 137 fungal strains (Figure 1 and 
Table S1) on a selection of solid media at variable temperatures in accordance with the OSMAC 
approach [16]. The extracts were prepared by the micro-extraction method developed by  
Smedsgaard [22]. To obtain a representative sample of the fungal colonies the plugs were taken across 
the colony. Sixty one (61) extracts showed activity towards CLL cells (Table S2). Seven of the 
candidates that displayed the highest level of activity (Figure 1) were selected for further bio-testing. 
Large-scale extracts were prepared from incubation on the media supporting the highest level of 
bioactivity, and the extracts were prefractionated before further testing. 
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Figure 1. Screening set-up. Two hundred and eighty nine (289) fungal extracts (from 137 
fungal strains) were tested for cell death-inducing activity for CLL cells but not for stromal 
cells. From the 61 active extracts the seven candidates that displayed the highest bio-assay 
activity were selected for single compound isolation in a large scale and further bio testing. 
 
2.1. MS Based Dereplication of Penicillium pulvillorum Extract 
The extract of P. pulvillorum (IBT 22393) was among the candidates that displayed the highest 
level of activity (≈1.25 µg/mL). The first five flash fractions (ranging from 15%–40% organic) were 
tested active against CLL cells in vitro. LC-DAD-HRMS revealed one major component shared 
between these fractions, with an elementary composition of C8H10O4 (−0.7 ppm mass accuracy) (Figure 2). 
AntiBase2012 [23] revealed penicillic acid as a likely candidate responsible for the observed activity. 
The tentative identification of penicillic acid was confirmed by comparison of the retention time to a 
standard from our in-house metabolite database (1,559 standards) as well as comparison of 1H- and  
13C-NMR chemical shifts to the literature data [24]. 
Figure 2. Dereplication of penicillic acid from P. pulvillorum mass spectrum of penicillic 
acid [23]. The mass spectrum shows a widespread adduct pattern that besides [M+H]+ 
contains ions that corresponds to neutral loss of water [M+H-H2O]+ and the sodiated 
adduct [M+Na]+, as well as the corresponding dimeric ions [2M+H]+, [2M+H-H2O]+,  
and [2M+Na]+. 
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To verify the observed anti-leukemic activity in the extract, penicillic acid was purified and tested 
on CLL cells, resulting in induced cell death in both CLL and stromal (HS-5) cells. No further work on 
this extract was done as penicillic acid is regarded as a generally cytotoxic compound [24]. 
2.2. Comparative Dereplication Based on Explorative Solid Phase Extraction (E-SPE) 
The E-SPE strategy was applied to a series of highly complex extracts, i.e., P. brasilianum  
(IBT 22244), P. decumbens (IBT 11843), P. cluniae (IBT 21051), Aspergillus sp. (Emericella-like state) 
(IBT 22838), and Fusarium compactum (IBT 9034). The extract of P. brasilianum (IBT 22244) was 
very potent against CLL cells in vitro (≈5 ng/mL) with the active compound retained on both anion-
exchangers (SAX and MAX) as well as the two normal-phase columns (diol and amino), while 
unretained on the cation-exchanger (SCX). The combined biological and chromatographic information 
lead to the conclusion that the bioactive compound contained a strong anion. The large scale extract 
was fractionated on a SAX column. Comparison of chromatographic peaks from the fraction that 
contained neutral/basic compounds (Figure 3a) and the fraction with acidic compounds (Figure 3b), 
showed that the anion-exchange was extremely selective, removing the majority of inactive 
compounds from the extract. 
Figure 3. E-SPE strategy based on a SAX column to separate co-eluting compounds in the 
crude extract of P. brasilianum. (a) UHPLC chromatograms of the SAX fraction that 
contained neutral/basic compounds. The ion trace of compound I (m/z 462.2387) is marked 
with red; (b) UHPLC chromatogram of the SAX fraction that contained acidic compounds. 
The ion trace of compound IV (m/z 548.1916) is marked with blue; (c) In the crude extract 
compound I and IV were co-eluting on a RP C18 column. 
 
In the initial extract, the two compounds I and IV co-eluted on a C18 RP column (Figure 3c). These 
were easily and quantitatively separated on the SAX column due to the difference in charged 
functionalities. Only three major acidic compounds were left in the bioactive fraction (Figures 3b and 4a), 
significantly simplifying the subsequent dereplication and purification process. Based on comparative 
HRMS analysis, compound II was immediately eliminated due to its presence in the inactive 
neutral/basic fraction. The molecular formula of compounds III and IV were established as C15H10O9 
(−0.7 ppm) and C30H31NO10 (−0.2 ppm), respectively. These were used as queries in AntiBase2012 
(Figure 4b) [23]. Compound II had no hits in AntiBase2012 that contained a strong anion, thus likely 
being a novel compound or novel analogue of a known compound. Compound IV had two hits in 
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AntiBase2012. One of the candidates had no strong anion and was consequently eliminated, which left 
viridicatumtoxin as the only candidate (Figure 4b). 
Figure 4. Dereplication of the P. brasilianum extract (a) UHPLC chromatogram of the 
active SAX fraction that contained the acidic compounds as well as UV and MS spectra of 
the potential candidates; (b) Hits in Antibase2012. 
(b) 
III: Unknown  IV: Viridicatumtoxin 
Query No. of candidates  Query No. of candidates 
C15H10O9 1  C30H31NO10 2 
Strong anion 0  Strong anion 1 
 
The identity of viridicatumtoxin as compound IV was confirmed: (1) by comparison to the retention 
time and UV spectrum of an in-house standard; (2) by the fact that it held a strong anion; and (3) by 
having similar 1H-NMR chemical shifts as published for viridicatumtoxin [25]. Viridicatumtoxin was 
isolated as one of the most cytotoxic compounds tested towards CLL cells in this screening campaign 
with a median lethal concentrations (LC50) value between 0.7 and 3.5 nM. Further testing revealed that 
the activity was not specific, as both CLL and stromal cells were targeted. 
One flash fraction (70% organic) from the P. decumbens (IBT 11843) extract was found active 
towards CLL cells (≈200 ng/mL). Further E-SPE analysis showed that the active compound was 
retained on SAX and MAX columns indicating the presence of a strong anion. By comparative 
dereplication tentative identifications of calbistrin A (Figure 5a) and B as well as their precursor (or 
decomposition product) versiol (Figure 5c) were established within the fraction. The MS based 
dereplication was complicated by the fact that the [M+H]+ ion was absent in the mass spectra of 
calbistrin A and B. The presences of strong adduct- and fragmentation patterns consisting of the 
sodiated, [M+Na]+, and the ammoniated, [M+NH4]+, adducts as well as neutral loss of one and two 
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water molecules assisted the establishment of the monoisotopic masses and hereby the molecular 
formulas of calbistrin A and B. The identity of calbistrin A was confirmed by the presence of a 
carboxylic acid and by comparison of retention time and UV spectrum to an in-house standard. The 
tentative identity of calbistrin B was confirmed by comparison of the UV spectrum to that of calbistrin 
A (Figure 5a). Testing of calbistrin A from our in-house metabolite collection showed general 
cytotoxic activity towards CLL and healthy cells. Comparative experiments with calbistrin C (Figure 5b) 
from the metabolite collection did not induce cell death, indicating that the pharmacophore is located 
in the versiol part (Figure 5c) of the molecule. 
Figure 5. Structure of (a) Calbistrin A, (b) Calbistrin C, and (c) Versiol. 
 
A bioactive flash fraction (activity approx. 100 ng/mL) from a Penicillium cluniae (IBT 21051) 
extract was likewise subjected to E-SPE. Here, the bioactivity profiled revealed that the active 
compound was a medium to apolar compound with no charged functionalities. By comparative 
dereplication, the active compound was tentatively identified as brefeldin A (Figure 6a), which was in 
accordance with the profile revealed by E-SPE. The identity of brefeldin A was confirmed by its 
retention time and UV spectrum compared to an in-house standard. Brefeldin A is a known anticancer 
compound [5,26] and commercially available, thus the activity was easily confirmed in the CLL assay. 
The compound displayed general cytotoxic activity for CLL cells (0.39–1.56 µM) and stromal cells. 
Figure 6. Examples of E-SPE and comparative dereplication (a) Brefeldin produced by  
P. cluniae, (b) Emestrin A produced by Aspergillus sp. (Emericella-like state), and (c) 
Neosolaniol monoacetate produced by F. compactum. 
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The E-SPE strategy of the bioactive extract (≈40 ng/mL) from Aspergillus sp. (Emericella-like 
state, IBT 22838) resulted in retention of the bioactive compound on the amino normal phase SPE 
column. Fast comparative dereplication based on UV spectra and retention times of in-house standards 
as well as comparison of 1H-NMR chemical shifts [27] led to an identification of the known antifungal 
and anticancer compound, emestrin A (Figure 6b) [5,28,29]. The pure emestrin A isolated form the 
active fractions showed cytotoxic activity towards CLL cells and stromal cells at the same concentration 
levels. Accordingly, emestrin A is regarded as a generally cytotoxic compound with no therapeutic 
window [30]. No further work was pursued on the Aspergillus sp. (Emericella-like state) extract. 
The last example of bio-guided isolation based on E-SPE is demonstrated by the F. compactum 
(IBT 9034) extract with an activity at approximately 200 ng/mL. The bioactive compound from  
F. compactum was retained on both the diol and amino columns in the E-SPE pre-fractionation 
experiment. Comparative dereplication revealed only one candidate that might be responsible for the 
activity. The compound was tentatively identified as the known trichothecene, neosolaniol 
monoacetate (Figure 6c). The compound was isolated and the 1H-NMR data was compared to the 
literature for final identification of neosolaniol monoacetate [31]. Neosolaniol monoacetate was tested 
in the CLL assay and found as a generally cytotoxic why no further work was performed on the  
F. compactum extract. The E-SPE approach with the optimized collection of ion-exchangers and 
normal phase SPE columns has turned out to be a good combination to evaluate and follow bioactivity 
of fungal extracts. 
2.3. Biological Structure-Activity Relationship of Ophiobolins 
The bioactive extract from a new species in Aspergillus section Usti (IBT 18591) was more 
selective than the above mentioned active extracts and in consequence selected for more detailed 
investigations. MS- and UV-based dereplication led to the tentative identification of the ophiobolin 
family of compounds. Ophiobolin K and 6-epiophiobolin K (Figure 7) [32] were isolated and 
ophiobolin K was found very potent against CLL cells in vitro. 
The ophiobolins are a family of naturally occurring sesterterpenoids, currently comprising more 
than 35 known analogues [33–37]. They all consist of a C25 skeleton with a dicyclopenta[a,d]cyclooctane 
ring system. Some ophiobolins have an extra ring incorporated, as observed in ophiobolin A and H 
(Figure 7), forming two different types of tetra-cyclic structures [38]. The absolute configuration of 
ophiobolin A and G have been determined by X-ray crystallography [39,40] and the conformations of 
all stereocenters except C6 is expected to be conserved based on the biosynthetic production of ophiobolins 
demonstrated by the first sesterterpene synthase described in 2013 [41]. Ophiobolins exhibit a broad 
spectrum of inhibitory activity against cancer cell lines, including lung cancer A549, breast cancer 
MCF7, colon cancer HT29, melanoma Mel20, leukemia P388 and L1210 cell lines [5,34,35,42–45].  
Further investigations of the anti-leukemic activity and pharmacophore of the ophiobolins in the 
CLL/stromal cell co-culture platform were performed with the purpose of isolating a high number of 
naturally occurring analogs as well as identification of novel analogues. Taking advantage of the huge 
biodiversity available in the IBT culture collection [19], we expanded the biodiversity and hereby the 
expected chemodiversity with 12 closely related Aspergilli from the section Usti (Table S7) [46]. 
Cultures of the 12 new strains were extracted in micro-scale [22] to explore their potential for 
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producing ophiobolins. A. insuetus (IBT 28266) and A. calidoustus (IBT 25726) were identified as 
potent ophiobolin producers with one likely novel and more known ophiobolins analogs compared to 
the original strain (Figure 8). 
The novel ophiobolin U (Figure 9) was isolated together with ophiobolin H [40] (Figure 7) and the 
rare 6-epiophiobolin N [43] (Figure 7) from the A. insuetus extract, while ophiobolin C [47] (Figure 7) 
and 6-epiophiobolin G [43] (Figure 7) were isolated from the A. calidoustus extract. 
The structure of the novel ophiobolin U was elucidated by 1D and 2D NMR spectroscopy. The  
1H-NMR spectrum of ophiobolin U was closely related to that of ophiobolin K with many practically 
identical chemical shifts (Table S8 and S9). The most remarkable difference between ophiobolin U and 
ophiobolin K was found at C5 that shifted 143.9 ppm upfield from 217.0 to 73.1 ppm in the carbon 
spectrum, indicating the disappearance of a ketone group. C5 had an additional HSQC correlation to a 
signal at 4.91 ppm (H5). This significant change indicated a reduction of the ketone (C5) in ophiobolin 
K to a secondary alcohol in ophiobolin U. This reduction was confirmed by the identification of a 
COSY spin system between H1-H2-H6 in ophiobolin K that in ophiobolin U was expanded with a 
vicinal coupling between the protons at 3.02 (H6) and 4.91 (H5) and further a vicinal coupling 
between H5 and the diastereotopic protons at 1.87 (H4a) and 2.68 ppm(H4b) (Figure 10a). 
Figure 7. Structures of ophiobolin A, 3-anhydro-ophiobolin A, 3-anhydro-6-epiophiobolin 
A, ophiobolin B, ophiobolin C, 6-epiophiobolin G, ophiobolin H, 6-epiophiobolin K, 
ophiobolin K, 6-epiophiobolin N, and ophiobolin U. 
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Figure 8. UHPLC chromatograms of (a) the new species in Aspergillus section Usti (IBT 
18591) producing ophiobolin K and 6-epiophiobolin K, (b) A. insuetus (IBT 28266) 
producing the novel ophiobolin U together with ophiobolin H, K, C as well as 6-epiophiobolin 
K and N and (c) A. calidoustus (IBT 25726) producing ophiobolin K and C as well as  
6-epiophiobolin K and G. 
 
Figure 9. Structure of ophiobolin U. 
 
The spin systems identified in the DQF-COSY spectrum of ophiobolin U were assembled through 
HMBC correlations, which also enabled the identification of the quaternary carbon atoms. The most 
important HMBC correlations are shown in Figure 10b. The COSY spin systems were connected by 
HMBC connectivities further confirming the presence of the eight-membered ring. HMBC 
connectivities were found from H5 to the quaternary carbons at 81.9 (C3) and 142.1 ppm (C7), from 
the diastereotopic protons at 1.03 (H1a) and 1.58 ppm (H1b) to C3 and the carbon at 54.0 ppm (C10), 
and finally from H9 to C7 and the quaternary carbon at 44.1 ppm (C11). The reduction at C5 changed 
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the chemical environment of the surrounding carbons (C2, C3, C6, C8 and C21) that were more 
deshielded and therefore shifted 1.8–6.5 ppm downfield compared to ophiobolin K (Table S8). The 
remaining chemical shifts in ophiobolin U matched the chemical shifts of ophiobolin K (Tables S8  
and S9). 
Figure 10. (a) Important DQF-COSY couplings and (b) important HMBC connectivities in 
the novel compound ophiobolin U. 
 
The stereochemistry of the A/B ring system in ophiobolin U (Figure 9) was assigned based on NOE 
correlations and chemical shifts. The A/B-cis ring system was established by the NOE correlations 
found between the protons at 2.30 (H2) and 3.02 ppm (H6), as demonstrated in Figure 11. The 
stereochemistry of C-5 was tentatively assigned through strong NOE correlations of the diastereotopic 
protons at 1.87 (H4a) and 2.68 ppm (H4b). H4a had NOE correlations to the protons at 1.26 ppm 
(H20) and H2, while H4b had a NOE correlation to H5, which indicated that the hydroxy group at C5 
was cis to H6. Other important NOE correlations are shown in Figure 11. 
Figure 11. Important NOE correlations in ophiobolin U. 
 
The A/B-cis was confirmed by chemical shifts. Earlier reports showed that C1 and C22 in 
ophiobolins with A/B-cis ring structure are more upfield compared to ophiobolins with A/B-trans ring 
structure [48]. In ophiobolin U and ophiobolin K, the chemical shifts of C1 and C22 were more upfield 
compared to 6-epiophiobolin K, which indicate a A/B-cis ring structure in ophiobolin U. Other reports 
have showed that the A/B-cis ring structure in ophiobolins causes a small deshielding (0.2–0.3 ppm) 
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for H2 and H8 as well as a small shielding (0.3–0.6 ppm) for H4 [49]. The 1H chemical shifts for 
ophiobolin U were inconclusive regarding conformation of the A/B ring system. The residual 
stereocenters of ophiobolin U were the same as in the known ophiobolins due to the stereospecificity 
of the biosynthetic pathway of the ophiobolins [41,50]. 
The stereochemistry of the A/B ring system of the remaining six ophiobolins (ophiobolin K,  
6-epiophiobolin K, 6-epiophiobolin N, 6-epiophiobolin G, ophiobolin H, and ophiobolin C) isolated in 
this study were confirmed by NOE correlations. Together with the general trend that C1 and C22 in the 
ophiobolins with A/B-cis ring structure were more upfield compared to ophiobolins with A/B-trans 
ring structure [43,48]. The shifting of chemical shifts for H2, H4, and H8 for the A/B-cis ring system 
were more ambiguous due to the small deshielding/shielding in chemical shifts and inconclusive for 
the seven ophiobolins. A comparison of the 13C and 1H chemical shifts of all the seven ophiobolins are 
found in Tables S8 and S9, respectively. 
Besides the seven purified ophiobolins: ophiobolin A, ophiobolin B, 3-anhydroophiobolin A, and  
3-anhydro-6-epiophiobolin A (Figure 7) were bought as standards with the aim of obtaining a broader 
understanding of the SAR of the ophiobolin family against CLL cells. Ophiobolin U was unstable and 
therefore not applied in any bioassay, but the remaining ten ophiobolins were tested for their cytotoxic 
activity towards CLL cells. Ophiobolin A, B, C, and K showed the strongest effects with LC50 values 
between 1 and 8 nM (results compiled in Table 1 and Figure 12a). Testing of normal lung fibroblasts 
revealed that ophiobolin A and B displayed cytotoxic effects at 10 nM concentration indicating a slight 
difference in bio-activity for CLL cells in comparison to healthy fibroblasts. Ophiobolin C and K 
displayed no effect towards normal lung fibroblasts in concentrations up to 10 nM (Figure S17). 
Interestingly, 3-anhydroophiobolin A, 3-anhydro-6-epiophiobolin A, 6-epiophiobolin G, ophiobolin H, 
6-epiophiobolin K, and 6-epiophiobolin N exhibited low or no activity towards CLL cells. In fact,  
6-epiophiobolin K targeted CLL cell viability only when applied at a 100-fold higher concentration 
than ophiobolin K (Figure 12b). Ophiobolin-treated cells were further stained with PE-labelled 
Annexin-V and 7-AAD, or antibodies for activated caspase-3 prior to flow cytometric analyses. 
Thereby, apoptosis was identified as the mode of killing of CLL cells as demonstrated recently for 
chaetoglobosin A [15]. 
Table 1. Apoptosis inducing activity (LC50 [nM]) of the 10 ophiobolins towards CLL cells. 
Compound LC50
Ophiobolin A 1 nM 
3-anhydro-ophiobolin A Inactive 
3-anhydro-6-epiophiobolin A Inactive 
Ophiobolin B 2 nM 
Ophiobolin C 8 nM 
6-epiophiobolin G Inactive 
Ophiobolin H Inactive 
Ophiobolin K 4 nM 
6-epiophiobolin K Inactive 
6-epiophiobolin H Inactive 
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Figure 12. Effects of different ophiobolins on CLL cell viability. (a) CLL cells cultured in 
HS-5 conditioned media were treated for 24 h with increasing concentrations of ophiobolin A, 
ophiobolin B, ophiobolin C, ophiobolin K, and 6-epiophiobolin K, and cell viability was 
analyzed by CellTiter-Glo® assay measuring each data point as duplicate. Relative cell 
viability compared to DMSO control (0.1%) is depicted as mean values +SD of 3 independent 
CLL samples; (b) As 6-epiophiobolin K treatment did not decrease cell viability in the 
concentration range tested in (a), CLL cells were treated with up to 900 nM of 6-epiophiobolin 
K, and cell viability was determined and compared to the active ophiobolin B. 
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The results displayed in Table 1 and Figure 12a indicates that presence of a hydroxy group at C3 
and an aldehyde at C21 is crucial for the activity of the ophiobolins. Our findings are thus in agreement 
with previous studies that have shown that these two groups covalently bind to calmodulin [51,52]. 
None of the 6-epiophiobolins tested were active against the CLL cells. To earn a broader understanding of 
the importance of this small steric change at C6, 3D-modeling of ophiobolin K (blue) and 6-epiophiobolin 
K (red) were done to give a visual representation of their lowest energy conformations (Figure 13). 
Figure 13. Modulated 3D structures of ophiobolin K (blue) and 6-epiophiobolin K (red) in 
their lowest energy conformations overlaid. H6 protons are marked in ophiobolin K (cyan) 
and 6-epiophiobolin K (orange). The chain extending from C14 in ring C is not displayed to 
get a better clarity of the structures (the cut-off point is marked with *). 
 
The difference in conformation between ophiobolin K and 6-epiophiobolin K involves a flipping of 
the eight-membered ring that result in a change of position of the C21 aldehyde from one to the other 
side of the plane observed in the figure. This conformational change is likely preventing the binding of 
calmodulin by the C21 aldehyde due to steric hindrance, resulting in the lack of activity for  
6-epiophiobolin K contrasting ophiobolin K.  
3. Experimental 
3.1. General 
The fungal strains used are from the IBT culture collection at Department of Systems Biology, 
Technical University of Denmark. The LC-MS analyses were performed on a maXis quadrupole time 
of flight (qTOF) mass spectrometer (Bruker Daltonics, Bremen, Germany) with an electrospray 
ionization (ESI) ion source. The maXis was calibrated using sodium formate automatically infused 
prior to each analytical run, providing a mass accuracy of below 1 ppm. The mass spectrometer was 
linked to an Ultimate 3000 UHPLC system (Dionex, Sunnyvale, CA, USA) with DAD. Separation was 
achieved on a Kinetex C18, 2.6 µm, 2.1 × 100 mm column (Phenomenex, Torrance, CA, USA) with a 
flow of 0.4 mL min−1 at 40 °C using a linear gradient 10% acetonitrile (ACN) in Milli-Q water (MQ) 
with 20 µM formic acid (FA) going to 100% ACN in 10 min. All compounds were isolated by bio-
guided fractionation started by flash chromatography of the crude extracts, fractionated with an Isolera 
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One automated flash system (Biotage, Uppsala, Sweden). The isolation of compounds were performed 
by a semi-preparative Gilson HPLC system (Middleton, WI, USA) with a 215 Liquid Handler,  
819 Injection Module and a 172 DAD and fully controlled with Trilution LC software or on a Waters 
600 chromatograph (Milford, MA, USA) attached to a Waters 600 DAD. One-dimensional and  
two-dimensional NMR experiments were acquired using standard pulse sequences on a 800 MHz 
Bruker Avance spectrometer with a 5 mm TCI cryoprobe at the Danish Instrument Centre for NMR 
Spectroscopy of Biological Macromolecules at Carlsberg Laboratory, alternatively on a 500 MHz 
Varian Unity Inova (Palo Alto, CA, USA) equipped with a HCP probe or a 400 MHz Bruker Avance 
III equipped a BBO Prodigy cryoprobe NMR spectrometers. 
3.2. Micro Extraction for Initial Screen 
Two hundred and eighty nine (289) fungal extracts were prepared from cultivation of 137 fungal 
strains (Table S1). All extracts were prepared in accordance with the micro-extraction method 
developed by Smedsgaard [22]. Five plugs were collected across the colony. The samples were 
subsequently extracted using (3:2:1 v/v/v) methanol (MeOH), dichloromethane (DCM) and ethyl 
acetate (EtOAc) with 0.5% FA. 
3.3. Cultivation and Extraction 
The seven extracts described here were P. pulvillorum (IBT 22393), P. brasilianum (IBT 22244),  
P. decumbens (IBT 11843), P. cluniae (IBT 21051), Aspergillus sp. (Emericella-like state, IBT 22838), 
F. compactum (IBT 9034), and a new species in Aspergillus section Usti (IBT 18591). Each fungus 
was cultivated on 50 plates (media are listed in supplementary) for 8 days at 25 °C in the dark with the 
exceptions of P. brasilianum. P. brasilianum (IBT 22244), A. insuetus (IBT 28266), and A. calidoustus 
(IBT 25726) were cultivated on 200 agar plates with Yeast Extract Sucrose (YES) for 14 days (except 
A. calidoustus that was incubated for 7 days) at 25 °C in the dark. All the fungi were extracted 
separately with EtOAc containing 1% FA. Unwanted carbohydrates from the media as well as fatty 
acids were removed from the four large extract (P. brasilianum, the new species in Aspergillus section 
Usti, A. insuetus, and A. calidoustus) by liquid-liquid extraction with water/MeOH and heptane, 
respectively leaving the crude extracts. 
3.4. Bioassay-Guided Fractionation 
The crude extract of P. decumbens, P. pulvillorum, P. cluniae, Aspergillus sp. (Emericella-like 
state), and F. compactum were fractionated on a RP C18 (25 g, 33 mL) column flash column with at 
gradient of: 15%–100% ACN in 20 min and flow rate 25 mL/min. No further fractionations were  
done with the bioactive flash fraction from the P. cluniae extract. Penicillic acid was purified from  
the bioactive flash fraction from the P. pulvillorum extract by semi-preparative HPLC LunaII C18  
(250 × 10 mm, 5 µm) column with at gradient of: 15%–100% ACN in 20 min and flow rate 5 mL/min. 
ACN and MQ were added 20 mM FA. 
Penicillic acid: White solid; UV (ACN) λmax: 227 nm; HRMS m/z 170.0573 (M+ calculated for 
C8H10O4, m/z 170.0574; 0.5 ppm). 
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3.4.1. E-SPE 
P. brasilianum, P. decumbens, Aspergillus sp. (Emericella-like state), and F. compactum extracts 
were prefractionated analytical in accordance with the E-SPE method developed by Månsson et al. [21] 
with SAX, MAX, and SCX ion-exchanger SPE columns though without the Sephadex LH-20 column. 
Additionally two normal phase (amino and diol) columns were add to the setup. For each extract, 5 mg 
was loaded on both the amino column (100 mg, 1 mL) and the diol column (100 mg, 1 mL). The 
compounds were eluted by 2 column volume (CV) heptane, 2 CV DCM, 2 CV DCM/EtOAc (1:1),  
2 CV EtOAc, 2 CV EtOAc/MeOH, 2 CV MeOH, 4 CV ACN, 2 CV ACN/MQ + 2% FA (75:25), 2 CV 
ACN/MQ + 2% FA (50:50), 2 CV ACN/MQ + 2% FA (25:75), 2 CV ACN/MQ + 2% FA (10:90). No 
further fractionations were done with the bioactive flash fraction from the P. decumbens extract. 
The bioactive C18 flash fraction from the Aspergillus sp. (Emericella-like state) extract was loaded 
on the amino column (10 g, 15 mL) and eluted by 2 CV heptane, 2 CV DCM, 2 CV DCM/EtOAc 
(1:1), 2 CV EtOAc, 2 CV EtOAc/MeOH, 2 CV MeOH, 4 CV ACN, 2 CV ACN/MQ + 2% FA(75:25), 
2 CV ACN/MQ + 2% FA (50:50), 2 CV ACN/MQ + 2% FA (25:75), 2 CV ACN/MQ + 2% FA 
(10:90). Emestrin A (1.1 mg) was finally isolated by preparative HPLC on a LunaII C18 (250 × 10 mm, 
5 µm) column with at gradient of: 50%–100% ACN in 20 min and flow rate 5 mL/min. ACN and MQ 
were added 50 ppm trifluoroacetic acid (TFA). 
Emestrin A: White solid; [α]589.3nm: +22°; UV (ACN) λmax: 230 (sh), 267 (sh), 285 (sh); HRMS m/z 
598.0713 (M+ calculated for C27H22N2O10S2, m/z 598.0711; 0.4 ppm).  
The bioactive C18 flash fraction from the F. compactum extract was loaded on a diol column (10 g, 
15 mL) and eluted by 2 CV heptane, 2 CV heptanes/DCM (1:1), 2 CV DCM, 2 CV DCM/EtOAc (1:1), 
2 CV EtoAc, 2 CV EtOAc/MeOH, 2 CV MeOH, 2 CV MeOH/ACN (1:1) and 2 CV ACN. Neosolaniol 
monoacetate was isolated with semi-preparative HPLC on a Luna II, C18, 5 µm, 10 × 250 mm column 
with 30%–70% ACN in 20 min and flow rate 5 mL/min. ACN and MQ were added 20 mM FA. 
Neosolaniol monoacetate: White solid; HRMS m/z 424.1728 (M+ calculated for C21H28O9, m/z 
424.1728; 0 ppm). 
The crude extract of P. brasilianum was loaded on a SAX column (100 g, 132 mL) and washed by 
1 CV 70% MeOH in MQ (pH 11) and 1 CV 100% MeOH (pH 7) giving the SAX-1 fraction. 
Subsequently eluted by 2 CV 100% MeOH (pH 2) giving the SAX-2 fraction. Viridicatumtoxin was 
isolated (27.5 mg) from SAX-2 on a RP C18 column with at gradient of: 30%–100% ACN in 60 min 
and flow rate 40 mL/min. ACN and MQ were added 50 ppm TFA. 
Viridicatumtoxin: Yellow solid; UV (ACN) λmax: 238, 286, 435 nm; HRMS m/z 565.1942 (M+ 
calculated for C30H31NO10, m/z 565.1942; 0 ppm). 
3.4.2. Ophiobolins 
The crude extract of a new species in Aspergillus section Usti (IBT 18591) was fractionated on a 
RP C18 (25 g, 33 mL) flash column with at gradient of: 15%–100% ACN in 20 min and flow rate  
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25 mL/min. Subsequently the active fraction was loaded on a diol flash column and eluted with 2 CV 
heptane, 2 CV heptanes/DCM (1:1), 2 CV DCM, 2 CV EtOAc, 2 CV MeOH. Ophiobolin K and  
6-epiophiobolin K were isolated from the active fraction by semi-preparative HPLC on a Luna II, C18, 
5 µm, 10 × 250 mm column by 70%–100% ACN in 25 min and flow rate 5 mL/min. 
Ophiobolin K: White solid; [α]589.3nm: +161°; UV (ACN) λmax: 241 nm; HRMS m/z 384.2658 (M+ 
calculated for C25H36O3, m/z 384.2659; 0.3 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
6-Epiophiobolin K: White solid; [α]589.3nm: +53°; UV (ACN) λmax: 239 nm; HRMS m/z 384.2658 (M+ 
calculated for C25H36O3, m/z 384.2659; 0.3 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
The crude extract of A. insuetus (IBT 28266) was loaded on a diol flash column and eluted with  
2 × 2 CV heptane, 2 CV heptanes/DCM (1:1), 2 CV DCM, 2 CV EtOAc, 2 CV MeOH. The active 
fraction was then loaded on a RP C18 flash column with at gradient of: 80%–100% ACN in  
45 min and flow rate 40 mL/min. Ophiobolin U, ophiobolin H and 6-epiophiobolin N were isolated 
from the active fraction by semi-preparative HPLC on a Gemini, C6-Ph, 5 µm, 10 × 250 mm column. 
Ophiobolin U was purified by 55%–70% ACN in 25 min and flow rate 5 mL/min. Ophiobolin H and  
6-epiophiobolin N were purified by 50% ACN isocratic in 15 min, then 50–60 min ACN in 15 min, 
and then up to 100% ACN in 5 min. ACN and MQ were added 50 ppm TFA. 
Ophiobolin U: White solid; [α]589.3nm: +3°; UV (ACN) λmax: 242 nm; HRMS m/z 386.2813 (M+ 
calculated for C25H38O3, m/z 386.2816; 0.5 ppm); 1H-NMR (800 MHz, CDCl3): δ 0.91 (2H, d, 6.7, H23), 
0.99 s (3H, s, H22), 1.03 (1H, m, H1a), 1.26 (3H, s, H20), 1.38 (2H, m, H12), 1.55 (1H, m, H10), 1.58 
(1H, m, H1b), 1.58 (1H, m, H13a), 1.74 (3H, s, H24), 1.78 (1H, m, H13b), 1.82 (3H, s, H25), 1.87 
(1H, dd, 4.1, 15.1, H4a), 2.09 (1H, m, H14), 2.24 (1H, m, H9a), 2.30 (1H, m, H2), 2.68 (1H, dd, 7.9, 
15.1, H4b), 2.72 (1H, m, H15), 2.89 (1H, dd, 8.5, 12.5, H9b), 3.02 d (1H, d, 9.6, H6), 4.91 (1H, dd, 
4.7, 7.9, H5), 5.21 (1H, t, 10.0, H16), 6.00 (1H, m, H18), 6.03 (1H, m, H17), 6.94 t (1H, d, 8.5, H8), 
9.26 (1H, s, H21); 13C-NMR (200 MHz, CDCl3): δ 18.3 (C24), 18.6 (C22), 20.6 (C23), 25.6 (C9), 26.3 
(C20), 26.7 (C13), 26.7 (C25), 35.2 (C1), 35.9 (C15), 42.0 (C12), 44.1 (C11), 47.4 (C14), 50.5 (C6), 
51.0 (C2), 53.4 (C4), 54.0 (C10), 73.1 (C5), 81.9 (C3), 120.2 (C18), 122.3 (C17), 135.9 (C19), 137.7 
(C16), 142.1 (C7), 164.1 (C8), 198.1 (C21). Full dataset is found in Table S10. 
Ophiobolin H: White solid; [α]589.3nm: +60°; UV (ACN) λmax: 241 nm; HRMS m/z 386.2817 (M+ calculated 
for C25H38O3, m/z 386.2816; −0.5 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
6-Epiophiobolin N: White solid; [α]589.3nm: +10°; UV (ACN) λmax: 232 nm; HRMS m/z 368.2711 (M+ 
calculated for C25H36O2, m/z 368.2710; −0.2 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
The crude extract of A. calidoustus (IBT 25726) was loaded on a diol flash column and eluted with  
2 CV heptane, 2 CV heptanes/DCM (1:1), 2 CV DCM, 2 CV EtOAc, 2 CV MeOH. Ophiobolin C and  
6-epiophiobolin G were isolated from the active fraction by semi-preparative HPLC on a Luna II, C18, 
5 µm, 10 × 250 mm column. Ophiobolin C was purified by 80% ACN in MQ and 6-epiophiobolin G 
was purified by 80% MeOH in MQ both isocratic with a flow rate of 5 mL/min. 
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Ophiobolin C: White solid; [α]589.3nm: +298°; UV (ACN) λmax: 240 nm; HRMS m/z 386.2813 (M+ 
calculated for C25H38O3, m/z 386.2816; 0.7 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
6-Epiophiobolin G: White solid; [α]589.3nm: +127°; UV (ACN) λmax: 234 nm; HRMS m/z 366.2553 (M+ 
calculated for C25H34O2, m/z 366.2554; 0.1 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
3.5. CLL Cells, Cell Viability and Apoptosis Assays 
Whole blood samples were obtained from patients that matched the standard diagnostic criteria for 
CLL after informed consent in accordance with the Declaration of Helsinki. All studies performed 
were approved by the ethics committee of the University of Ulm. Peripheral blood mononuclear cells 
(PBMC) were isolated by Ficoll density gradient and consisted of at least 80% CD5+CD19+ leukemic 
cells as determined by flow cytometry. For the initial screen, cocultures of HS-5 stromal cells and CLL 
cells were established as previously described [53]. For retesting of bio-active substances, CLL cells 
were cultured in conditioned media of HS-5 cells, which was harvested after 3–4 days of culture and 
80% confluency and depleted of HS-5 cells and debris by centrifugation. CLL cells were seeded in 
duplicates at a density of 3 × 105 cells/well in opaque-walled 96-well plates. Fractions or pure 
compounds were added in different concentrations and incubated for 24 h. 0.1% DMSO was used as a 
negative control. Cell viability was assessed using CellTiter-Glo® assay (Promega, Madison, WI, 
USA) according to manufacturer’s protocol. Luminescence signals were recorded using a Mithras 
LB940 plate reader (Berthold Technologies, Bad Wildbad, Germany). Background signals of medium 
were subtracted from each well as described by Knudsen et al. [15]. 
Apoptotic cell death was detected by flow cytometry using Annexin V-phycoerythrin (PE) and  
7-aminoactinomycin (7-AAD) staining kit (BD Biosciences, Heidelberg, Germany) as described by 
Seiffert et al. [12]. To confirm apoptosis induction, staining for active caspase 3 was performed  
after fixation and permeabilization of cells using BD Cytofix/CytopermTM solution as described by  
the manufacturer by using PE-conjugated anti-active caspase 3 antibodies (clone C92-605, BD 
Biosciences). All flow cytometry analyses were carried out using a FACSCanto II flow cytometer 
equipped with FACSDiva software (BD Biosciences). 
4. Conclusions 
In conclusion, our combined bio-guided and dereplication based discovery approach has proven to 
be effective for fast dereplication and discovery of bioactive fungal natural products that target CLL 
cells. Comparative testing of active extracts on CLL cells as well as healthy cells identified compounds 
with general and selective bioactivity. The ophiobolin family showed high activity for CLL cells. The 
known ophiobolins A, B, C and K induced apoptosis in CLL cells with LC50 values of 1, 2, 8, and 4 nM, 
respectively with a lower bioactivity for healthy fibroblasts. The high activities for CLL cells were 
found only in ophiobolins with a hydroxy group at C3, an aldehyde at C21, and A/B-cis ring structure. 
In the remaining six bioactive extracts, the compounds responsible for the activity were tentatively 
identified by dereplication, and the activities towards CLL cells were verified by testing the pure 
compounds. The six active compounds, penicillic acid, viridicatumtoxin, calbistrin A, brefeldin A, 
emestrin A, and neosolaniol monoacetate, were all known and generally cytotoxic. In order to identify 
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substances that are of therapeutic value for cancer cells, selective active substances need to be retested 
on a large cohort of cancer and healthy cells. In general, cytotoxic compounds are only suitable as  
anti-cancer pharmaceuticals if they selectively target the cancer cells and not healthy cells, or at least 
have a higher impact on the tumor cells. Activity optimization is well exemplified with these studies 
demonstrating the great potential of looking into the chemistry of closely related species to obtain 
more analogue compounds of a promising scaffold. 
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1. Strains tested in the initial screening against chronic lymphocytic leukemia (CLL) 
Table S1. Strains tested in the initial screening. 
Isolate number Species Isolate number Species 
21947 Aspergillus cystallinus 22516, 22523 Penicillium faroense 
3234, 5265 Aspergillus cavernicola 21051 Penicillium cluniae 
24813 Aspergillus granulosus 11843 Penicillium decumbens 
24666 Aspergillus conjunctus 26291 Penicillium bialowiezense 
10526, 18590 Aspergillus caespitosus 18329 Penicillium brevicompactum 
22551 Aspergillus diversus 22244 Penicillium brasillianum 
22564, 24812 Aspergillus funiculosis 22393 Penicillium pulvillorum 
11054 Aspergillus deflectus 23856 Penicillium svalbardense 
22568 Aspergillus varians 23667 Penicillium lapatayae 
4537, 28161 Aspergillus pseudoustus 16536 Penicillium alpinium 
14906, 23076 Aspergillus subvesicolor 14084 Penicillium caseium 
10525 Aspergillus neocaespitos 16545 Penicillium pinicola 
23282 Aspergillus microcysticus 22760 Penicillium aquamarinum 
24752,  22153 Aspergillus karnakataense 22662 Penicillium groenlandense 
26386, 22274 Aspergillus janus 24414 Penicillium algidum 
17337 Aspergillus aureolatus 24411 Penicillium 
jamesonlandense 
11835 Aspergillus sydowii 22544 Penicillium eidiense 
10127 Aspergillus quasivesicolor 22356 Penicillium monticola 
18591 New sp. in the Aspergillus 
section Usti 
22663 Penicillium floccosum 
21781, 22558 Aspergillus brevis 17760 Penicillium artemision 
13670, 13691 Aspergillus neopuniceus 14073 Penicillium wyomingense 
20587 Aspergillus neoustus 13954 Penicillium minitum 
16756 Aspergillus panamensis 24420 Penicillium rivulorum 
11860, 11847  Aspergillus protuberus 29798 Penicillium diversicolor 
11821, 25061 Aspergillus vesicolor 16537 Penicillium ribeum 
23160 Aspergillus subsessilis 16625 Penicillium turcosum 
22554, 25041 Aspergillus ustus 22779 Penicillium jugorum 
17674 Aspergillus 
pseudoversicolor 
30014 Penicillium galathea 
4332 Aspergillus neovesicolor 30013 Penicillium 
nassarsuaquense 
18288 Aspergillus arizonae fel 248, cml 832 Pestalotiopsis 
13989 Aspergillus aculeatus fel 64 Arthrinium phaeospermum 
22838 Aspergillus sp. 
(Emericella-like state)
fel 192 Ascochyta 
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Table S1. Cont. 
Isolate number Species Isolate number Species 
9194 Cylindrocarpon olidum fell 01 Acremonium 
8893 Fusarium poae fel 240 Paraconiothyrium 
8988 Fusarium avenaceum cml 1707 Nodulisporium 
8979, 9077, 
9115 
Fusarium equiseti fel 89, fel 355, fel 364 Phomopsis 
8977 Fusarium tricinctum fel 302 Cytospora 
8945, 7785 Epicoccum nigrum fel 159 Bipolaris sp. 
9034 Fusarium compactum fel 06 Glomerella cingulata 
9044 Fusarium culmorum fel 307, fel 308 Lecanicillium pasalliotae 
9063 Fusarium cerealis fel 17, fel 42 Paraconiothyrium 
sporulosum 
9085 Fusarium oxysporum fel 05, fel 30, cml 
1716 
Periconia 
9096 Fusarium redolens fel 299A Curvularia 
9089 Fusarium merismoides fel 142 Tubercularia sp. 
9087 Fusarium torulosum fel 315 Verticillium leptobactum 
9086, 9206 Fusarium solani cml 1692 Lasiodiplodia theobromae 
9103 Fusarium flocciferum cml 1709 Collototrichum crassipes 
9112, 9121  Fusarium pallidoroseum cml 1681 Cuvularia prasadii 
9107 Fusarium proliferatum cml 1671 Libertella 
9117 Fusarium verticillioides fel 58, cml 1702, 
cml 1703, cml 1690 
Microsphaeropsis 
1807 Fusarium sambucinam cml 1670A Clonostachys 
9184 Fusarium 
chlamydosporum 
cml 1693 Spegazzinia deightonii 
9181 Fusarium neohelle cml 1695 Virgatospora echinofibrosa 
9182 Fusarium neochlam fel 09, fel 241 Paraconiothyrium 
brasiliense 
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2. Strains found active against chronic lymphocytic leukemia (CLL) 
Table S2. Strains found active in the initial screening. 
Isolate number Species 
Maximum activity 
observed on media 
9103 Fusarium occiferum YES 
9034 Fusarium compactum YES 
22838 Aspergillus sp. (Emericella-like 
state)
YES 
13989 Aspergillus aculeatus CYA 
23105 Aspergillus pseudovesicolor YES 
3235 Aspergillus cavernicola YES 
18950 Aspergillus caespitosus YES 
22564 Aspergillus funiculosis YES 
22551 Aspergillus diversus YES 
14906 Aspergillus subvesicolor CYA 
23282 Aspergillus microcysticus CYA 
24752 Aspergillus karnakataense YES 
18951 New sp. in the Aspergillus section 
Usti 
YES 
20587 Aspergillus neoustus YES 
23160 Aspergillus subsessilis CYA 
26291 Penicillium bialowienze YES 
18329 Penicillium brevicompactum YES 
21051 Penicillium cluniae YES 
22393 Penicillium pulvillorum YES 
22244 Penicillium brasilianum YES 
11843 Penicillium decumbens YES 
18288 Aspergillus arizonae CYA 
16545 Penicillium pinicola YES 
22760 Penicillium aquamarinum CYA 
22523 Penicillium faroense YES 
22662 Penicillium groenlandense ALK 
24411 Penicillium jamesonlandense CYA 
22544 Penicillium eidense YES 
22356 Penicillium monticola CYA 
22663 Penicillium occosum CYA 
17760 Penicillium artemision  YES 
29798 Penicillium diversicolor YES 
16537 Penicillium ribeum YES 
16625 Penicillium turcosum ALK 
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Table S2. Cont. 
Isolate number Species 
Maximum activity 
observed on media 
22779 Penicillium jugorum CYA 
30014 Penicillium galathea CYA 
fel 248  Pestalotiopsis MEA 
fel 64 Arthrinium phaeospermum MEA 
fel 355 Phomopsis MEA 
fel 302 Cytospora MEA 
fel 159 Bipolaris sp  YES 
fel 308 Lecanicillium psalliotae YES 
fel 240 Paraconiothyrium brasiliense YES 
fel 17 Paraconiothyrium sporulosum YES 
fel 05, fel 30 and cml 
1716 
Periconia YES 
fel 299A Curvularia YES 
fel 142 Tubercularia YES 
cml 1692 Lasiodiplodia theobromae YES 
cml 1709 Collototrichum crassipes YES 
cml 1692 Libertella YES 
cml 1703, cml 1690 Microphaeropsis YES 
cml 1707 Nodulisporium YES 
cml 1670A Clonostachys YES 
cml 1693 Spegazzinia deightonii YES 
cml 1695 Virgatospora echinofibrosa YES 
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3. Penicillic acid isolated from Penicillium pulvillorum (IBT 22393) 
Figure S1. 1H-NMR spectrum of penicillic acid in DMSO-d6 at 500 MHz  
 
 
Table S3. 1H and 13C-NMR for penicillic acid in DMSO at 500 MHz for 1H and 125 MHz for 13C. 
 δH mult. (J (Hz)) δC * 
1  169.8 
2 5.39 1 H, s 89.6 
3  178.6 
4  106.3 
4-OH 3.33 1 H, br.s.  
5  140.4 
6a 5.16 1 H, s 115.4 
6b 5.33 1 H, br.s. 115.4 
7 1.65 3 H, s 16.9 
8 3.84 3 H, s 58.5 
* 13C-NMR chemical shifts determined from HSQC and HMBC experiments. 
 
 
6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
 
Molecules 2013, 18              
          
S9
4. Viridicatumtoxin isolated from P. brasilianum (IBT 22244) 
Figure S2. 1H-NMR spectrum of viridicatumtoxin in DMSO-d6 at 400 MHz. 
 
Table S4. 1H-NMR for viridicatumtoxin in DMSO at 500 MHz. 
 δH mult. (J (Hz))  
4α 2.55 (1H, m) 
 
4β 2.81 (1H, m) 
5 4.66 (1H, br.s.) 
9 6.68 (1H, s) 
14α 2.91 (1H, m) 
14β 3.17 (1H, m) 
17 5.40 (1H, br.s.) 
18α 1.98 (1H, m) 
18β 2.13 (1H, m) 
19α 1.30 (1H, dd, 5.6, 12.8) 
19β 1.75 (1H, m) 
21 0.45 (3H, s) 
22 0.87 (3H, s) 
23 1.43 (3H, s) 
24 3.79 (3H,s) 
OH 5.59 (1H, br.s.) 
OH 6.79 (1H, br.s.) 
OH 8.84 (1H, br.s.) 
OH 9.73 (1H, br.s.) 
OH 14.64 (1H, br.s.) 
 
15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 ppm
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5. Emestrin A isolated from Aspergillus sp. (Emericella-like state) (IBT 22838) 
Figure S3. 1H-NMR spectrum of emestrin A in DMSO-d6 at 500 MHz. 
 
 
  
12345678910 ppm
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Table S5. 1H and 13C-NMR for emestrin A in DMSO at 500 MHz for 1H and 125 MHz for 13C. 
 δH mult. (J (Hz)) δC *  
1  80.8 ‡ 
 
2  164.2 † 
3  80.8 ‡ 
4  164.2 † 
5a 5.67 1 H, dd (2.5, 7.4) 59.8 
5b  160.2 
6 4.67 1 H, ddd (2.0, 2.5, 7.4) 74.6 
7 4.91 1 H, dd (2.0, 8.5) 106.2 
8 6.42 1 H, dd (2.5, 8.5) 137.1 
10 7.06 1 H, d (2.5) 141.1 
11 5.46 1 H, d (7.2) 72.6 
11-OH 6.25 1 H, d (7.2)  
12 3.25 3 H, s 27.1 
1'  127.2 
2' 7.76 1 H, d (1.9) 122.5 
3'  143.6 
4'  149.0 
4'-OH 9.73 1 H, s  
5' 6.88 1 H, d (8.3) 115.2 
6' 7.16 1 H, dd (2.0, 8.3) 124.8 
7' 4.96 1 H, d (4.6) 74.6 
7'-OH 5.99 1 H, d (4.6)  
1''  145.6 
2''  153.4 
3'' 7.21 1 H, d (8.6) 112.1 
4'' 7.57 1 H, dd (1.9, 8.6) 123.8 
5''  122.0 
6'' 7.37 1 H, d (1.9) 120.0 
7''  164.3 
8'' 3.94 3 H, s 55.7 
* 13C-NMR chemical shifts determined from HSQC and HMBC experiments; ‡ Not possible to distinguish 
between C1 and C3; † Not possible to distinguish between C2 and C4. 
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6. Neosolaniol monoacetate isolated from Fusarium compactum (IBT 9034) 
Figure S4. 1H-NMR spectrum of neosolaniol monoacetate in DMSO-d6 at 500 MHz. 
 
Table S6. 1H-NMR for neosolaniol monoacetate in DMSO at 500 MHz. 
 δH mult. (J (Hz))  
2 3.41 1H, d (5.0) 
 
3 4.07 1H, dd, (3.0; 5.0) 
4 5.39 1H, d (3.2) 
5  
6  
7a 2.18 1H, dd (5.3; 15.7)
7b 1.94 1H, m 
8 5.15 1H, d, (5.3) 
9  
10 5.67 1H, d (5.7) 
11 4.1 1H, d (5.7) 
12  
13a 2.78 1H, d (3.9) 
13b 2.98 1H, d (3.9) 
14 0.59 3H, s 
15a 3.94 1H, d (12.2) 
15b 4.16 1H, d (12.2) 
16 1.66 3H, s 
C=O C4  
C=O C8  
C=O C15  
CH3 C4 1.96 3H, s 
CH3 C8 2.04 3H, s 
CH3 C15 1.93 3H, s 
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
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7. Ophiobolins 
7.1 Potential ophiobolin producing strains from the Aspergilli section Usti 
Table S7. Aspergilli section Usti. 
IBT number Species 
4537 
10619 
20587 
22554 
25041 
Aspergillus ustus 
10524 
24673 
24708 
Aspergillus keveii 
28266 
28267 
Aspergillus insuetus 
13091 
25726 
Aspergillus calidoustus 
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7.2 NMR data for ophiobolin U, ophiobolin K, 6-epiophiobolin K, ophiobolin C, ophiobolin H, 
6-epiophiobolin H, and 6-epiophiobolin G 
Table S8. 13C-NMR data for ophiobolin U, ophiobolin K, 6-epiophiobolin K, ophiobolin C, 
ophiobolin H, 6-epiophiobolin H, and 6-epiophiobolin G. (* 125 MHz in dimethyl 
sulfoxide (DMSO)-d6, † 125 MHz in CDCl3, or ‡ 200 MHz in CDCl3, δC). 
Ophiobolin U ‡ K * 6-epi-K * C † H ‡ 6-epi-N ‡ 6-epi-G †
1 35.2 34.5 41.0 36.0 35.7 45.6 45.8
2 51.0 49.2 49.6 50.8 50.9 49.3 49.2
3 81.9 76.2 74.7 76.6 80.2 179.8 178.1
4 53.4 53.9 54.7 54.6 50.8 130.0 130.2
5 73.1 217.0 216.1 217.5 116.0 209.6 208.2
6 50.5 48.3 48.2 48.4 52.8 49.9 50.0
7 142.1 140.6 141.5 141.5 138.5 140.1 139.9
8 164.1 157.6 159.9 163.8 123.6 157.3 158.1
9 25.6 24.3 30.0 24.7 25.0 31.0 30.9
10 54.0 53.0 43.1 53.4 55.0 43.1 43.8
11 44.1 43.3 44.9 43.6 43.6 45.0 45.4
12 42.0 42.2 44.4 42.6 43.0 44.5 44.3
13 26.7 25.4 27.1 22.8 26.8 27.1 27.8
14 47.4 46.2 51.4 45.2 47.2 51.1 52.1
15 35.9 34.4 31.9 32.7 35.5 31.8 32.6
16 137.7 136.9 136.0 36.8 138.0 37.1 135.7
17 122.3 121.7 123.3 26.0 121.7 25.6 124.0
18 120.2 119.9 120.1 124.3 120.4 124.4 120.0
19 135.9 134.6 135.3 131.0 135.2 131.6 136.6
20 26.3 25.7 25.2 25.4 25.4 17.4 17.3
21 198.1 193.1 194.7 195.9 71.5 193.0 193.0
22 18.6 18.2 22.8 19.0 18.7 23.1 22.9
23 20.6 19.6 21.1 16.4 20.4 18.6 21.3
24 18.3 18.0 17.9 17.6 18.2 17.7 18.2
25 26.7 25.9 26.1 25.6 26.6 25.7 26.5
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Table S9. 1H-NMR data for ophiobolin U, ophiobolin K, 6-epiophiobolin K, ophiobolin C, 
ophiobolin H, 6-epiophiobolin H, and 6-epiophiobolin G. (* 500 MHz in DMSO-d6,  
† 500 MHz in CDCl3, or ‡ 800 MHz in CDCl3, δH mult. (J (Hz))). 
Ophiobolin U ‡ K * 6-epi-K * C † H ‡ 6-epi-N ‡ 6-epi-G †
1a 1.03 m 1.14 m 1.58 m 1.26 m 1.36 m 1.18 m 1.15 m 
1b 1.58 m 1.58 m 1.65 m 1.81 m 1.42 m 2.04 dd 
(3.7; 13.2) 
2.03 m 
2 2.30 m 2.25 m 1.91 m 2.38 m 2.26 m 2.71 m 2.66 m 
3-OH   6.51 br.s.     
4a 1.87 dd 
(4.1, 15.1) 
2.35 m 2.21 m 2.49 m 2.10 m 6.11 s 6.04 s 
4b 2.68 dd 
(7.9, 15.1) 
2.50 m 2.77 d (16.0) 2.80 m 2.18 m   
5 4.91 dd 
(4.7, 7.9) 
      
6 3.02 d (9.6) 3.22 d (9.8) 3.04 d (10.8) 3.26 m 3.17 d (9.8) 3.54 d (3.7) 3.40 m 
8 6.94 t (8.5) 7.02 t (8.5) 6.96 m 7.21 m 5.64 br.s. 6.86 dd 
(2.0; 6.3) 
6.80 m 
9a 2.24 m 2.04 m 2.27 m 2.31 m 1.70 m 2.25 m 2.20 m 
9b 2.89 dd 
(8.5, 12.5) 
2.69 m 2.65 m 2.45 m 2.50 dd 
(8.6; 13.8) 
2.71 m 2.93 m 
10 1.55 m 1.56 m 2.46 m 1.67 m 1.60 m 2.72 m 2.63 m 
12a 1.38 m 1.33 m 1.38 m 1.41 m 1.40 dd 
(7.6; 11.7) 
1.42 m 1.43 m 
12b  1.35 m 1.44 m 1.44 m 1.57 m 1.51 m 1.52 m 
13a 1.58 m 1.54 m 1.22 m 1.46 m 1.54 m 1.23 m 1.25 m 
13b 1.78 m 1.69 m 1.57 m 1.55 m 1.76 m 1.58 m 1.67 m 
14 2.09 m 2.09 m 1.87 m 2.36 m 2.05 m 1.75 m 1.89 m 
15 2.72 m 2.72 m 2.61 m 1.65 m 2.68 m 1.42 m 2.55 m 
16a 5.21 t (10.0) 5.23 t (9.5) 5.25 t (9.3) 1.18 m 5.20 m 0.99 m 5.11 t (1.3) 
16b    1.24 m  1.45 m  
17a 6.03 m 5.99 m 6.11 m 1.95 m 5.99 m 1.94 m 6.10 m 
17b    2.00 m  2.07 m  
18 6.00 m 6.04 m 6.09 m 5.09 m 5.98 m 5.12 t (7.0) 6.00 m 
20 1.26 s 1.19 s 1.26 s 1.36 s 1.24 s 2.10 s 2.06 s 
21a 9.26 s 9.14 s 9.12 s 9.23 s 4.48 br.s. 9.30 s 9.26 s 
21b     4.59 d (12.2)   
22 0.99 s 0.91 s 0.77 s 0.90 s 0.90 s 0.86 m 0.85 s 
23 0.91 d (6.7) 0.85 d (6.6) 0.92 d (6.6) 0.78 d (6.8) 0.88 d (6.7) 0.91 d (6.4) 0.97 d (6.8) 
24 1.74 s 1.68 s 1.70 s 1.61 s 1.73 s 1.61 s 1.76 s 
25 1.82 s 1.76 s 1.79 s 1.69 s 1.80 s 1.69 s 1.83 s 
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7.3 Ophiobolin U isolated from A. insuetus (IBT 28266) 
Figure S5. 1H-NMR spectrum of ophiobolin U in CDCl3 at 800 MHz. 
 
Figure S6. 13C-NMR spectrum of ophiobolin U in CDCl3 at 200 MHz. 
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Table S10. 1H- and 13C-NMR for ophiobolin U in CDCl3 at 800 MHz for 1H and 200 MHz 
for 13C. 
 δH mult. (J (Hz)) δC HMBC connectivities NOE connectivities 
1a 1.03 (1H, m) 35.2 2, 3, 10, 11, 22 1b 
1b 1.58 (1H, m) 35.2 3, 10, 12 1a, 2, 15, 20, 22 
2 2.30 (1H, m) 51.0 1, 3, 6, 7 6, 20, 22 
3  81.9   
4a 1.87 (1H, dd, 4.1, 
15.1) 
53.4 3, 5 2, 4b, 20 
4b 2.68 (1H, dd, 7.9, 
15.1) 
53.4 2, 3, 6 4a, 5 
5 4.91 (1H, dd, 4.7, 
7.9) 
73.1 3, 6, 7 4b, 6 
6 3.02 d (1H, d, 9.6) 50.5 2, 3, 5, 7, 8, 21 2, 5, 9a, 22 
7  142.1 - - 
8 6.94 t (1H, d, 8.5) 164.1 6, 9, 21 9a, 9b, 10, 21 
9a 2.24 (1H, m) 25.6 7, 8, 10, 11 6, 8, 9b, 22 
9b 2.89 (1H, dd, 8.5, 
12.5) 
25.6 7, 8, 10, 11, 14 8, 9a, 10, 14, 15, 16 
10 1.55 (1H, m) 54.0 8, 9, 11, 14, 15, 22 8, 9b, 14 
11  44.1 - - 
12 1.38 (2H, m) 42.0 10, 11, 13, 14, 22 13a, 13b, 22 
13a 1.58 (1H, m) 26.7 11, 14, 15 12, 13b, 22, 23 
13b 1.78 (1H, m) 26.7 10, 11, 14, 15 12, 13a, 14 
14 2.09 (1H, m) 47.4 10, 11, 13, 15, 16, 23 9b, 10, 13b, 15, 16, 23 
15 2.72 (1H, m) 35.9 14, 16, 17, 23 9b, 1b, 14, 16, 18, 22, 23 
16 5.21 (1H, t, 10.0) 137.7 14, 15, 18, 23 9b, 14, 15, 17, 23 
17 6.03 (1H, m) 122.3 15, 19 16, 24 
18 6.00 (1H, m) 120.2 24, 25 15, 25 
19  135.9   
20 1.26 (3H, s) 26.3 2; 3; 4 1b, 2, 4a 
21 9.26 (1H, s) 198.1 6, 7, 8 5, 8 
22 0.99 s (3H, s) 18.6 1, 10, 11, 14 1b, 2, 6, 9a, 12, 13a, 15 
23 0.91 (2H, d, 6.7) 20.6 14, 15, 16 13a, 14, 15, 16 
24 1.74 (3H, s) 18.3 18, 19, 25 17 
25 1.82 (3H, s) 26.7 18, 19, 24 18 
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7.4 Ophiobolin H isolated from A. insuetus (IBT 28266) 
Figure S7. 1H-NMR spectrum of ophiobolin H in CDCl3 at 800 MHz. 
 
Figure S8. 13C-NMR spectrum of ophiobolin H in CDCl3 at 200 MHz. 
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Table S11. 1H- and 13C-NMR for ophiobolin H in CDCl3 at 800 MHz for 1H and 200 MHz for 13C. 
 δH mult. (J (Hz)) δC HMBC connectivities NOE connectivities 
1a 1.36 m 35.7 2, 6, 10, 11, 22 1b 
1b 1.42 m 35.7  1a, 2, 8, 20 
2 2.26 m 50.9  1b, 6, 20, 22 
3  80.2   
4a 2.10 m 50.8  4b, 20 
4b 2.18 m 50.8  4a 
5  116.0   
6 3.17 d (9.8) 52.8  2, 9a, 22 
7  138.5   
8 5.64 br.s. 123.6  1b, 9b 
9a 1.70 m 25.0 8, 10, 11 6, 9b, 22 
9b 2.50 dd (8.6; 13.8) 25.0 7, 8, 10, 11, 14 8, 9a, 10, 15, 16 
10 1.60 m 55.0 8, 9, 11, 14, 15, 22 9b, 14 
11  43.6   
12a 1.40 dd (7.6; 11.7) 43.0 10, 11, 14, 22 12b, 13a, 22 
12b 1.57 m 43.0 13, 15 12a, 13b 
13a 1.54 m 26.8 12, 14, 15 12a, 13b, 23 
13b 1.76 m 26.8 10, 11, 14 12b, 13a, 14 
14 2.05 m 47.2 10, 11, 13, 15, 16, 23 10, 13b, 16, 23 
15 2.68 m 35.5 14, 16, 23 9b, 18, 22 
16 5.20 m 138.0 18 9b, 14, 17, 23 
17 5.99 m 121.7 15, 19 16, 24 
18 5.98 m 120.4 16, 24, 25 15, 23, 25 
19  135.2   
20 1.24 s 25.4 2, 3 1b, 2, 4a 
21a 4.48 br.s. 71.5   
21b 4.59 d (12.2) 71.5   
22 0.90 s 18.7 1, 10, 11 2, 6, 9a, 12a, 15 
23 0.88 d (6.7) 20.4 14, 15, 16 13a, 14, 16, 18 
24 1.73 s 18.2 18, 19, 25 17 
25 1.80 s 26.6 18, 19, 24 18 
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7.5 6-epiophiobolin N isolated from A. insuetus (IBT 28266) 
Figure S9. 1H-NMR spectrum of 6-epiophiobolin N in CDCl3 at 800 MHz. 
 
Figure S10. 13C-NMR spectrum of 6-epiophiobolin N in CDCl3 at 200 MHz. 
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Table S12. 1H and 13C NMR for 6-epiophiobolin N in CDCl3.at 800 MHz for 1H and 200 MHz for 13C. 
 δH mult. (J (Hz)) δC HMBC connectivities NOE connectivities 
1a 1.18 m 45.6 2; 3; 10; 12; 22 1b, 6, 10, 12a/15 * 
1b 2.04 dd (3.7; 13.2) 45.6 2, 6, 10, 11 1a, 10, 12a/15 *, 12b, 22 
2 2.71 m 49.3 8, 11 8. 9a, 16b, 20, 22 
3  179.8   
4 6.11 s 130.0 3; 5; 6; 20 20 
5  209.6   
6 3.54 d (3.7) 49.9 1; 2; 5; 7; 8; 21 1a; 2; (8); 9a, 10 
7  140.1   
8 6.86 dd (2.0; 6.3) 157.3 6; 10; 21 2/9b **, (6), 9a, 21, 22 
9a 2.25 m 31.0 7; 8; 10 2/9b **, 6, 8, 12a, 22 
9b 2.71 m 31.0 8, 11 8. 9a, 12a/15 *, 20, 22 
10 2.72 m 43.1 1, 7, 13, 14, 22 1a, 1b, 6, 14, 16b 
11  45.0   
12a 1.42 m 44.5 1, 13, 22 1a, 1b, 9b, 12b, 13b, 14, 17a, 23 
12b 1.51 m 44.5 10; 11; 14; 22 1b; 12a/15 *; 13a; 13b; 22 
13a 1.23 m 27.1 12; 14; 15 12b; 13b; 22; 23 
13b 1.58 m 27.1 10; 11 13a; 14, 12a/15 *; 23 
14 1.75 m 51.1  9b, 10, 12a/15 *, 13b  
15 1.42 m 31.8  1a, 1b, 9b, 12b, 13b, 14, 17a, 23 
16a 0.99 m 37.1 15; 17; 18; 23 10; 17b; 18 
16b 1.45 m 37.1 23 2/9b **; 10, 16a 
17a 1.94 m 25.6 16; 18; 19 12a/15 *; 17b; 23 
17b 2.07 m 25.6  16a; 17a; 23 
18 5.12 t (7.0) 124.4 24; 25 15; 16a; 25 
19  131.6   
20 2.10 s 17.4 2, 3, 4 2/9b **; 4 
21 9.30 s 193.0 6, 7 8 
22 0.86 m 23.1 1; 10; 12 1b; 2/9b **; 8; 9a; 12b; 13a 
23 0.91 d (6.4) 18.6 14; 15; 16 10; 13a; 13b; 15; 16a; 17a; 17b 
24 1.61 s 17.7 18; 19; 25 25 
25 1.69 s 25.7 18; 19; 24 18; 24 
* Not possible to distinguish between H12a and H15; ** Not possible to distinguish between H2 and H9b. 
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7.6 Ophiobolin K isolated from a new sp. in the Aspergillus section Usti (IBT 18591) 
Figure S11. 1H-NMR spectrum of ophiobolin K in CDCl3 at 800 MHz. 
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Table S13. 1H and 13C-NMR for ophiobolin K in DMSO-d6 at 500 MHz for 1H and 125 MHz for 13C. 
 δH mult. (J (Hz)) δC * HMBC connectivities NOE connectivities 
1a 1.14 m 34.5 6, 10, 11, 22  
1b 1.58 m  6, 10, 11 2, 12a, 20 
2 2.25 m 49.2 1, 4, 6, 7 1b, 4a, 6, 20, 22 
3  76.2   
4a 2.35 m 53.9 3, 5, 20 2, 20 
4b 2.50 m  2, 3, 5  
5  217.0   
6 3.22 d (9.8) 48.3 2, 3, 5, 7, 8, 21 2, 9a, 22 
7  140.6   
8  7.02 t (8.5) 157.6 6, 9, 21 9b, 10, 21 
9a 2.04 m 24.3 7, 8, 10, 11 6, 22 
9b 2.69 m  7, 8, 10, 11, 14 8, 10, 16 
10 1.56 m 53.0 1, 8, 9, 11, 14, 22 8, 9b, 12 
11  43.3   
12a  1.33 m 42.2 10, 11, 13, 14, 22 1b, 13b, 22 
12b 1.35 m    
13a 1.54 m 25.4 11, 15 14, 22, 23, 24 
13b 1.69 m  11 12a, 14 
14 2.09 m 46.2 10, 11, 13, 15, 16, 23  13a/b, 15, 16 , 23 
15  2.72 m 34.4 16, 17, 23 14, 18, 22, 23 
16 5.23 t (9.5) 136.9 14, 15, 18, 23  9b, 14, 17, 23 
17 5.99 m 121.7 15, 18 16, 24 
18  6.04 m 119.9 16, 19, 24, 25 15, 23, 25 
19  134.6   
20 1.19 s 25.7 2, 3, 4 1b, 2, 4a 
21  9.14 s 193.1 6, 7, 8 8 
22 0.91 s 18.2 1, 10, 11 2, 6, 9a, 12a, 13a,15 
23  0.85 d (6.6) 19.6 14, 15, 16 13a, 14, 15, 16, 18 
24 1.68 s 18.0 18, 19, 25 13a, 17, 25 
25 1.76 s 25.9 18, 19, 24 18, 24 
* 13C NMR chemical shifts determined from HSQC and HMBC experiments. 
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7.7 6-Epiophiobolin K isolated from a new sp. in the Aspergillus section Usti (IBT 18591) 
Figure S12. 1H-NMR spectrum of 6-epiophiobolin K in CDCl3 at 800 MHz. 
 
Figure S13. 13C-NMR spectrum of 6-epiophiobolin K in CDCl3 at 200 MHz. 
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Table S14. 1H and 13C-NMR for 6-epiophiobolin K in DMSO-d6 at 500 MHz for 1H and 
125 MHz for 13C. 
 δH mult. (J (Hz)) δC HMBC connectivities NOE connectivities 
1a 1.58 m 41.0 2, 6, 10, 22 6, 12a 
1b 1.65 m   2, 20, 22 
2 1.91 m 49.6 6, 7 1a/b , 4b, 20, 22 
3  74.7   
3-OH 6.51 br.s.    
4a 2.21 m 54.7 2, 3, 5 20 (w) 
4b 2.77 d (16.0)  3, 5, 20 2, 20 
5  216.1 -  
6 3.04 d (10.8) 48.2 1, 2, 5, 7, 21 1a, 2 (w), 10 
7  141.5   
8 6.96 m 159.9 6, 10, 21 9a/b, 21, 22 
9a 2.27 m 30.0 7, 8 8, 22 (w) 
9b 2.65 m   8, 10 
10 2.46 m 43.1  6, 9b, 14 
11  44.9   
12a 1.38 m 44.4 10, 22 1a 
12b 1.44 m  10, 22 22 
13a 1.22 m 27.1 14, 15 22 
13b 1.57 m   14, 23 
14 1.87 m 51.4  10, 13b, 16, 23 
15 2.61 m 31.9  17, 23 
16 5.25 t (9.3) 136.0 14, 18 14, 17, 23 
17 6.11 m 123.3 15, 19 16, 24 
18 6.09 m 120.1 24, 25 15, 23, 25 
19  135.3   
20 1.26 s 25.2 2, 3, 4 1b, 2, 4b 
21 9.12 s 194.7 6, 7, 8 8 
22 0.77 s 22.8 1, 10, 11 1b, 2, 8, 9a, 12b, 13a 
23 0.92 d (6.6) 21.1 14, 15, 16 13b, 14, 15, 16, 17 
24 1.70 s 17.9 18, 19, 25 17 
25 1.79 s 26.1 18, 19, 24 17 
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7.8 Ophiobolin C isolated from A. calidoustus (IBT 25726) 
Figure S14. 1H-NMR spectrum of ophiobolin C in CDCl3 at 800 MHz. 
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Table S15. 1H and 13C-NMR for ophiobolin C in CDCl3 at 800 MHz for 1H and 200 MHz for 13C. 
 δH mult. (J (Hz)) δC * HMBC connectivities NOE connectivities 
1a 1.26 m 36.0 2, 10, 11  
1b 1.81 m  6, 10 2, 12a, 20 
2 2.38 m 50.8  1b, 4a, 6, 20, 22 
3  76.6   
4a 2.49 m 54.6 5, 20 2, 20 
4b 2.80 m  2, 3, 5 20 
5  217.5   
6 3.26 m 48.4 2, 3, 5, 7, 8, 21 2, 9a, 22 
7  141.5   
8 7.21 m 163.8 6, 9, 21 9b, 10, 21 
9a 2.31 m 24.7 7, 8, 10, 11 6, 22, 23 
9b 2.45 m  7, 8, 10, 11 8, 10 
10 1.67 m 53.4 8, 14, 15 8, 9b, 16b 
11  43.6   
12a 1.41 m 42.6  1b, 22 
12b 1.44 m    
13a 1.46 m 22.8 11 23 
13b 1.55 m  10, 11 14 
14 2.36 m 45.2  13b, 15, 16b, 17b 
15  1.65 m 32.7 16 14, 23 
16a 1.18 m 36.8 14, 15, 17, 18, 23 17a, 23 
16b 1.24 m  14, 15, 17, 18, 23 1b, 10, 14,17b, 18 
17a 1.95 m 26.0 15, 16, 18, 19 16a,18 
17b 2.00 m  16, 18, 19 14, 16b, 23, 24 
18  5.09 m 124.3 24, 25 16b, 17a, 25 
19  131.0   
20 1.36 s 25.4 2, 3, 4 1b, 2, 4a/b 
21 9.23 s 195.9 6, 7 8 
22 0.90 s 19.0 10, 11, 12 2, 6, 9a, 12a 
23 0.78 d (6.8) 16.4 14, 15, 16 9a, 13a, 15, 16a, 17b 
24 1.61 s 17.6 18, 19, 25 17b 
25 1.69 s 25.6 18, 19, 24 18 
* 13C NMR chemichal shifts determinated from HSQC and HMBC experiments. 
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7.9 6-epiophiobolin G isolated from A. calidoustus (IBT 25726) 
Figure S15. 1H-NMR spectrum of 6-epiophiobolin G in CDCl3 at 800 MHz. 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f1 (ppm)
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SK0082 in CDCl3
32 scans
290512
 
Figure S16. 13C-NMR spectrum of 6-epiophiobolin G in CDCl3 at 200 MHz. 
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Table S16. 1H and 13C-NMR for 6-epiophiobolin G in CDCl3 at 800 MHz for 1H and 200 MHz for 13C. 
 δH mult. (J (Hz)) δC HMBC connectivities NOE connectivities 
1a 1.15 m 45.8 2, 3, 10, 11, 22 6, 10, 12a 
1b 2.03 m  3, 6, 12, 22 2, 22 
2 2.66 m 49.2 1 1b, 22 
3  178.1   
4 6.04 s 130.2 3, 5, 6, 20 20 
5  208.2   
6 3.40 m 50.0 1, 2, 5, 7, 8, 21  1a, 10 
7  139.9   
8 6.80 m 158.1 6, 9, 10, 21 9a/b, 21, 22 
9a 2.20 m 30.9 7, 8, 10, 14 8, 15, 22 
9b 2.93 m  7, 8, 10, 11 8, 10 
10 2.63 m 43.8 8, 9, 11, 13, 14, 22 1a, 6, 9b, 14 
11  45.4   
12a 1.43 m 44.3 1, 13, 14, 22 1a, 13b 
12b 1.52 m  1, 10, 13, 14, 22 22 
13a 1.25 m 27.8 12, 14, 15 22 
13b 1.67 m  10, 11, 14 12a, 14, 23 
14 1.89 m 52.1 9, 10, 13, 15, 16, 23 10, 13b, 16, 23 
15  2.55 m 32.6 14, 16, 17, 23 9a/b, 18, 23 
16 5.11 t (1.3) 135.7 14, 15, 17, 18, 23 14, 17, 23 
17 6.10 m 124.0 15, 18, 19, 23 16, 24 
18  6.00 m 120.0 16, 17, 24, 25 15, 23, 25 
19  136.6   
20 2.06 s 17.3 2, 3, 4, 5 4 
21 9.26 s 193.0 6, 7 8 
22 0.85 s 22.9 1, 12 1b, 2, 8, 9a, 12b, 13a 
23 0.97 d (6.8) 21.3 14, 15, 16 13b, 14, 15, 16,18 
24 1.76 s 18.2 18,19, 25 17 
25 1.83 s 26.5 18,19, 24 18 
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7.10 Activity of ophiobolin A, B, C and K + 6-epiophiobolin K towards healthy fibroblasts (Wi-
38) cells 
Figure S17. Activity of ophiobolin A, B, C and K + 6-epiophioboln K towards healthy 
fibroblasts (Wi-38). 
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7.11 Apoptosis induction in CLL cells by different ophiobolins 
Figure S18. CLL cells cultured in DMEM were treated for 24 hours with two different 
concentrations of ophiobolin A, ophiobolin B, ophiobolin C and ophiobolin K. In order to 
analyze apoptosis induction, cells of each well were divided into two parts and analyzed by 
flow cytometry using two different staining strategies. (a) cell survival was analyzed by 
gating on cells that were negative for Annexin V-phycoerythrin (PE) and 7-amino-
actinomycin (7-AAD). Relative survival compared to DMSO control (0.1%) is depicted as 
mean values +SD of 4 independent CLL samples; (b) Caspase-3 activity is depicted as 
mean values +SD of 4 independent CLL samples relative to DMSO control (0.1%). 
(a) 
 
 
(b) 
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Experimental (Penicillium jugorum and Penicillium pinicola) 
 
The P. jugorum (IBT 22779) and P. pinicola (IBT16545) extracts were prepared for initial screen in 
accordance with the micro-extraction method developed by Smedsgaard [Smedsgaard, J. J. Chromatogr. A 
1997, 760, 264–270][1]. Five plugs were collected across the colony. The samples were subsequently 
extracted using (3:2:1 v/v/v) MeOH, DCM and EtOAc with 0.5 % FA. 
 
For large scale P. jugorum and P. pinicola  were cultivated on 50 plates on CYA and YES, respectively 
for 8 days at 25°C in the dark and extracted with EtOAc + 1 % FA. The crude extracts were fractionated on a 
RP C18 (25 g, 33 ml) column flash column with at gradient of: 15-100 % ACN in 20 min and flow rate 25 
ml/min.  
Both extracts were fractionated in analytical (5 mg per column) scale in accordance with the E-SPE 
method developed by Månsson et al. [2]. The E-SPE setup contained SAX, MAX, and SCX ion-exchanger 
SPE columns though without the Sephadex LH-20 column. Additionally two normal phase (amino and diol) 
columns were add to the setup. For each extract, 5 mg was loaded on both the amino column (100 mg, 1 ml) 
and the diol column (100 mg, 1 ml). The compounds were eluted by 2 column volume (CV) heptane, 2 CV 
DCM, 2 CV DCM:EtOAc (1:1), 2 CV EtOAc, 2 CV EtOAc:MeOH, 2 CV MeOH, 4 CV ACN, 2 CV 
ACN:MQ + 2% FA (75:25), 2 CV ACN:MQ + 2% FA (50:50), 2 CV ACN:MQ + 2% FA (25:75), 2 CV 
ACN:MQ + 2% FA (10:90). No further fractionations were done with the P. jugorum and P. pinicola 
extract.s. 
 
 
References: 
1. Smedsgaard, J. Micro-scale extraction procedure for standardized screening of fungal metabolite 
production in cultures. J. Chromatogr. A 1997, 760, 264–270. 
2. Månsson, M.; Phipps, R. K.; Gram, L.; Munro, M. H. G.; Larsen, T. O.; Nielsen, K. F. Explorative solid-
phase extraction (E-SPE) for accelerated microbial natural product discovery, dereplication, and purification. 
J. Nat. Prod. 2010, 73, 1126–1132.  
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ABSTRACT: Two new cytochalasans, sclerotionigrin A (1) and B (2) were isolated together with the known proxiphomin 
(3) from the filamentous fungus Aspergillus sclerotioniger. The structures and relative stereochemistry of 1 and 2 were de-
termined based on comparison with 3, and from extensive 1D and 2D NMR spectroscopic analysis, supported by high reso-
lution mass spectrometry (HRMS). All three compound displayed cytotoxic activity towards chronic lymphocytic leukemia 
cells in vitro, with 3 as the most active. 
Chronic lymphocytic leukemia (CLL) is the most common 
type of leukemia among adults in the Western World. CLL is 
considered as an incurable disease and todays applied treat-
ment strategies primarily aim at prolonging patient survival
1,2
. 
Consequently discovery of compounds that act against CLL 
and other types of cancer cells is crucial. Numerous types of 
anticancer compounds have been reported in the literature
3,4
, 
and with the increase in specific biological assays, both novel 
and previously described compounds might display promising 
novel bioactivities
5,6
. An important and diverse group of fun-
gal anticancer compounds that have caught our interest are the 
cytochalasans due to their wide range of biological functions
7
. 
In particular this includes inhibitory activities towards lung, 
ovarian, and human colon cancer as well as human leuke-
mia
8,9
. Recently, we have demonstrated that chaetoglobosin A, 
produced by Penicillium aquamarinum, selectively induce 
apoptosis in CLL cells with a median lethal dose (LD50) value 
of 2.8 µM.
10
 Encouraged by this finding we searched for po-
tential novel cytochalasan type of compounds in black asper-
gilli. The only indication of production of any cytochalasans in 
Aspergillus subgenus Circumdati section Nigri is aspergillin 
PZ, for which the precursor aspochalasin C or D has been sug-
gested
11,12
. However in the sister clade Aspergillus subgenus 
Circumdati section Flavipedes, many cytochalasans have been 
reported, including aspochalasin A-D
13
, E
14
, F & G
15
, D & H
16
, 
I-K
17,18
, L
19
, U
20
 and TMC-169
21
 in addition to aspochalamin 
A-D, aspochalasin D & Z
22
, rosellichalasin
23
, and cytochalasin 
E, 5,6-dehydro-7-hydroxy cytochalasin E, and a Δ
6,12
-5,6-
dehydro-7-hydroxy cytochalasin E, 10-phenyl-[12]-
cytochalasin Z16, 10-phenyl-[12]-cytochalasin Z17, cyto-
chalasin Z11, cytochalasin Z13, Z16-Z20, and rosellichalas-
in
24,25,26,27,28
. In another species of Aspergillus subgenus Cir-
cumdati section Circumdati, Aspergillus elegans aspochalasin 
A1, B, D, H, I, J, cytochalasin Z24, zygosporin D, rosel-
lichalasin and aspergillin PZ were found
29
 supporting the view 
that aspochalasin D is a precursor of aspergillin PZ. Finally in 
the less closely related Aspergillus clavatus in Aspergillus 
subgenus Fumigati section Clavati cytochalasin E and K have 
been isolated
30,31
. 
Here we report the target-guided isolation and structure elu-
cidation of the two novel cytochalasins sclerotionigrin A (1) 
and B (2) based on UV, MS, and NMR data. 1 and 2 were 
isolated from Aspergillus sclerotioniger (IBT 22905) together 
with the known cytochalasin proxiphomin (3)
32
. We have pre-
viously reported ochratoxin A, ochratoxin B and pyranonigrin 
A from this isolate
33
. 
A. sclerotioniger (IBT 22905) was inoculated and extracted. 
After work up the extract was dryloaded on diol resin and 
fractionated on a 50 g pre-packed diol column using an Isolera 
flash purification system (Biotage). The compounds were elut-
ed using a 7 step gradient of heptane-DCM-EtOAc-MeOH 
 with a flow rate of 40 ml/min. Fractions were collected auto-
matically (66 ml in each fraction). The Isolera fractions were 
subjected to further purification on a semi-preparative HPLC 
Waters 600 Controller with a 996 photodiode array detector 
(Waters) on a Luna II C18 column (250 x 10 mm, 5 μm, Phe-
nomenex). A flowrate of 5 mL/min was used and 50 % ACN 
isocratic for 5 min, then to 100 % in 15 min. 50 ppm TFA was 
added to ACN and milliQ-water. This yielded 1 (7.8 mg), 2 
(2.1 mg), and 3 (1.3 mg). 
The structure of compound 3 was tentatively identified 
through UHPLC-DAD-HRMS based dereplication of the 
crude extract. The pseudomolecular ion, [M+H]
+
, was recog-
nized from the mass spectrum due to the presence of the sodi-
ated adduct, [M+Na]
+
 and the corresponding dimeric adducts 
[2M+H]
+
 and [2M+Na]
+
. The molecular formula C29H37NO2 
was established with an accuracy of 0.8 ppm through the mo-
noisotopic mass of [M+H]
+
 of m/z 432.2901. The formula was 
used for a query in Antibase2012
34
 with one resulting hit, 
proxiphomin (3). NMR data and optical rotation of 3
35
 
matched published data
32
. 
Compound 1 was purified as a yellow powder. The UV 
spectrum displayed absorption maxima at 210 nm. The ESI
+
 
spectrum showed a distinct adduct pattern consisting of 
[M+H]
+
, [M+Na]
+
, [2M+H]
+
 and [2M+Na]
+
. The molecular 
formula C29H37NO3 (12 double-bond equivalents) was ob-
tained from HRMS of [M+H]
+
 (m/z 448.2843) with an accura-
cy of 2.3 ppm. The 
1
H NMR spectra revealed the presence of 
one amide proton, 15 methines (five which were vinylic and 
five aromatic), six methylene, and three methyls (Table 1). 
The DQF-COSY spectrum of 1 defined four spin systems. 
The linking between COSY spin systems and assignments of 
the remaining signals and quaternary carbons were accom-
plished through detailed analysis of HMBC experimental data 
(Figure 1). 
1 
Figure 1. Important HMBC correlations connecting the three 
COSY spin systems (marked in bold) in 1. The remaining HMBC 
correlations are found in Table 1. 
The HMBC correlations from the protons at δH 1.65 ppm 
(H10) and 7.26 (H27 and H29) to a quaternary carbon at δC 
137.8 (C25), together with HMBC correlations from the pro-
tons at δH 7.14 (H26 and H30) to the carbon at δC 42.6 (C10) 
linked two of the spin systems belonging to the Phe moiety in 
1. The amide proton at δH 8.00 ppm (H2) displayed HMBC 
correlations to the carbons at δC 54.2 (C3) and 170.6 ppm 
(C1). Combination of these HMBC correlations established 
the Phe moiety of 1, which was incorporated on the polyketide 
(PK) part of the molecule. 
 
 
 
 
Table 1. NMR data for sclerotionigrin A (1).† 
No. 
δH (integral, 
mult., J [Hz]) 
δC  HMBC NOESY 
1 - 170.6 - - 
2 8.00 (1H, s) - 1, 3, 4, 9 3, 10 
3 3.09 (1H, td, 
5.8, 3.1) 
54.2 - 2, 4, 10, 11, 
12, 26/30 
4 2.53 (1H, dd, 
4.2, 3.1) 
49.1 3, 5, 6, 9 3, 10, 11, 
26/30 
5 2.57 (1H, m) 33.6 - 7, 8, 11 
6 - 140.0 - - 
7 5.25 (1H, m) 123.6 - 5,8, 12 
8 3.15 (1H, m) 45.8 - 5, 7, 13, 14 
9 - 85.4 - - 
10 2.82 (2H, dd, 
5.8, 2.2) 
42.6 3, 4, 25, 
26/30 
3, 4, 26/30 
11 0.68 (3H, d, 
7.1) 
12.8 4, 5, 6 3, 4, 5, 12, 
26/30  
12 1.65 (3H, s) 19.4 5, 6, 7 3, 7, 11 
13 5.85 (1H, ddd, 
14.8, 10.0, 1.2) 
128.9 15 8, 15 
14 5.22 (1H, m) 132.6 8 8, 15’, 16 
15 1.60 (1H, d, 
13.5) 
40.7 13, 14, 16 13, 15’ 
15’ 2.07 (1H, dd, 
13.5, 2.1) 
40.7 - 14, 15, 16, 
20’, 24 
16 1.36 (1H, m) 31.9 - 14, 15’, 19’ 
17 0.61 (1H, m) 33.8 - 17’, 18’, 24 
17’ 1.66 (1H, m) 33.8 - 17 
18 1.14 (1H, m) 25.9 - 18’ 
18’ 1.53 (1H, m) 25.9 - 17, 18 
19 1.29 (1H, m) 25.3 - 24 
19’ 1.68 (1H, m) 25.3 - 16, 21 
20 2.23 (1H, m) 33.1 - 20’, 21 
20’ 2.29 (1H, m) 33.1 - 15’, 20, 22 
21 6.96 (1H, ddd, 
15.5, 8.6, 6.8) 
151.7 23 19’, 20, 22 
22 5.65 (1H, d, 
15.5) 
120.6 20, 23 20’, 21 
23 - 163.5 - - 
24 0.84 (3H, d, 
6.3) 
20.0 15, 16, 17 15’, 17, 19 
25 - 137.8 - - 
26‡ 7.14 (1H, d, 
7.5) 
129.5 10, 26/30 
28 
3, 4, 10, 11 
27‡ 7.26 (1H, t, 
7.4) 
128.0 25, 29 - 
28 7.18 (1H, t, 
7.5) 
126.1 26, 30 - 
29‡ 7.26 (1H, t, 
7.5) 
128.0 25, 27 - 
30‡ 7.14 (1H, d, 
7.5) 
129.5 10, 26/30, 
28 
3, 4, 10, 11 
† 1H NMR data were obtained at 500 MHz in DMSO-d6 and 
13C data were obtained at 125 MHz in DMSO-d6. 
13C-NMR 
chemical shifts determined from HSQC and HMBC experiments. 
‡It was not possible to distinguish between no. 26 and 30 as well 
as no. 27 and 29. 
The PK part of 1, could be established through a large 
COSY spin system (from H7 to H22), equal to that seen in 3. 
Furthermore a COSY coupling was found between the proton 
at δH 2.57 ppm (H5) and a methyl group at 0.68 ppm (C11). 
This part was coupled to the PK part by a week COSY cou-
pling between H5 and H7 identified as a w-coupling. The 
COSY spin system could furthermore be connected via 
HMBC correlations to the above mentioned Phe moiety as 
well as the PK part. The protons at δH 1.65 (H12) correlated to 
the carbons at δC 33.6 (C5) and 123.6 ppm (C7) where proton 
at δH 0.68 (H11) correlated to the carbons at δC 49.1 (C4) and 
140.0 ppm (C6). The proton at 2.53 ppm (H4) correlated to 
 C5, C6 and the quaternary carbon at δC 85.4 ppm (C9). Finally 
the PK chain was closed via an ester bond assigned from 
HMBC correlations from the vinylic protons at δH 5.65 (H22) 
and 6.96 ppm (H21) to the carbonyl carbon at δC 163.5 ppm 
(C23) supported by the high chemical shift of the quaternary 
carbon at δC 85.4 ppm (C9) indicating that C9 is bound to ox-
ygen, and a carbonyl group, similar to what is seen in several 
other cytochalasans.
7
  
This structure accounted for all the degree of unsaturation 
required by the formula allowing the assignment of 1 as scle-
rotionigrin A.36 The size of the vicinal coupling constants 
(
3
JHH) for H13/H14 and H21/H22 were rather large (14.8 and 
15.5 Hz respectively) suggestion trans stereochemistry. 
NOESY experiments enabled determination of the relative 
stereochemistry for most of the stereogenic centers of 1 to be 
very similar to those of 3. NOE connectivities were found 
between the proton at δH 3.09 ppm (H3), δH 2.53 (H4) and the 
methyl at δH 0.68 ppm (H11) placing these protons at the same 
side of the central ring system. Other NOE connectivities were 
observed between the protons at δH 2.57 ppm (H5), 5.25 (H7) 
and 3.15 (H8), whereas no NOE connectivities could be seen 
to H3, H4 or H11, strongly indicating the positioning of H5, 
H7 and H8 on the opposite side of the central ring system 
compared to H3, H4 and H11. The stereocenters at C9 and 
C16 could not be assigned through NOESY correlations, how-
ever being biosynthesized by the same fungus we propose that 
the stereochemistry at these centers are identical to those of 3. 
Especially we note that the extra oxidation between C9 and 
C23 in other cytochalasans never leads to a change in stereo-
chemistry at C9.
7,15
 We do however note that the optical rota-
tion of 1 and 2 are positive as opposed to that of 3 and other 
similar cytochalasans,
15
 indicating a possible difference in 
stereochemistry. Further experiments, e.g. X-ray crystallog-
raphy or circular dichroism (CD) are needed to clarify the 
absolute stereochemistry of 1. 
Compound 2, was isolated as a yellow powder, and dis-
played UV absorption maxima at 212 nm and the ESI
+
 MS 
adducts [M+H]
+
, [M+Na]
+
, [2M+H]
+
 and [2M+Na]
+
. The mo-
lecular formula of 2, C29H37NO4 was deduced from the monoi-
sotopic mass obtained from the [M+H]
+
 ion (m/z 464.2797) 
with the accuracy of 1.2 ppm. Examination of the NMR spec-
tra of 2 displayed a high similarity compared to 1. Comparison 
of the NMR spectra of 1 and 2 (see Tables 1 and 2, respective-
ly) revealed that the difference between them is located in 
position five, six and seven. 
The Phe moiety in 2 was identified through a connection of 
the two COSY spin systems linked by HMBC correlations as 
demonstrated for 1. The COSY spin system of the PK chain 
terminated with a proton at δH 3.68 ppm (H7), indicating a 
binding to a hydroxy group instead of the vinyllic methine 
group observed for 1 at this position. This was also evident 
from the carbon chemical shift moving to δC 69.1 ppm (C7). 
 
 
 
 
 
Table 2. NMR data for sclerotionigrin B (2).† 
No. 
δH (integral, 
mult., J [Hz]) 
δC  HMBC NOESY 
1 - 171.2 - - 
2 8.34 (1H, br. s) - 3, 4, 9 3, 10’ 
3 3.39 (1H, m) 57.7 1, 4, 5, 9 2, 10, 10’, 11, 
26/30 
4 3.32 (1H, m) 47.1 1, 5, 6, 9 13, 26/30 
5 - 123.9 - - 
6 - 134.2 - - 
7 3.68 (1H, d, 
9.7) 
69.1 - 8, 12, 13 
8 3.05 (1H, t, 
10.0) 
48.3 1, 4, 7, 9, 
13, 14 
7, 13, 14 
9 - 83.6 - - 
10 2.55 (1H, dd, 
13.0, 10.1) 
42.5 3, 4, 25, 
26/30 
3, 10’, 26/30 
10’ 2.92 (1H, dd, 
13.0, 5.0) 
42.5 3, 4, 25, 
26/30 
2, 3, 10, 
26/30 
11 1.16 (3H, s) 16.7 4, 5, 6 3, 26/30 
12 1.52 (3H, s) 14.3 5, 6, 7 7 
13 6.03 (1H, dd, 
15.0, 11.3) 
128.4 8, 15/15’ 4, 7, 8, 14, 15 
14 5.00 (1H, ddd, 
15.0, 10.8, 3.4) 
132.7 8, 15/15’ 8, 13, 15, 15’ 
15 1.58 (1H, dd, 
24.3, 11.1) 
41.6 16 13, 14, 15’, 
16, 17’ 
15’ 2.00 (1H, br. 
d., 11.6) 
41.6 - 14, 15, 16, 24 
16 1.13 (1H, m) 32.5 - 15, 15’, 17’, 
18, 24 
17 0.52 (1H, dd, 
19.4, 11.0) 
34.5 - 17’ 
17’ 1.67 (1H, m) 34.5 24 15, 16, 17, 
18, 24 
18 0.86 (1H, m) 26.1 - 16, 17’, 18’ 
18’ 1.68 (1H, m) 26.1 20 18, 19, 21 
19 1.30 (1H, dd, 
21.5, 10.2) 
25.4 - 18’, 19’ 
19’ 1.73 (1H, m) 25.4 - 19 
20 2.11 (1H, dd, 
20.8, 10.9) 
33.4 - 20’, 22 
20’ 2.41 (1H, dd, 
12.7, 4.6) 
33.4 - 20, 21 
21 6.89 (1H, ddd, 
15.7, 10.8, 5.0)  
151.4 20, 23 18’, 20’, 22 
22 5.79 (1H, d, 
16.1) 
121.3 20, 23 20, 21 
23 - 163.8 - - 
24 0.83 (3H, d, 
6.6) 
19.9 15, 16, 17 15’, 16, 17’ 
25 - 137.4 - - 
26‡ 7.08 (1H, d, 
7.1) 
128.9 10, 28, 30 3, 4, 10, 10’, 
11, 27/29 
27‡ 7.31 (1H, t, 
7.5) 
128.2 25, 29 26/30, 28 
28 7.23 (1H, t, 
7.4) 
126.3 26, 30 27/29 
29‡ 7.31(1H, t, 7.5) 128.2 25, 27 26/30, 28 
30‡ 7.08 (1H, d, 
7.1) 
128.9 10, 26, 28 3, 4, 10, 
10’,11, 27/29 
† 1H NMR data were obtained at 500 MHz in DMSO-d6 and 
13C data were obtained at 125 MHz in DMSO-d6. 
13C-NMR 
chemical shifts determined from HSQC and HMBC experiments. 
‡It was not possible to distinguish between no. 26 and 30 as well 
as no. 27 and 29. 
HMBC correlations from the three protons of the methyl 
group at δH 1.52 ppm (H12) to the carbons at δC 123.9 (C5), 
134.2 (C6) and 69.1 (C7), combined with correlations from the 
protons at δH 1.16 ppm (H11) to the carbons at δC 47.1 (C4) 
and 123.9 ppm (C5) and 134.2 (C6) linked the Phe moiety to 
 the spin system in the polyketide chain (Figure 2). The re-
maining chemical shifts in 2 matched the chemical shifts of 1 
(Table 1 and 2) and the structure of 237 was established alto-
gether giving a classic methylated cytochalasin carbon skele-
ton.7 
 2 
Figure 2. Important HMBC correlations establishing the quater-
nary carbon C5 and C6 in 2. The remaining HMBC correlations 
are found in Table 2. Individual COSY spin systems are marked 
in bold. 
 
As the optical rotation of 2 was similar to the optical rota-
tion of 1, the two compounds most likely have the same rela-
tive stereochemistry. The absolute stereochemistry of 2 has 
not yet been solved. 
Biological testing of the cytotoxicity of compounds 1-3 to-
wards CLL cells in vitro were performed using a CellTiter-
Glo® assay (see Supplementary S18).10 Compound 3 dis-
played the strongest effects with estimated medial lethal con-
centration (LC50) values of ca 48 µM. Where no effect was 
found towards healthy B-cells in concentrations < 100 µM. 
Compounds 1 and 2 only showed minor activities at concen-
trations below 100 µM (Figure S18). 
In summary the two new cytochalasins, sclerotionigrin A 
(1) and B (2) have been isolated from A. sclerotioniger togeth-
er with the known proxiphomin (3). Compound 3 displayed 
the strongest cytotoxic effects towards CLL, however not as 
promising as recently demonstrated for chaetoglobosin A.10 
This is the first report of cytochalasan production from one of 
the currently more than twenty-five known black Aspergillus 
species.
16
 even though cytochalasans are very common in the 
related yellow Aspergillus species such as A. flavipes, A. 
terreus and A. elegans 29
,38. Further species in Aspergillus sec-
tion Nigri should be examined for cytochalasan production, as 
the cytochalasan related metabolite, aspergillin PZ, has also 
been found in this group in addition to proxiphomin, and scle-
rotionigrin A and B. This may be important for both drug dis-
covery and food safety, as the black Aspergilli are common in 
foods. 
ASSOCIATED CONTENT  
Supporting Information. General experimental procedures, 
1
H, DQF-COSY, HSQC, HMBC and NOESY spectra for all 
three compounds, as well as bioassay results are available in 
the supporting information. 
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S1	 General	Experimental	Procedures	
Aspergillus sclerotieoniger (IBT 22905) is from the IBT culture collection at Department of Systems Biology, Technical 
University of Denmark. A. sclerotieoniger was inoculated as three point inoculations on czapek yeast agar (CYA ) on 100 
plates at 25 °C for 7 days in the dark. CYA plates were prepared as described by Frisvad and Samson.1 The plates were 
harvested and extracted twice overnight with ethyl acetate (EtOAc) containing 1 % formic acid. The extracts were filtered 
and concentrated in vacuo. Work up: The combined extract was dissolved in methanol (MeOH)/milliQ-water (9:1) and an 
equal amount of heptane was added followed by seperation of phases. Additional milliQ-water was added to the 
MeOH/water phase untill a ratio of 1:1, and metabolites were extracted with dichloromethane (DCM). The phases were then 
concentrated separately in vacuo. The DCM phase was used for further fractionation. 
The LC-MS analyses were performed on a maXis quadrupole time of flight (qTOF) mass spectrometer (Bruker 
Daltonics) with an electrospray ionization (ESI) ion source. The maXis was calibrated using sodium formate automatically 
infused prior to each analytical run, providing a mass accuracy of below 1 ppm. The mass spectrometer was linked to an 
Ultimate 3000 UHPLC system (Dionex) with DAD. Separation was achieved on a Kinetex C18, 2.6µm, 2.1x100 mm column 
(Phenomenex) with a flow of 0.4 ml min-1 at 40°C using a linear gradient 10 % acetonitrile (ACN) in Milli-Q water (MQ) 
with 20 µM formic acid (FA) going to 100 % ACN in 10 min. All compounds were isolated started by flash 
chromatography of the crude extracts, fractionated with an Isolera One automated flash system (Biotage). The isolation of 
compounds were performed by a semi-preparative Waters 600 DAD. One-dimensional and two-dimensional NMR 
experiments were acquired on a 500 MHz Varian Unity Inova equipped with a HCP probe. 1H, DQF-COSY, edHSQC, 
HMBC and NOESY experiments were acquired using standard pulse sequences. Optical rotation values were obtained on a 
Perkin-Elmer 241 Polarimeter at 589 nm. 
S2	 1H	NMR	spectrum	for	Sclerotionigrin	A	(1)	at	500	MHz	in	DMSO‐d6	
                                                          
1 Samson, R.A.; Houbraken, J.; Thrane, U.; Frisvad, J.C.; Andersen, B.. Food and Indoor Fungi. CBS Laboratory Manual Series 2, CBS KNAW Fungal 
Biodiversity Centre: Utrecht (NL), 2010 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
S3	 DQF‐COSY	spectrum	for	Sclerotionigrin	A	(1)	in	DMSO‐d6	
 
 
 
 	
ppm
8 7 6 5 4 3 2 1 ppm
8
7
6
5
4
3
2
1
S4	 edHSQC	spectrum	for	Sclerotionigrin	A	(1)	in	DMSO‐d6	
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
f2 (ppm)
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
f1
 (
pp
m
)
LMP04245_hsqced.060913
LMP04245 in DMSO-d6
HSQC edited nt=32 ni=512/2
060913
 
 
 
 	
S5	 HMBC	spectrum	for	Sclerotionigrin	A	(1)	in	DMSO‐d6	
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S7	 1H	NMR	spectrum	for	Sclerotionigrin	B	(2)	at	500	MHz	in	DMSO‐d6	
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S12	 NMR	data	for	proxiphomin	(3)	
 
 
 
Atom 
assignment 
1H-chemical shift [ppm]/ 
J coupling constants [Hz]† 
13C-
chemical shift 
[ppm]† 
HMBC 
correlations NOESY connectivities 
1 - 173.6 - - 
2 7.94 (1H, s) - 3, 4, 9 3 
3 3.25 (1H, m) 53.0 - 2, 4, 10, 10’, 11, 12, 
26, 30 
4 2.80 (1H, dd, 5.8, 2.6) 47.2 1, 3, 5, 6, 9, 10, 23 3, 5, 10, 10’, 11, 26, 
30 
5 2.20 (1H, m) 33.7 1 4, 8, 11 
6 - 139.1 - - 
7 5.27 (1H, m) 125.8 - 8, 12, 13 
8 2.63 (1H, m) 47.0 1 7, 5, 13, 14, 22 
9 - 65.7 - - 
10 2.40 (1H, dd, 13.2, 7.3) 43.1 1, 3, 4, 25, 26, 30 3, 4, 10’, 26, 30 
10’ 2.60 (1H, dd, 13.2, 4.9) 43.1 1, 3, 4, 25, 26, 30 3, 4, 10, 26, 30 
11 0.77 (3H, d, 7.2) 12.6 4, 5, 6 3, 4, 5 
12 1.66 (3H, s) 19.3 5, 7 3, 7, 13 
13 6.18 (1H, ddd, 15.2, 9.8, 1.7) 129.3 15 7, 8, 12, 14, 22 
14 5.11 (1H, dddd, 15.2, 14.0, 
10.5, 3.1) 
131.6 8 8, 13, 15’ 
15 1.67 (1H, m) 39.7 16 15’ 
15’ 1.99 (1H, m) 39.7 16 14, 15, 16, 17 24 
16 1.38 (1H, m) 31.9 - 15’ 
17 1.23 (2H, m) 28.5 - 15’, 18 
18 1.13 (2H, m) 23.1 - 17 
19 1.41 (1H, m) 25.2 - 19’ 
19’ 1.56 (1H, m) 25.2 - 19 
20 2.02 (1H, m) 31.1 - 20’, 21, 22 
20’ 2.28 (1H, m) 31.1 - 20 
21 6.54 (1H, dddd, 20.6, 15.5, 
10.3, 5.3) 
145.7 20, 23 20 
22 6.86 (1H, d, 15.5) 127.3 20, 23 8, 13, 20 
23 - 196.9 - - 
24 0.85 (3H, d, 6.7) 20.8 15, 16 15’ 
25 - 136.7 - - 
26‡ 7.10 (1H, d, 7.5) 129.5 10, 28, 30 3, 4, 10, 10’ 
27‡ 7.25 (1H, dd, 7.4, 1.0) 127.9 25, 29  
28 7.16 (1H, d, 7.5) 126.0 26, 30  
29‡ 7.25 (1H, dd, 7.4, 1.0) 127.9 25, 27  
30‡ 7.10 (1H, d, 7.5) 129.5 10, 26, 28 3, 4, 10, 10’ 
† 1H NMR data were obtained  at 500 MHz in DMSO-d6 and 13C data were obtained at 125 MHz in DMSO-d6. 
‡It was not possible to distinguish between 26 and 30 as well as 27 and 29. 
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S15	 edHSQC	spectrum	for	proxiphomin	(3)	in	DMSO‐d6	
 
 
ppm
12345678 ppm
20
40
60
80
100
120
140
S16	 HMBC	spectrum	for	proxiphomin	(3)	in	DMSO‐d6	
 
 
 	
ppm
12345678 ppm
20
40
60
80
100
120
140
160
180
200
S17	 NOESY	spectrum	for	proxiphomin	(3)	in	DMSO‐d6	
 
 
 
  
ppm
9 8 7 6 5 4 3 2 1 0 ppm
9
8
7
6
5
4
3
2
1
0
S18	 Bioactivity	
Whole blood samples were obtained from healthy donors or patients that matched the standard diagnostic criteria for 
CLL after informed consent in accordance with the Declaration of Helsinki. All studies performed were approved by the 
ethics committee of the University of Ulm. Peripheral blood B cells were isolated by Ficoll density gradient followed by 
magnetic cell enrichment using CD19-MACS beads (Miltenyi Biotech, Bergisch Gladbach, Germany). Healthy donor B 
cells or CLL cells were cultured in conditioned medium of HS-5 cells, which was harvested after 3–4 days of culture and 
80% confluency and depleted of HS-5 cells and debris by centrifugation. Cells were seeded in duplicates at a density of 3 × 
105 cells/well in opaque-walled 96-well plates. Pure compounds were added in different concentrations and incubated for 24 
hours. A final concentration of 0.1% DMSO was used as negative control. Cell viability was assessed using CellTiter-Glo® 
assay (Promega, Madison, WI, USA) according to manufacturer’s protocol. Luminescence signals were recorded using a 
Mithras LB940 plate reader (Berthold Technologies, Bad Wildbad, Germany). Relative cell viability was calculated as 
described by Knudsen et al. 2 Mean values ±SEM of four CLL samples and three healthy donor samples are depicted. 
 
Figure S1. Effects of 1-3 on CLL cell viabiltiy. CLL cells were treated for 24 hours with increasing 
concentrations of 1-3 and cell viability was analyzed by CellTiter-Glo® assay. Relative cell viability is 
compared to DMSO control (0.1%). 
 
 
 
 
 
 
 
 
                                                          
2 Knudsen, P. B.; Hanna, B.; Ohl, S.; Sellner, L.; Zenz, T.; Stilgenbauer, S.; Larsen, T. O.; Lichter, P.; Seiffert, M. Chaetoglobosin A preferentially induces 
apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton. Leukemia 2013 doi: 10.1038/leu.2013.360. [Epub ahead of print] 
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Figure S2. Effects of 1-3 on healthy B-cells cell viabiltiy. Healthy B-cells were treated for 24 hours 
with increasing concentrations of 1-3 and cell viability was analyzed by CellTiter-Glo® assay. Relative 
cell viability is compared to DMSO control (0.1%). 
 
 
 
 
Estimated LC50 values 
 LC50 values 
Compound CLL Healthy B-cells 
Sclerotionigrin A 72 µM No effect 
Sclerotionigrin B No effect No effect 
Proxiphomin 48 µM No effect 
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a b s t r a c t
Three new micropeptins, micropeptin KR1030, KR1002 and KR998 and the known microcyclamide
GL546A were isolated from the extract of Microcystis sp. bloom material collected in Kabul Reservoir,
Israel. The planar structures of the compounds were determined by homonuclear and inverse-
heteronuclear 2D-NMR techniques as well as high-resolution mass spectrometry. The absolute conﬁg-
uration of the asymmetric centres of the amino acids was studied using Marfey’s method for HPLC. The
inhibitory activity of the compounds was determined for the serine proteases: trypsin, chymotrypsin and
elastase.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Cyanobacterial genera that form natural blooms are proliﬁc
producers of a large array of toxic and non-toxic metabolites. These
genera of cyanobacteria, including the genus Microcystis, most
frequently produce the toxic microcystins, which are potent protein
phosphatase (PP’s) inhibitors1 and mammal hepatotoxins.2 Ninety
different variants of these toxins have been described to date.3 The
non-toxic metabolites that accompany themicrocystins, are usually
members of ﬁve discrete families of protease inhibitors: micro-
peptins,4 aerugenosins,5 microginins,6 anabaenopeptins7 and
microviridins.8 Cyanobacterial blooms, toxic and non-toxic, usually
contain one or several of these groups of protease inhibitors and in
certain cases also other groups of non-toxic metabolites.9 In most
cases the latter non-toxic secondary metabolites are cyclic and
linear modiﬁed peptides. Modiﬁcation of proteinogenic amino
acids, by cyanobacteria, results in new amino acid mimics, i.e., 3-
amino-6-hydroxy-2-piperidone (Ahp), and amino acid de-
rivatives, i.e., hydroxycyclohexenyl alanine (HcAla), dehydroamino
butyric acid (Dhb), homotyrosine (Hty), NMe-Tyr, m-Cl or Br-Tyr,
OMe-Tyr to name only a few incorporated into the micropeptins.
The acid residue sequence of the micropeptine family of cyclic
peptolides is highly variable, as can be ﬁgured from the 139
members of the family.10 Some of the positions present high ten-
dency and frequency for acid variation while others vary only
between two closely related acids. The ﬁfth position from the C-
termini of these peptolides has attracted most of the attention in
this respect, since the nature of the amino acid at this position
selects between trypsin and chymotrypsin types of enzyme in-
hibition.11 Recently, we have shown that also the second position
might alter this selectivity.12 The side chain of the micropeptins is
also highly variable in the length (0e3, most frequently two acid
residues) and acid composition and is always terminated by either
hydroxy acid (hydroxyphenyllactic acid or glyceric acid derivatives)
or a short chain fatty acid (1e8 carbons). The most potent protease
inhibitors among the micropeptins are those displaying Phe13 or
Thr14 at the third position. As part of our continuing interest in the
chemical ecology of cyanobacterial water blooms and the search for
novel drugs for human diseases,10 we examined the extracts of
a Microcystis sp. bloom material collected in September 2009 at
Kabul Reservoir, Israel. The extract of this bloom (Sample IL-403)
afforded three non-toxic secondary metabolites: micropeptins
KR1030 (1), KR1002 (2) and KR998 (3) and the known micro-
cyclamide GL546A.15 The structure elucidation and the biological
activity of the compounds are discussed below.
2. Results and discussion
Micropeptin KR1030 (1), a glassy material, presented an ESI
MS pseudo-molecular [MþNa]þ ion at m/z 1053.5288, corre-
sponding to the molecular formula C53H74N8NaO13 and 21 de-
grees of unsaturation. Examination of the NMR spectra of 1, in
DMSO-d6, revealed its peptide nature; i.e., nine carboxyamide
* Corresponding author. Tel.: þ972 3 6408550; fax: þ972 3 6409293; e-mail
address: carmeli@post.tau.ac.il (S. Carmeli).
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journal homepage: www.elsevier .com/locate/ tet
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carbons in the 13C NMR spectrum and ﬁve amide doublet protons
in the 1H NMR spectrum. Some characteristic signals suggested
that it was a micropeptin type compound.11 Taking into account
the NMe-aromatic amino acid (NMeTyr) and the N,N-di-
substituted-amino acid (N,N-disubstituted-Phe) of the micro-
peptins, suggested that this micropeptin was assembled from
seven amino acid moieties. In addition, two doublet hydroxyls,
resonating at 4.61 and 5.99 ppm were evident in the 1H NMR
spectrum. Analyses of the COSY, TOCSY, and HSQC 2D NMR ex-
periments, (Table 1) allowed the assignment of the side chains of
three proteogenic amino acids: valine, threonine, glutamine. In
addition, these analyses assigned two ABX spin-systems that
were in agreement with the aliphatic fragments of two N,N-di-
substituted aromatic amino acids, a para-substituted phenol ring
and a phenyl ring. Finally, an amino hydroxy piperidone (Ahp)
moiety and an extended spin system that didn’t ﬁt any proteo-
genic amino acid were assigned. In the micropeptins, the amide
proton of any amino acid residue that occupies the ﬁfth position
from the C-terminus resonates above dH 8.00 ppm.11 COSY cor-
relation of the amide proton at dH 8.40 ppm assigned the
methine proton at dH 4.33 ppm as H-2 of this amino acid. Using
the COSY and TOCSY correlations (see Table 1) the a-methine
proton was connected to a methylene, which in turn was con-
nected to a methine that was part of a 4-hydroxycyclohex-2-enyl
moiety. This amino acid moiety was thus established as the rare
3-(7-hydroxycyclohex-5-enyl)-alanyl (HcAla) previously identi-
ﬁed in four cases in micropeptins.16e19 Assuming a twisted boat
conformation for the cyclohexenyl moiety, the pseudoaxial H-8
(H-8pax) and H-9 (H-9pax) were identiﬁed by their shift to
higher ﬁeld. NOE correlation of H-9pax with H-7 and of H-8pax
with H-4, as well as, the rest of the NOE’s of this spin system
shown in Fig. 1, established both as pseudoaxial, and the relative
conﬁguration of the hydroxycyclohexenyl moiety as 4S*,7R*. Al-
though the NOE pattern of H-2,3a,3b and 4 pointed to a restricted
rotation (Fig. 1) it was not possible to assume the relative con-
ﬁguration of positions 2 and 4. The complete structure of the
other residues and the assignment of the carboxamide carbons to
the amino acid side chains, were achieved by analysis of the
HMBC spectrum of 1 (see Table 1). This procedure established the
structure of Val, NMeTyr, N,N-disubstituted-Phe, Ahp, HcAla, 3-O-
substituted-Thr, Gln and hexanoic acid (HA) residues. The se-
quence of the amino acids of 1: Val, NMeTyr, N,N-disubstituted-
Phe, Ahp, HcAla, Thr, Gln and HA was assigned on the basis of
HMBC and ROESY correlations as follows: HMBC correlations
between the carboxyamide of NMeTyr and Val NH, the carbox-
yamide of N,N-disubstituted-Phe and the NMe of NMeTyr, the
carboxyamide of Ahp and H-2 of N,N-disubstituted-Phe, carbox-
yamide of HcAla and NH of Ahp, the carboxyamide of Thr and NH
of HcAla, the carboxyamide of Gln and the NH of Thr and the
carboxyamide of HA and the NH of Gln. The ester-linkage be-
tween Thr and Val was established through the HMBC correlation
of Thr H-3 and the carboxyl of Val and the NOE between Val H-2
and Thr H-3. Acid hydrolysis of 1 and derivatization with Mar-
fey’s reagent,20 followed by HPLC analysis, demonstrated the L-
conﬁguration of Val, NMe-tyrosine, phenylalanine, threonine,
and glutamic acid residues. Marfey’s analysis using 1-ﬂuoro-2,4-
dinitrophenyl-5-L-alanine amide (FDAA) as Marfey’s reagent20
fails to distinguish L-threonine from L-allo-threonine and thus
additional evidence was needed to support their establishment.
The observed J-value (0e1 Hz) between H-2 and H-3 of the N,O-
disubstituted threonine in 1, suggested that, as in the case of all
known micropeptins, it should be L-threonine and not L-allo-
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Table 1
NMR data of micropeptin KR1030 (1) in DMSO-d6a
Position dC, mult.b dH, mult., J (Hz) LR H-C correlationsc NOE correlationsd
Val-1 172.2 s
2 55.8 d 4.73 m Val-1, NMeTyr-1 Val-3,4,5
3 31.0 d 2.07 m Val-4,5,NH, Thr-3
4 19.5 q 0.84 d 6.5 Val-2,3,5 Val-2,3,NH, NMeTyr-NMe
5 17.3 q 0.71 d 6.9 Val2,3,4 Val-2,3,NH, Ahp-6-OH, NMeTyr-NMe
NH 7.36 d 9.6 NMeTyr-1 Val-4,5, NMeTyr-2,NMe, Ahp-6-OH
NMeTyr-1 169.3 s
2 61.0 d 4.85 dd 12.0, 2.2 NMeTyr-1 Val-NH, NMeTyr-3b,5,50,NMe, Phe-2
3 33.0 t 2.70 dd 14.0, 12.0
3.08 dd 14.0, 2.2
NMeTyr-5,50
NMeTyr-5,50
NMeTyr-3b,5,50
NMeTyr-2,3a,5,50 ,6,60
4 127.7 s
5,50 130.6 dx2 6.98 dx2 8.2 NMeTyr-3,5,50 ,7 NMeTyr-2,3a,3b,6,60 , NMe, Phe-2
6,60 115.5 dx2 6.74 dx2 8.2 NMeTyr-4,5,50 ,7 NMeTyr-5,50 ,7-OH, Phe-6,60
7 156.4 d
7-OH 9.33 s NMeTyr-6,60 ,7 NMeTyr-5,50 ,6,60
NMe 30.5 q 2.75 s NMeTyr-2, Phe-2 Val-4,5NH, NMeTyr-2,5,50 ,6,60 , Ahp-6-OH
Phe-1 170.5 s
2 50.4 d 4.72 m Ahp-2 NMeTyr-2, Phe-3a,5,50
3 35.5 t 1.78 dd 14.0, 3.8
2.85 dd 14.0, 12.3
Phe-5,50
Phe-2,5,50
NMeTyr-6,60 , Phe-2,3b,5,50
Phe-3a,5,50 , Ahp-6
4 136.9 s
5,50 129.6 dx2 6.82 dx2 7.1 Phe-50 ,5,6,7 Phe-2,3a,3b,6,60 , Ahp-4a,6
6,60 127.9 dx2 7.17 tx2 7.1 Phe-4,60 ,6 NMeTyr-6,60 , Phe-5,50
7 126.4 d 7.13 t 7.1 Phe-5
Ahp-2 169.0 s
3 48.6 d 3.61 m Ahp-2 Phe-5,50 , Ahp-4a,NH
4 21.8 t 1.54 m
2.39 dq 3.0, 12.3
Ahp-3,4b,5
Ahp-4a,5a,6-OH,NH
5 29.4 t 1.66 m
1.52 m
Ahp-4b,6,6-OH
6 73.9 d 5.05 dt 1.8, 3.2 Phe-3b,5,50 , Ahp-5a,5b,6-OH
6-OH 5.99 d 3.2 Val-40 ,5,NH, Ahp-5a,6, NMeTyr-NMe
NH 7.08 d 9.1 HcAla-1 Ahp-3,4b, AcAla-2,NH, Thr-3
HcAla-1 170.1 s
2 49.6 d 4.23 br dd 10.6, 8.8 Ahp-NH, HcAla-3b
3 36.4 t 1.40 br t 10.6
1.69 m
HcAla-3b,4,5,6,NH
HcAla-2,3a
4 31.7 d 1.92 m HcAla-3a,5,6,8pax,NH
5 132.2 d 5.37 m HcAla-7 HcAla-3a,4,6,7
6 132.9 d 5.55 br d 10.3 HcAla-8 HcAla-3a,4,5,7,7-OH
7 65.3 d 3.95 m HcAla-6,7,7-OH,8peq,9pax
7-OH 4.61 d 5.3 HcAla-6,7,8 HcAla-6,7,8pax
8pax
peq
31.5 t 1.20 m
1.79 m
HcAla-4,7-OH,8peq,9peq
HcAla-7,8pax,9pax
9pax
peq
26.0 t 0.95 td 12.7, 3.0
1.66 m
HcAla-4 HcAla-7,8peq,9peq
HcAla-8pax,9peq
NH 8.40 d 8.8 Thr-1 Ahp-NH, HcAla-3a,4, Thr-2
Thr-1 169.5 s
2 54.9 d 4.55 d 9.1 Thr-1 HcAla-NH, Thr-3,4
3 71.8 d 5.37 m Val-1 HcAla-NH, Thr-2,4, Val-3
4 17.6 q 1.17 d 6.6 Thr-2,3 Thr-2,3, Gln-2
NH 7.96 d 9.1 Gln-1 Thr-4, Gln-2
Gln-1 172.8 s
2 52.2 d 4.38 dt 6.0, 8.0 Gln-1 Thr-4,NH, Gln-3a,3b,NH, HA-4
3 27.9 t 1.69 m
1.84 m
Gln-2,4 Gln-2,3b,NH
Gln-2,3a,NH
4 31.8 t 2.07 m
2.08 m
Gln-5
Gln-5
5 174.0 s
5-NH2 (a)
(b)
6.73 s
7.21 s
Gln-4
Gln-5
Gln-4
NH 7.98 d 8.0 HA-1 Gln-2,3a
HA-1 172.5 s
2 35.2 t 2.08 m HA-1,4 HA-3
3 25.1 t 1.49 m HA-1,4 HA-2
4 31.5 t 1.20 m HA-1,3,5
5 22.0 t 1.23 m HA-3,4,6
6 14.0 q 0.84 t 7.0 HA-5
a 500 MHz for 1H, 125 MHz for 13C.
b Multiplicity and assignment from HSQC experiment.
c Determined from HMBC experiment, nJCH¼8 Hz, recycle time 1 s.
d Selected NOE’s from a ROESY experiment.
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threonine.11 Jones oxidation21 of 1, followed by a similar hydro-
lysis, derivatization and HPLC analysis, determined the 3S-con-
ﬁguration for the Ahp residue (oxidation and subsequent
hydrolysis liberated L-glutamic acid from Ahp). An attempt to
determine the absolute conﬁguration of C-2 in HcAla by advance
Marfey’s procedure failed most probably due to its de-
composition during hydrolysis. The conﬁguration of C-6 of the
Ahp moiety was determined as R on the basis of the following
evidences: (i) The coupling constants of H-6, 1.8 and 3.2 Hz, with
pseudo-equatorial-H-5 and pseudo-axial-H-5, respectively,
which pointed to an equatorial orientation of H-6; (ii) The
chemical shift of the pseudo-axial-H-4, dH 2.39 dq (3.0,12.3),
which is down-ﬁeld shifted by the axial 6-hydroxy-group; (iii)
The trans-diaxial relationship of H-4pax with H-3 (mutual cou-
pling constant of 12.3 Hz); (iv) The NOE correlation between H-
4pax with the 6-OH. Based on these ﬁndings the structure of
micropeptin KR1030 was established as 1.
Examination of the NMR spectra of micropeptin KR1002 (2)
revealed that its 1H and 13C NMR spectra are similar to those of 1.
The molecular formula of 2, C51H70N8O13, was deduced from the
high-resolution ESI-MSmeasurements of its sodiatedmolecular ion
cluster at m/z 1025.4958. Comparison of the NMR data of micro-
peptin KR1030 (1) and micropeptin KR1002 (2) (see Tables 1 and 2,
respectively) revealed that the difference between them is located
in the fatty acid moiety at the N-termini of these cyclic peptolides.
Two methylene carbons (dC 31.5 and 25.1) of the aliphatic residue
and four proton signal (dHw1.20), which appeared in the spectra of
1 were missing from the spectra of 2, suggesting that the HA resi-
due in 1 is replaced by a butyric acid (BA) residue in 2. Full as-
signment of 2 was achieved by interpretation of the COSY, TOCSY,
ROESY, HSQC and HMBC 2D NMR correlations (see Table 2), re-
vealing the composition and sequence of acid residues of 2 as, Val,
NMeTyr, N,N-disubstituted-Phe, Ahp, HcAla, Thr, Gln and BA. Acid
hydrolysis of 2 and derivatization with Marfey’s reagent,20 as de-
scribed above for 1 followed by HPLC analysis, demonstrated the L-
conﬁgurations for all of the amino acid residues except of HcAla.
The absolute conﬁguration of the Ahp residue was determined in
the same way as for 1. Based on these ﬁndings the structure of
micropeptin KR1002 was established as 2.
Micropeptin KR998 (3), a glassy material, presented an ESI MS
pseudo-molecular [MþNa]þ ion atm/z 1021.4666, corresponding to
the molecular formula C51H66N8O13 and 23 degrees of unsaturation.
Comparisonwith 2 revealed two additional degrees of unsaturation
in 3. The 1H and 13C NMR spectra of 3were comparablewith those of
2, but revealed somedifferences aswell. In the aromatic regionof the
1HNMR spectrum of 3, two additionalmutually-coupled (8.2 Hz) 2H
doublet signals at dH 6.89 and 6.56 ppm and a singlet proton at dH
9.07 ppm were evident. In the aliphatic region two additional ben-
zylic protons (dH 3.11 and 2.50) were observed, while the signals
corresponding to the HcAla in 2 were missing. In the 13C NMR
spectrum of 3 four new aromatic signals (dC 128.3 s, 129.8 dx2,
115.2 dx2 and 155.7 s), of a para-substituted phenol moiety were
observed, while the signals of HcAla observed in 2 were missing
(Tables 2 and 3). The data summarized above and the molecular
formula of 3 relative to that of 2 suggested that in 3 a tyrosinemoiety
substitute the HcAla of 2, while the rest of the structures of these
compounds are identical. Full assignment of the tyrosinemoiety and
the rest of themoieties that compose 3 aswell as their sequencewas
achieved using COSY, TOCSY, ROESY, HSQC and HMBC 2D NMR cor-
relations (see Table 3). Marfey’s analysis as described above for 1
established the absolute conﬁguration of all amino acids including C-
3 of Ahp as L. The absolute conﬁguration of C-6 of the Ahp residue
was determined in the sameway as for 1. Based on these ﬁndings the
structure of micropeptin KR998 was established as 3.
2.1. Biological activity
The crude cyanobacterial extract exhibited signiﬁcant inhibition
of the serine protease chymotrypsin at a concentration of 1 mg/ml.
Puriﬁcation of the proteases-inhibiting components of the extract
revealed that micropeptins 1e3were responsible for the inhibition
of chymotrypsin. This ﬁnding was in accordance with the known
activity of the micropeptins that contain aromatic or aliphatic
amino acid next to the Ahp moiety, which usually are potent chy-
motrypsin inhibitors.10 The inhibitory activity of 1e3 was de-
termined for serine protease chymotrypsin, elastase and trypsin.
Micropeptins 1e3 did not inhibit trypsin at a concentration of
45.5 mM. Chymotrypsin was inhibited by micropeptin KR1030 (1)
with an IC50 of 13.9 mM, by micropeptin KR1002 (2) with an IC50 of
18.8 mM, by micropeptin KR998 (3) with an IC50 of 5.9 mM. Elastase
was inhibited by micropeptin KR1030 (1) and micropeptin KR1002
(2) with an IC50 of 28.0 mM, but not by micropeptin KR998 (3) at
a concentration of 50 mM. The relative potency of 1e3 to chymo-
trypsin is in accordance with the published data.11
3. Conclusions
This study describes the isolation of three new micropeptins
together with the known microcyclamide GL546A from the water
bloom material of the cyanobacterium Microcystis sp. This research
adds to the growing library of micropeptins and illuminates the
variety of the metabolites produced by these fresh water cyano-
bacteria. The use of non-proteogenic amino acids allows the ex-
pansion of the library of micropeptins that are biosynthesized
by cyanobacteria. The purpose for the incorporation of non-
proteogenic amino acids into these peptides might be derived
from the need to avoid recognition of the amino acids in the peptide
by proteolytic enzymes or to produce special epitopes to be recog-
nized by special receptors in the producing organisms. HcAla, which
is incorporated in two of the three new micropeptins described
here, is most probably derived from L-arogenate, the precursor of
phenylalanine and tyrosine. It is presumably biosynthesized by re-
duction and decarboxylation of L-arogenate (Fig. 2), in analogy with
the biosynthesis of the proline mimicking amino acid, Choi, in the
aeruginosins.22 It is of great interest to study the biosynthesis of
HcAla, which we intend to do in the near future.
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Fig. 1. NOE correlations instrumental for determining the relative conﬁguration of the
hydroxycyclohexenyl alanine moiety.
Fig. 2. Possible route from arogenate to HcAla.
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Table 2
NMR data of micropeptin KR1002 (2) in DMSO-d6a
Position dC, mult.b dH, mult., J (Hz) LR H-C correlationsc NOE correlationsd
Val-1 172.6 s
2 55.6 d 4.73 dd 9.8, 4.2 Val-5 Val-3,4,NH, NMeTyr-2
3 30.9 d 2.07 m Val-2,4,5
4 19.3 q 0.86 d 6.7 Val-2,3,5 Val-3, NMeTyr-NMe
5 17.1 q 0.71 d 6.7 Val-2,3,4 Val-3,NH, NMeTyr-NMe, Ahp-6-OH
NH 7.38 d 9.8 NMeTyr-1 Val-2,3, NMeTyr-2,NMe
NMeTyr-1 168.9 s
2 60.9 d 4.89 dd 11.5, 2.0 NMeTyr-1 Val-2, NMeTyr-3b,5,50 ,NMe
3 32.8 t 2.71 dd 13.2, 11.5
3.09 dd 13.2, 2.0
NMeTyr-5,50
NMeTyr-4,5,50
Val-NH, NMeTyr-3b,5,50,6,60
NMeTyr-2,3a,5,50
4 127.5 s
5,50 130.4 dx2 6.99 dx2 8.2 NMeTyr-3,50 ,5,7 NMeTyr-2,3a,3b, Phe-2
6,60 115.3 dx2 6.76 dx2 8.2 NMeTyr-4,60 ,6,7 NMeTyr-3a,7-OH, Phe-3a
7 156.2 s
7-OH 9.33 NMeTyr-60 ,6,7 NMeTyr-6,60
NMe 30.3 q 2.75 s NMeTyr-2 Val-4,5,NH, NMeTyr-2,5,50
Phe-1 170.3 s
2 50.2 d 4.75 dd 11.9, 3.9 Phe-1 NMeTyr-5,50 , Phe-3a,5,50
3 38.5 t 1.79 m
2.85 dd 11.9, 14.0
Phe-5,50
Phe-5,50
Phe-2,3b,5,50 , NMeTyr-6,60
Phe-3,5,50 , Ahp-6
4 136.7 s
5,50 129.4 dx2 6.82 dx2 7.1 Phe-3,50 ,6,7 Phe-2,3a,3b, Ahp-4a
6,60 127.7 dx2 7.17 tx2 7.1 Phe-4,5,6 HcAla-OH
7 126.2 d 7.13 t 7.1 Phe-5 Ahp-3
Ahp-2 169.3 s
3 48.5 d 3.60 ddd 7.1, 9.1, 12.7 Ahp-4a,NH, Phe-7
4 21.6 t 1.55 m
2.39 br q 12.7
Ahp-3,4b,6, Phe-6,60
Ahp-4a,NH,6-OH
5 29.6 t 1.67 m
1.55 m
Ahp-6-OH, HcAla–5
6 73.7 d 5.05 br s Phe-3b, Ahp-4,5,6-OH
6-OH 5.99 d 2.5 Ahp-4b,5,6, Val-5,NH, HcAla-NH
NH 7.08 d 9.1 HcAla-1 Ahp-3,4b, HcAla-2,9,NH
HcAla-1 170.0 s
2 49.4 d 4.23 br dd 11.4, 7.4 Ahp-NH, HcAla-3b,4
3 36.4 t 1.40 dt 3.7, 11.4
1.71 m
HcAla-3b,4,5,6
HcAla-2,3a
4 31.6 d 1.92 m HcAla-2,3a,5,6,8pax,NH
5 132.0 d 5.37 br d 10.2 HcAla-3a,4,6,7
6 132.7 d 5.55 dd 10.2, 1.0 HcAla-4 HcAla-3a,4,5,7,7-OH
7 65.1 d 3.94 br m HcAla-5,6,7-OH,8peq,9pax
8 peq
pax
31.6 t 1.79 m
1.20 m
HcAla-7,7-OH,8pax,9pax
HcAla-4,8peq,9peq,7-OH
9 peq
pax
25.8 t 1.70 m
0.93 br q 11.3
HcAla-4,8pax,9pax
HcAla-7,8peq,9peq
7-OH 4.61 d 5.4 HcAla-6,7,8 HcAla-6,7,8peq,8pax
NH 8.40 d 8.4 Ahp-NH, HcAla-3a,4, Thr-2,3
Thr-1 169.1 s
2 54.9 d 4.55 br d 9.1 Thr-1, Gln-1 HcAla-NH, Thr-4
3 71.7 d 5.39 q 6.5 Thr-4 HcAla-NH, Thr-4
4 17.6 q 1.17 d 6.5 Thr-2,3 HcAla-7-OH, Thr-2,3,NH
NH 7.91 d 9.0 Gln-1 HcAla-NH, Thr-4
Gln-1 172.2 s
2 52.0 d 4.38 m Gln-1 Thr-NH, Gln-3a,3b,4b
3 27.7 t 1.69 m
1.84 m
Gln-4 Gln-2,3b,NH, BA-3
Gln-3a,NH
4 31.6 t 2.11 m Gln-5 Gln-2,NH,5-NH2
5 173.9 s
5-NH2(a)
(b)
6.72 s
7.21 s
Gln-4 Gln-4
NH 7.99 d 7.5 BA-1 Gln-3a,4
BA-1 172.0 s
2 37.0 t 2.09 m BA-1,3,4 Gln-2
3 18.9 t 1.51 m BA-1,2,4 Gln-3a
4 13.6 q 0.84 t 7.3 BA-2,3 Val-2
a 400 MHz for 1H, 100 MHz for 13C.
b Multiplicity and assignment from HSQC experiment.
c Determined from HMBC experiment, nJCH¼8 Hz, recycle time 1 s.
d Selected NOE’s from a ROESY experiment.
T. Thorskov Bladt et al. / Tetrahedron 70 (2014) 936e943940
4. Experimental section
4.1. General experimental procedures
Mass spectra were recorded on a Waters MaldiSynapt in-
strument. UV spectra were recorded on an Agilent 8453 spectro-
photometer. Optical rotation valueswere obtained on a Jasco P-1010
polarimeter at the sodium D line (589 nm). NMR spectra were
recorded on a Bruker Avance 500 spectrometer at 500.13MHz for 1H
and 125.76 MHz for 13C and a Bruker Avance 400 Spectrometer at
400.13 MHz for 1H, 100.62 MHz for 13C. DEPT, COSY-45, gTOCSY,
gROESY, gHSQC, gHMQC and gHMBC spectra were recorded using
standard Bruker pulse sequences. HPLC separations were per-
formed on a JASCO HPLC system (model PU-2080 Plus pump, model
LG-2080-04 Quaternary Gradient unit and model PU-2010 Plus
MultiwavelengthDetector), on aMerckHitachi HPLC system (model
Table 3
NMR data of micropeptin KR998 (3) in DMSO-d6a
Position dC, mult.b dH, mult., J (Hz) LR H-C correlationsc NOE correlationsd
Val-1 172.1 s
2 55.9 d 4.66 dd 9.5, 4.3 Val-1,3,5 Val-3,4,5,NH, Gln-NH2
3 31.0 d 2.02 m Val-2,4,5 Val-2,4,5,NH, Thr-2
4 19.4 q 0.85 d 5.7 Val-2,3,5 Val-2,3,NH, NMeTyr-NMe
5 17.3 q 0.70 d 6.7 Val-2,3,4 Val-2,3,NH, NMeTyr-NMe, Ahp-6-OH
NH 7.37 d 9.5 NMeTyr-1 Val-2,3,4,5, NMeTyr-2,NMe, Ahp-6-OH
NMeTyr-1 169.0 s
2 61.0 d 4.89 br d 11.4 NMeTyr-1,NMe Val-NH, NMeTyr-3b,5,50
3 33.0 t 2.71 dd 13.4, 11.4
3.08 br d 13.4
NMeTyr-2,5,50
NMeTyr-4,5,50
NMeTyr-3b,6,60
NMeTyr-2,3a,5,50
4 127.7 s
5,50 130.6 dx2 6.99 dx2 8.0 NMeTyr-3,50 ,5,6,60 ,7 NMeTyr-2,3b,NMe, Phe-2,3a
6,60 11.5.5 dx2 6.77 dx2 8.0 NMeTyr-4,6,60 ,7 NMeTyr-NMe,OH, Phe-3a
7 156.4 s
NMe 30.5 q 2.75 s NMeTyr-2, Phe-1 NMePhe-5,50 ,7, Val-4,5,NH
Phe-1 170.5 s
2 50.4 d 4.74 dd 11.3, 3.6 Phe-1 NMeTyr-5,50 , Phe-3a,5,50
3 35.5 t 1.78 m
2.86 dd 11.7, 13.8
Phe-5,50 NMeTyr-5,50 ,6,60 , Phe-2,3b,5,50
Phe-3a,5,50 , Ahp-6
4 136.9 s
5,50 129.6 dx2 6.83 dx2 7.1 Phe-3,50 ,5,7 Phe-2,3a,3b, Ahp-3,5a,6
6,60 127.9 dx2 7.18 tx2 7.1 Phe-4,5,50 ,60 ,6 Ahp-3
7 126.4 d 7.14 t 7.1 Phe-5,50
Ahp-2 169.0 s
3 49.0 d 3.60 ddd 11.6, 8.2, 6.0 Ahp-2,4 Phe-5,50 , Ahp-4a,NH
4 21.7 t 1.62 m
2.40 br q 12.4
Ahp-3,4b
Ahp-4a,5b,NH
5 29.4 t 1.68 m
1.57 m
Ahp-6,6-OH
Ahp-4b
6 73.9 d 5.05 br s Phe-3b,5,50 , Ahp-5a,5b
6-OH 5.99 d 2.1 Ahp-5b,6, Val-5,NH
NH 7.07 d 10.2 Ahp-3,4b, Tyr-2,NH
Tyr-1 169.7 s
2 53.6 d 4.35 ddd 3.8, 9.0, 13.0 Ahp-NH, Tyr-3a,3b,5,50 ,NH
3 35.1 t 2.50 dd 13.0, 14.7
3.11 dd 3.8, 14.7
Tyr-2,4,5 Tyr-2,3b,5,50
Tyr-2,3a,NH
4 128.3 s
5,50 129.8 dx2 6.89 dx2 8.2 Tyr-3,5,50 ,6,60 ,7 Tyr-2,3a,NH
6,60 115.2 dx2 6.56 dx2 8.2 Tyr-4,60 ,6,7 Tyr-5,50 ,7-OH
7 155.7 s
7-OH 9.07 s Tyr-6,60 Tyr-6,60
NH 8.45 d 9.0 Thr-1 Ahp-NH, Tyr-2,3a,5,50 , Thr-2,3
Thr-1 169.0 s
2 554.4 d 4.45 br d 9.4 Thr-1,4, Gln-1 Tyr-NH, Thr-4,NH, Ahp-NH
3 72.2 d 5.37 q 6.5 Thr-4, Val-1 Ahp-NH, Tyr-NH, Thr-4
4 17.7 q 1.10 d 6.5 Thr-2,3 Thr-2,3,NH
NH 7.69 d d 9.4 Gln-1 Thr-2,3,4, Gln-2,3b
Gln-1 172.3 s
2 52.2 d 4.30 dt 5.3, 8.3 Gln-3 Thr-NH, Gln-3a,3b,4,NH
3 27.5 t 1.70 m
1.80 m
Gln-2,4,5
Gln-1,2,4,5
Gln-2,NH
Thr-NH, Gln-2
4 31.7 t 2.05 m Gln-2,3,5 Gln-2,NH,5-NH2(a,b)
5 174.3 s
5-NH2a
b
6.81 s
7.24 s
Gln-4,5
Gln-5
Gln-4
Gln-4
NH 7.98 d 7.8 BA-1 Gln-2,a3,4
BA-1 172.4 s
2 37.4 t 2.10 m BA-1,3,4
3 18.9 t 1.50 tq 7.3, 7.3 BA-1,2,4
4 13.8 q 0.85 t 7.2 BA-2,3
a 500 MHz for 1H, 125 MHz for 13C.
b Multiplicity and assignment from HSQC experiment.
c Determined from HMBC experiment, nJCH¼8 Hz, recycle time 1 s.
d Selected NOE’s from a ROESY experiment.
T. Thorskov Bladt et al. / Tetrahedron 70 (2014) 936e943 941
L-6200A pump andmodel L-4200UVeVis detector), and on aMerck
Hitachi HPLC system (model L-7000A intelligent pump and model
L-6200 UVevis detector). An Elisa ELx808 plate reader (BioTek In-
struments, Inc.) was used for proteases inhibition assays.
4.2. Cyanobacterial material
Microcystis sp., TAU sample IL-403, was collected in September
2009 at Kabul Reservoir, Israel. Samples of the cyanobacteria are
deposited at the culture collection of Tel Aviv University.
4.3. Isolation procedure
The freeze dried cyanobacterial mass (199 g) was extracted with
MeOH/water (70:30) and the crude extract (26 g) was separated on
a ﬂash RP-C18 column with increasing amounts of MeOH in water
resulting in 12 fractions. Fraction 5 and 6 were combined (40e50%
MeOH inwater, 474 mg) and separated on Sephadex LH-20 column
with chloroform/MeOH (1:1). The fractions from this column were
further separated by preparative HPLC on a Waters Cosmosil 5C8-
MS (25020 mm, 5 mm) column eluted at a rate of 5 ml/min using
DAD detection. Fraction 2 (130 mg) was separated by preparative
HPLC with 35:65 ACN/0.1% TFA in water to obtain micropeptin
KR1030 (1, 3.9 mg). Further isocratic HPLC fractionation of fraction
4 and 5 from the previous HPLC separation with 3:7 ACN/0.1% TFA
in water yielded micropeptins KR1002 and KR998 (2, 3.7 and 3,
1.4 mg, respectively).
4.3.1. Micropeptin KR1030 (1). Glassy material; [a]D25 19.1 (c 0.04,
MeOH); UV (MeOH) lmax (Log ε) 202 (4.44), 222 (3.95), 277 (3.18)
nm; IR (CHCl3): 3361, 2923, 2853, 1654, 1025, 993, 669 cm1;
HRESIMS m/z 1053.5288 [MþNa]þ (calculated for C53H74N8NaO13,
1053.5273); Retention times of AAMarfey’s derivatives (L-FDAA): L-
Thr 33.4 min (D-Thr 36.3 min), L-Glu, 35.2 min (D-Glu 36.2 min), L-
Val 44.2 min (D-Val 48.1 min), L-Phe 48.8 min (D-Phe 51.8 min), L-
NMe-Tyr 53.3 min.
4.3.2. Micropeptin KR1002 (2). Glassy material; [a]D25 14.6 (c 0.04,
MeOH); UV (MeOH) lmax (Log ε) 202 (3.90), 222 (3.27), 278 (2.73)
nm; IR (CHCl3): 3360, 2924, 2853, 1653, 1025, 994, 669 cm1;
HRESIMS m/z 1025.4958 [MþNa]þ (calculated for C51H70N8NaO13,
1025.4960); Retention times of AAMarfey’s derivatives (L-FDAA): L-
Thr 33.3 min (D-Thr 36.3 min), L-Glu, 35.8 min (D-Glu 36.7 min), L-
Val 44.0 min (D-Val 48.1 min), L-Phe 48.9 min (D-Phe 51.9 min), L-
NMe-Tyr 53.6 min.
4.3.3. Micropeptin KR998 (3). Glassy material; [a]D25 40.0 (c 0.01,
MeOH); UV (MeOH) lmax (Log ε) 202 (4.73), 222 (4.30), 278 (3.46)
nm; IR (CHCl3): 3360, 2923, 2853, 1654, 1635, 1025, 997, 669 cm1;
HRESIMS m/z 1021.4666 [MþNa]þ (calculated for C51H66N8NaO13,
1021.4647); Retention time of AA Marfey’s derivatives: L-Thr
33.6 min (D-Thr 36.5 min), L-Glu 35.8 min (D-Glu 36.8 min), L-Val
44.5 min (D-Val 48.3 min), L-Phe 48.9 min (D-Phe 51.6 min), L-NMe-
Tyr 53.4 min, L-Tyr 54.4 min (D-Tyr 57.9 min).
4.4. Determination of the absolute conﬁguration of the
amino acids
0.5 mg portions of compounds 1e3 were dissolved in 6 N HCl
(1mL). The reactionmixturewas then placed in a sealed glass bomb
at 110 C for 16 h. In another experiment, 0.25 mg portions of
compounds 1e3 were ﬁrst oxidized with Jones reagent (1 drop) in
acetone (1 mL) at 0 C for 10 min. Following the usual work-up, the
residue was dissolved in 6 MHCl (1 mL) and placed in a sealed glass
bomb at 104 C for 18 h. After the removal of HCl, by repeated
evaporation in vacuo, the hydrolysate was resuspended in water
(40 mL). A solution of (1-ﬂuoro-2,4-dinitrophenyl)-5-L-alanine
amide (L-FDAA) (4.2 mM) in acetone (150 mL) and 1 M NaHCO3
(20mL) was added to each reaction vessel and the reaction mixture
was stirred at 40 C for 2 h. A 2MHCl solution (10mL) was added to
each reaction vessel and the solution was evaporated in vacuo. The
N-[(2,4-dinitrophenyl)-5-L-alanine amide]-amino acid derivatives,
from hydrolysates, were compared with similarly derivatized
standard amino-acids by HPLC analysis: LichroCART RP-18, 5 mm,
4.6250 mm, ﬂow rate: 1 mL/min, UV detection at 340 nm, linear
gradient elution from 0.1% TFA in water (pH 3) to 4:6 0.1% TFA in
water/acetonitrile within 60 min. The determination of the abso-
lute conﬁguration of each amino acid was conﬁrmed by spiking the
derivatized hydrolysates with the derivatized authentic amino
acids.
4.5. Protease inhibition assays
Trypsin, chymotrypsin and elastase were purchased from Sigma
Chemical Co. Trypsin (1 mg/mL) and chymotrypsin (10 mg/mL)
were dissolved in 0.05 M TriseHCl/100 mM NaCl/1 mM CaCl2, pH
7.5 buffer solution. Benzoyl-L-arginine-p-nitroanilide hydrochlo-
ride (BAPNA), the trypsin substrate, was dissolved in a solution of
1:9 DMSO: Tris-buffer (0.85 g/mL). Suc-Gly-Gly-p-nitroanilide
(SGGPNA), the substrate for chymotrypsin, was dissolved in Tris-
buffer (1 mg/mL). Test samples were dissolved in DMSO (1 mg/
mL). A 100 mL buffer solution, 10 mL enzyme solution and 10 mL
sample solution were added to each microtiter plate well and pre-
incubated at 37 C for 10 min. Then, 10 mL of substrate solution was
added and the kinetics of the reaction were measured at 405 nm,
37 C for 30 min. Elastase (75 mg/mL) was dissolved in 0.2 M
TriseHCl, pH 8 buffer solution. Z-Gly-Pro-Arg-4MbNA-acetate salt,
the thrombin substrate, was dissolved in Tris buffer (0.5 mg/ml). N-
Suc-Ala-Ala-Ala-p-nitroanilide, the elastase substrate, was dis-
solved in Tris buffer (1 mg/mL). The test samples were dissolved in
DMSO (1 mg/mL). For elastase, 150 mL buffer solution, 10 mL enzyme
solution and 10 mL sample solution were added to each microtiter
plate well and pre-incubated at 30 C for 20 min. Then, 30 mL of
substrate solution were added and the kinetics of the reaction was
measured at 405 nm, 37 C for 20 min.
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S2. 13C NMR Spectrum of Micropeptin KR1030 (1) in DMSO-d6
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S3. HSQC Spectrum of Micropeptin KR1030 (1) in DMSO-d6
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S4. HMBC Spectrum of Micropeptin KR1030 (1) in DMSO-d6
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S5. COSY Spectrum of Micropeptin KR1030 (1) in DMSO-d6
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S7. TOCSY of Micropeptin KR1030 (1) in DMSO-d6 
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8. HR ESI MS of Micropeptin KR1030 (1) 
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S9. 1H NMR Spectrum of Micropeptin KR1002 (2) in DMSO-d6
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S10. 13C NMR Spectrum of Micropeptin KR1002 (2) in DMSO-d6
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S11. HSQC Spectrum of Micropeptin KR1002 (2) in DMSO-d6
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S12. HMBC Spectrum of Micropeptin KR1002 (2) in DMSO-d6
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S13. COSY Spectrum of Micropeptin KR1002 (2) in DMSO-d6
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S15. TOCSY of Micropeptin KR1030 (1) in DMSO-d6 
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16. HR ESI MS of Micropeptin KR1002 (2) 
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S17. 1H NMR Spectrum of Micropeptin KR998 (3) in DMSO-d6
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S18. 13C NMR Spectrum of Micropeptin KR998 (3) in DMSO-d6
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S19. HSQC NMR of Micropeptin KR998 (3) in DMSO-d6
ppm
10 9 8 7 6 5 4 3 2 1 ppm
20
40
60
80
100
120
140
160
180
200
22 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
S20. HMBC Spectrum of Micropeptin KR998 (3) in DMSO-d6
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S23. TOCSY of Micropeptin KR1030 (1) in DMSO-d6 
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24. HR ESI MS of Micropeptin KR998 (3) 
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Known microcyclamide GL546A 
The identity of the known microcyclamide GL546A was found through NMR data that matched the data 
from the literature [Raveh, A. et al. Tetrahedron, 66(14), 2705–2712]. 
Structure of microcyclamide GL546A (4). 
 
NMR data of microcyclamide GL546A (4) in DMSO-d6.
a 
Position δC, mult.
b δH, mult., J (Hz) LR H-C correlationsc 
1 158.9 s   
2 148.1 s   
3 125.2 d 8.37 s 2, 4 
4 168.0 s   
5 54.3 d 5.32 dd 7.4, 6.0 4, 6, 9, 10 
6 40.2 d 1.97 m  
7a 25.3 t 1.16 m 6 
7b 1.58 m 9 
8 11.5 q 0.92 t 7.3 6, 7 
9 14.5 q 0.79 d 6.8 5, 6, 7 
N2(H)  8.39 d 7.4 4, 10 
10 159.6 s   
11 127.8 s   
12 153.4 s   
13 11.2 q 2.60 s 11, 12 
14 161.3 s   
15 43.9 d 5.19 p 6.3 14, 16 
16 19.1 q 1.52 m 14, 15 
N(4)H  8.54 d 6.3 14, 17 
17 159.2 s   
18 147.6 s   
19 125.7 d 8.40 s 18, 20 
20 170.1 s   
21 48.1 d 5.80 dt 8.2, 5.1 20, 23 
22 40.5 t 3.07 d 5.1 20, 21, 23 
23 171.5 s   
N6(H)  8.77 d 8.2 1 
a500 MHz for 1H, 125 MHz for 13C. bMultiplicity and assignment from HSQC experiment. cDetermined 
from HMBC experiment, 
n
JCH=8 Hz, recycle time 1s.  
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